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Abstract
The Arenaviridae family of segmented RNA viruses includes several important
human pathogens, some of which are the causative agents of haemorrhagic fever,
a disease with severe morbidity and high mortality. Currently, effective therapeutic
and preventative measures for such pathogens are limited. The prototypical
arenavirus is lymphocytic choriomeningitis virus (LCMV), which on account of its
low pathogenicity in humans provides the opportunity to understand more about
arenavirus infections under bio-safety level 2 containment.
The work described here sought to develop and exploit molecular tools for arenavirus
study. Firstly, a high-affinity antibody reactive against LCMV nucleocapsid protein
(NP) was generated. This LCMV NP antibody was subsequently used to investigate
the intracellular localisation of the NP during the viral lifecycle and to develop
a method for the titration of non-cytolytic LCMV, allowing the quantification of
infectious virus.
Secondly, the LCMV NP antibody and the titration method were subsequently used
to optimise a reverse genetics system, designed to recover infectious recombinant
LCMV entirely from cDNAs. This system was further engineered to introduce
the eGFP gene into the S segment of LCMV, permitting simple and rapid
monitoring of LCMV gene expression and infection through fluorescent live cell
analysis. The reverse genetics system was further engineered to successfully generate
infectious LCMV carrying a C-terminal-6xHis-tagged NP, which could be utilised to
purify native viral ribonucleoprotein complexes from infected cells. The successful
production of both of these tagged replication-competent recombinant LCMV
variants are valuable tools for the study of arenaviruses.
Using the molecular tools generated here, LCMV was highly concentrated and
purified for its examination by cryo-electron tomography, alongside another
arenavirus, Pichindé virus (PICV), providing a direct comparison between the two
arenaviruses. Sub-tomogram averaging was then used to resolve the structures
of the native glycoprotein complex (GPC) entry spikes, present on the viral
surface. These results indicated structural differences of the GPC between multiple
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kDa kilodalton
L segment large segment
LACV La Crosse virus




LCMV lymphocytic choriomeningitis virus
LCMV-ARM LCMV; armstrong strain
LCMV-Cl13 LCMV; clone-13 derivative
LDS lithium dodecyl sulphate
LP L Polymerase
LUJV Lujo virus
M segment medium segment
M7G 7-methylguanosine
MACV Machupo virus
MOI multiplicity of infection
MOPV Mopeia virus
mRNA messenger ribonucleic acid
Ni2+-NTA nickel-nitrilotriacetic acid




ORF open reading frame
P2A porcine teschovirus 1 2A
PAMP pathogen-associated molecular pattern
PCR polymerase chain reaction






RdRp RNA-dependent RNA polymerase






S segment small segment
SBAV Sabiá virus
SDS-PAGE sodium dodecyl sulphate–polyacrylamide
gel electrophoresis
SEC size-exclusion chromatography
SFM serum-free Dulbecco’s modified eagle medium
xv
SKI-1/S1P subtilisin kexin isozyme-1/Site-1 protease
SUMO small ubiquitin-related modifier
T7P T7 RNA polymerase
TAE tris-acetate-EDTA
TCRV Tacaribe virus
Tsg101 tumour susceptibility gene 101
UHV University of Helsinki virus
ULP1 ubiquitin-like-specific protease 1
UTR untranslated region
VLP virus-like particle
vRNA virion-associated ribonucleic acid
ZP Z matrix protein
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Chapter 1
Introduction to the Arenaviruses
1.1 General Introduction
1.1.1 Discovery
The first arenavirus was isolated in 1933 in St. Louis (USA), during sampling to
find the etiological cause of an outbreak of encephalitis (Armstrong and Lillie, 1934).
It was temporarily called the virus of experimental lymphocytic choriomeningitis
(Armstrong and Lillie, 1934) and was later renamed to lymphocytic choriomeningitis
virus (LCMV). In 1935, it was identified as a cause of aseptic meningitis in humans
(Rivers and Scott, 1936) and the natural reservoir host was identified as the common
house mouse (Mus musculus) (Traub, 1935). The original isolated LCMV strain
was named the Armstrong strain, after Charles Armstrong who had isolated it
(Armstrong and Lillie, 1934). Two other LCMV strains, Traub and WE, were also
isolated in the 1930s, from laboratory-infected mice and a human who had been
exposed to persistently infected mice (Takagi et al., 2012; Welsh and Seedhom,
2008). The Traub strain was named after Erich Traub, who had isolated the strain,
whereas the WE strain was named after the person it was isolated from (Traub,
1935; Rivers and Scott, 1936).
The next arenaviruses discovered were Tacaribe virus (TCRV; Trinidad and Tobago;
1956 (Downs et al., 1963)) and Junín virus (JUNV; Argentina; 1958 (Parodi
et al., 1958, 1959)). These viruses were shown to be serologically cross-reactive
in complement fixation assays and were easily distinguishable from LCMV by
neutralisation assays, leading to the establishment of the Tacaribe antigenic complex
(Casals et al., 1963). By the 1970s, several other arenaviruses had been discovered
and were added to this grouping due to their cross-reactivity in the complement
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fixation assays (Machupo (Johnson et al., 1965); Amaparí (Pinheiro et al., 1966);
Latino (first mentioned in (Murphy et al., 1970)); Parana (Johnson et al., 1965);
Pichindé (Trapido and Sanmartín, 1971); and Tamiami (Lord et al., 1970)). Some
of these newly identified arenaviruses did not cause disease in humans, whilst others
caused severe, and often fatal, human diseases, which were clinically quite similar
(Radoshitzky et al., 2015).
Members of the Tacaribe antigenic complex were not serologically cross-reactive
with LCMV, but there was cross-reactivity between these viruses in indirect
immunofluorescence assays (Rowe et al., 1970a). Furthermore, examination by
thin-section electron microscopy revealed these viruses to be morphologically
indistinguishable from LCMV (Murphy et al., 1970). This led to the establishment
of a new taxonomic group of viruses called the Arenaviruses (initially Arenoviruses
(Rowe et al., 1970b)). The group was named as such because the electron
microscopic investigation revealed the presence of electron-dense granules, proposed
to be host cell ribosomes, in the viral particles, giving them a sandy (Latin;
arenosus) appearance (Rowe et al., 1970b; Dalton et al., 1968). LCMV was made
the prototypic virus of this group (Rowe et al., 1970b). In 1969, another arenavirus
was discovered in patients suffering from Lassa fever in Nigeria (Frame et al., 1970).
Lassa virus (LASV) was serologically cross-reactive, using the complement fixation
assay, with LCMV and some members of the Tacaribe antigenic complex (Buckley
et al., 1970), and shared morphological similarities with LCMV (Wood et al., 1970).
In addition to the serological and morphological similarities shared by these viruses,
the viruses also shared similar biological and biochemical properties and all persisted
in nature by establishing chronic infections of rodent hosts (Howard and Young,
1984; Radoshitzky et al., 2015). This provided enough evidence for the International
Committee on Taxonomy of Viruses (ICTV) to establish a new taxon; the Arenavirus
genus, which later developed into the Arenaviridae family (Fenner, 1976).
Over the years, serological evidence has guided the addition of newly discovered
arenaviruses to the Arenaviridae family. During the last ten years, there has
been a significant increase in the rate of discovery of arenaviruses (table 1.2).
This is the result of the technological advancements in next-generation sequencing.
This development has also led to an expansion of arenavirus-harbouring hosts,
including shrews, reptiles (specifically snakes) and fish. This has also resulted in
2
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the reclassification of the Arenaviridae family, incorporating a further three genera
(Garry and Garry, 2019)).
1.1.2 Classification of the Bunyavirales Order
Recently, the ICTV reorganised virus taxonomy in order for the organisation to
better reflect that of other biological taxonomies. This would assist the discovery
of novel viruses and their taxonomic assignment. Therefore, the ICTV created
the first viral realm; Riboviria, comprising all viruses with RNA as genomic
material. The reorganisation of the taxonomy led to the establishment of the
Bunyavirales order (Realm: Riboviria > Kingdom: Orthornavirae > Phylum:
Negarnaviricota > Subphylum: Polyploviricotina > Class: Ellioviricetes), into
which the Arenaviridae family was classified. Other families within the Bunyavirales
order include Cruliviridae, Fimoviridae, Hantaviridae, Leishbuviridae, Mypoviridae,
Nairoviridae, Peribunyaviridae, Phasmaviridae, Phenuiviridae, Tospoviridae and
Wupedeviridae. The Bunyavirales order was created in order to group together
related viruses, all of which have a single-stranded, segmented RNA genome in
either negative-sense or ambisense orientation (Maes et al., 2018). There are 477
virus species classified within the Bunyavirales order, which infect a wide range
of hosts, including mammals, reptiles, birds, fish, insects, plants and arthropods,
reflecting the diversity of the order (figure 1.1).
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Figure 1.1: Phylogenetic Tree of the Bunyavirales Order The 13 families of the
Bunyavirales Order were organised into a phylogenetic tree based on the nucleocapsid
protein amino acid sequences. In families where a virus has not been specified, the
type virus species was used for analysis. The vector species have been included for
the Nairoviridae (mosquito, tick), Peribunyaviridae (mosquito), Arenaviridae (rodent),
Hantaviridae (rodent), and Phenuiviridae (sandfly, mosquito, tick) families. The tree was
assembled by (Leventhal et al., 2021), using Geneious Prime tree builder global alignment
and the tree was transformed to make the branches equal length, therefore it is not to
scale. GenBank accession numbers for sequences have been included alongside the virus
name.
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1.1.3 Classification of the Arenaviridae Family
Based on phylogenetic analysis of the sequences of the viral RNA-dependent
RNA-polymerase (LP) and the nucleocapsid protein (NP), the Arenaviridae
family has been recently organised into four genera; Antennavirus, Hartmanivirus,
Mammarenavirus and Reptarenavirus, comprising a total of 50 species (as of July
2019, (Walker et al., 2019)). Table 1.1 describes the classification of all the arenavirus
species within the Arenaviridae family, whereas the phylogeny of the arenavirus
species has been shown in figure 1.2.
For a novel arenavirus to be designated as a new arenavirus species, it must fulfil
the following ICTV criteria; the virus must have been isolated from a new natural
host species, the virus must be present in a new distinct geographic region and the
viral nucleocapsid protein (NP) sequence must be sufficiently different from others
by at least 12 % (Radoshitzky et al., 2015; Salvato et al., 2005).
Table 1.1: ICTV-Accepted Taxonomic Organisation of the Arenaviridae Family.
Genus Species Viruses Abbr.
Antennavirus Hairy antennavirus Wēnľıng frogfish arenavirus 2 WlFAV-2
Striated antennavirus Wēnľıng frogfish arenavirus 1 WlFAV-1
Hartmanivirus Haartman hartmanivirus Haartman Institute snake virus 1 HISV-1
Haartman Institute snake virus 2 HISV-2
Muikkunen hartmanivirus Dante Muikkunen virus 1 DMaV-1
Schoolhouse hartmanivirus old schoolhouse hartmanivirus 1 OScV-1
old schoolhouse hartmanivirus 2 OScV-2
Zurich hartmanivirus veterinary pathology Zurich virus 1 VPZV-1
veterinary pathology Zurich virus 2 VPZV-2
Mammarenavirus Allpahuayo mammarenavirus Allpahuayo virus ALLV
Alxa mammarenavirus Alxa virus ALXV
Argentinian mammarenavirus Junín virus JUNV
Bear Canyon mammarenavirus Bear Canyon virus BCNV
Brazilian mammarenavirus Sabiá virus SBAV
Cali mammarenavirus Pichindé virus PICV
Chapare mammarenavirus Chapare virus CHAPV
Chevrier mammarenavirus Lìjiāng virus LIJV
Cupixi mammarenavirus Cupixi virus CUPXV
Flexal mammarenavirus Flexal virus FLEV
Gairo mammarenavirus Gairo virus GAIV
Guanarito mammarenavirus Guanarito virus GTOV
Ippy mammarenavirus Ippy virus IPPYV
Lassa mammarenavirus Lassa virus LASV
Latino mammarenavirus Latino virus LATV
Loei River mammarenavirus Loei River virus LORV
Lujo mammarenavirus Lujo virus LUJV
Luna mammarenavirus Luli virus LULV
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Continuation of Table 1.1
Genus Species Viruses Abbr.
Luna virus LUAV




lymphocytic choriomeningitis virus LCMV
Machupo mammarenavirus Machupo virus MACV
Mariental mammarenavirus Mariental virus MRLV
Merino Walk mammarenavirus Merino Walk virus MRWV
Mobala mammarenavirus mobala virus MOBV
Mopeia mammarenavirus Mopeia virus MOPV
Morogoro virus MORV
Okahandja mammarenavirus Okahandja virus OKAV
Oliveros mammarenavirus Oliveros virus OLVV
Paraguayan mammarenavirus Paraná virus PRAV
Pirital mammarenavirus Pirital virus PIRV
Planalto mammarenavirus Aporé virus APOV
Ryukyu mammarenavirus Ryukyu virus RYKV
Serra do Navio mammarenavirus Amaparí virus AMAV
Solwezi mammarenavirus Solwezi virus SOLV
Souris mammarenavirus souris virus SOUV
Tacaribe mammarenavirus Tacaribe virus TCRV
Tamiami mammarenavirus Tamiami virus TMMV
Wenzhou mammarenavirus Wēnzhōu virus WENV
Whitewater Arroyo mammarenavirus Big Brushy Tank virus BBRTV
Catarina virus CTNV
Skinner Tank virus SKTV
Tonto Creek virus TTCV
Whitewater Arroyo virus WWAV
Xapuri mammarenavirus Xapuri virus XAPV
Reptarenavirus California reptarenavirus CAS virus CASV
Giessen reptarenavirus University of Giessen virus 1 UGV-1
University of Giessen virus 2 UGV-2
University of Giessen virus 3 UGV-3
Golden reptarenavirus Golden Gate virus GOGV
Ordinary reptarenavirus tavallinen suomalainen mies virus 2 TSMV-2
Rotterdam reptarenavirus ROUT virus 1 ROUTV
University of Helsinki virus 1 UHV-1
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Figure 1.2: Phylogenetic Tree of the Arenaviridae Family 50 species from the
Arenaviridae family were organised into a phylogenetic tree based on the L polymerase
amino acid sequence. The species cluster into the four genera; Antennavirus (blue),
Hartmanivirus (green), Reptarenavirus (yellow) and Mammarenavirus (red). There
are also two unclassified virus species (blue rings). The tree was assembled by
(Radoshitzky et al., 2019) and was mid-point rooted and visualised using FigTree
(http://tree.bio.ed.ac.uk).
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The Mammarenavirus genus comprises all the arenaviruses which have a mammalian
host. Mammarenaviruses have a negative-sense RNA genome, which is bisegmented
and encodes four proteins (L polymerase [LP], nucleocapsid protein [NP], the
glycoprotein complex [GPC] and the Z matrix protein [ZP]) in an ambisense
orientation, whereby LP and NP are transcribed from the negative-sense
virion-associated RNA (vRNA) and GPC and ZP are transcribed from the
positive-sense replicate of the vRNA (complement RNA; cRNA). The species
in the Mammarenavirus genus are organised into Old World (Lassa-lymphocytic
choriomeningitis serocomplex) and New World (Tacaribe serocomplex) groups. The
New World group is further classified into four lineages; clades A, B, C and
A/Recombinant (tentatively named D) (table 1.2). The Mammarenavirus genus
has been traditionally organised into these groups since the late 1970s, based
on serological analysis, geographical distribution and host association (Matthews,
1979). Subsequent phylogenetic analysis of the viral genes has supported this
organisation (Radoshitzky et al., 2015). Viruses in clade D have been formed
through recombination events between the arenaviruses. The S segments of clade
D arenaviruses appear to have a chimeric origin, with an NP sequence most closely
related to clade A arenaviruses and a GPC sequence most closely related to clade B
arenaviruses (Archer and Rico-Hesse, 2002; Charrel et al., 2001, 2002; Fulhorst et al.,
2002). Xapuri virus (XAPV; Brazil; 2015 (Fernandes et al., 2018)) was recently
assigned to the New World group but phylogenetic analysis could not assign this
virus to a clade. Phylogenetic analysis of the S segment, and the GPC sequence,
revealed that it was most closely related to clade C viruses, whereas analysis of the L
segment, and the NP, LP and ZP amino acid sequences, showed it was most closely
related to viruses within clade B (Fernandes et al., 2018). Therefore, it was placed
between clades B and C and it is thought that XAPV could be the first natural
reassortant of the mammarenaviruses (Fernandes et al., 2018).
In 2015, the Arenaviridae family was extended by the creation of the Reptarenavirus
genus, after the discovery of several novel arenaviruses in captive snakes exhibiting
boid inclusion body disease (BIBD) (Stenglein et al., 2012; Bodewes et al.,
2013; Hetzel et al., 2013). These reptarenaviruses had the distinctive arenavirus
genome organisation, including the canonical ambisense orientation of the four
mammarenavirus open reading frames, as well as the characteristic non-translated
8
CHAPTER 1. INTRODUCTION TO THE ARENAVIRUSES
gene regulatory elements. However, the reptarenaviruses were quite divergent from
the mammarenaviruses in terms of sequence, with low overall homology between
the amino acid sequences of NP (23-26 %) and LP (17-19 %) (Stenglein et al.,
2012). In contrast, the reptarenaviruses were quite similar to each other, with NP
and LP sequences exhibiting 55 % and 50 % identity, respectively (Stenglein et al.,
2012) and thus supporting the establishment of an independent phylogeny, and
new genus within the Arenaviridae family. The reptarenaviruses were even more
divergent from the mammarenaviruses in the ZP sequence (16 %) ((Stenglein et al.,
2012; Pontremoli et al., 2019)) and the reptarenavirus GPCs did not contain the
structural features commonly associated with mammarenavirus GPCs. Interestingly
though, the reptarenavirus GPCs shared a higher homology with the glycoproteins
of filoviruses (e.g. Ebola virus) (Stenglein et al., 2012; Garry and Garry, 2019)
suggesting a potential common ancestor virus of the Arenaviridae and Filoviridae
families. Cryo-electron tomographic 3D reconstruction of the University of Helsinki
virus (UHV) glycoproteins further supported this assertion, revealing structural
homology between the reptarenavirus glycoprotein and Ebola virus glycoprotein,
and striking differences between the UHV glycoprotein and the LASV glycoprotein
(Hetzel et al., 2013; Li et al., 2016).
The Hartmanivirus genus was formed in 2018 (Maes et al., 2018) after pairwise
sequence comparison (PASC) analysis on the BIBD-isolates suggested one of the
novel reptarenaviruses, Haartman Institute snake virus (HISV), was sufficiently
distant from the other reptarenaviruses to represent a new genus (Hepojoki
et al., 2015, 2018). Next generation sequencing analysis and de novo sequence
assembly revealed further information about the HISV1 isolate and identified three
additional novel species (Hepojoki et al., 2018). Extensive sequencing revealed
that hartmaniviruses possessed S and L segments, but that the L segment only
encoded the LP, so these viruses did not appear to express a ZP (Hepojoki et al.,
2018; Garry and Garry, 2019). Unlike members in the Reptarenavirus genus, the
hartmanivirus glycoproteins share many of the proposed structural motifs present
within the mammarenavirus glycoproteins (Hepojoki et al., 2018). There was
also higher sequence homology between the hartmanivirus glycoprotein and the
mammarenavirus glycoprotein (23 %), as opposed to 16 % when reptarenavirus
Golden Gate virus (GGV) and LCMV were compared (Hepojoki et al., 2018; Garry
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and Garry, 2019). Also, unlike reptarenaviruses, hartmaniviruses have not as yet
been associated with any pathological effect in snakes (Hepojoki et al., 2018).
The Antennavirus genus is the most recently established genus of the Arenaviridae
family (Abudurexiti et al., 2019) and their discovery resulted from a large
metatranscriptomic study that identified hundreds of novel RNA viruses present
in cold-blooded vertebrates (Shi et al., 2018), of which two were novel arenaviruses,
infecting frogfish (Antennarius striatus) (Shi et al., 2018). Not only was this
another expansion in the host range of the arenaviruses, but it represented the
first arenaviruses with three RNA genomic segments instead of two. Antennaviruses
have a negative-sense S segment, encoding the NP ORF; a negative-sense L segment,
encoding the LP ORF; and an additional ambisense M segment, encoding the
GPC ORF and a protein of unknown function (Shi et al., 2018; Garry and Garry,
2019). Similarly to members of the Hartmanivirus genus, antennaviruses do not
encode a ZP. The antennaviruses were placed into the Arenaviridae family after
sequence homology was found between the antennavirus NP and LP sequences
and hartmanivirus NP and LP sequences (Shi et al., 2018; Pontremoli et al.,
2019). Whilst the antennavirus GPC did not share sequence homology with
arenavirus GPCs, it did share predicted structural motifs with mammarenaviruses
and hartmaniviruses, but not reptarenaviruses (Garry and Garry, 2019).
1.1.4 Hosts and Transmission
Hosts of Arenaviruses
Each mammarenavirus is associated with a single or a small number of specific rodent
reservoir hosts, except for TCRV. Generally, the reservoir hosts of any given virus
are defined as animals or plants that permit persistence of an infectious agent in the
environment, but do not typically experience disease upon infection (Salazar-Bravo
et al., 2002). The rodent species with which each arenavirus is associated has been
listed in table 1.2. The close association between rodent hosts and arenaviruses is
thought to determine the geographic distribution of the arenaviruses. Nearly all
the rodent host species of mammarenaviruses are classified within the Muroidea
superfamily. The majority of Old World mammarenaviruses are associated with
rodent species classified within Family: Muridae; Subfamily: Murinae, with the
10
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exception of Alxa virus (associated with rodent species classified within the sister
Superfamily: Dipodoidea; Family: Dipodidae; Subfamily: Dipodinae), Mariental
and Okahandja viruses (associated with rodent species classified only within the
Muridae family) and Wēnzhōu virus (associated with one rodent species that is
classified within Family: Soricidae). New World mammarenaviruses are associated
with rodent species classified within Family: Cricetidae; Subfamily: Sigmodontinae,
with the exception of viruses in clade D, which are associated with rodent species
classified within Family: Cricetidae; Subfamily: Neotominae. Some arenaviruses,
such as MOPV and LASV, share rodent hosts. This can be beneficial to humans
living in regions that are endemic for MOPV, because infection with MOPV can
offer cross-protection for LASV, resulting in fewer cases of Lassa fever in that region
(Zapata and Salvato, 2013).
TCRV is the only arenavirus which has never been associated with any rodent
host. It was first isolated from fruit bats (Artibeus spp.) in Trinidad during a
surveillance programme for rabies virus (Downs et al., 1963). It was also initially
isolated from mosquitoes (Downs et al., 1963), although subsequent attempts to
repeat this feat have proven unsuccessful (Sayler et al., 2014; Salazar-Bravo et al.,
2002). Since its discovery, all attempts to identify a rodent host for TCRV have
failed (Downs et al., 1963; Sayler et al., 2014). Bats were then proposed to be the
natural reservoir of TCRV, but this has since been disputed (Cogswell-Hawkinson
et al., 2012). There is serological evidence of TCRV infection in Artibeus bats, but
there is no evidence it causes a persistent infection, suggesting bats are not the
reservoir hosts (Malmlov et al., 2017). It has also been suggested that TCRV causes
a fatal infection in bats (Cogswell-Hawkinson et al., 2012). It has subsequently been
suggested that the reservoir host may be lone star ticks (Amblyomma americanum),
giving the only known arthropod host of the arenaviruses (Sayler et al., 2014).
Subsequent metatranscriptomic studies in arthropod hosts have not revealed any
novel arenaviruses associated with arthropods (Shi et al., 2016). The natural hosts of
reptilian arenaviruses have not been identified because they have only been detected
in captive snakes and are associated with disease (Hetzel et al., 2013; Hepojoki et al.,
2015, 2018; Stenglein et al., 2012).
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Arenavirus Infection in Rodents
Arenavirus infection in rodent host species typically manifests as persistent and
sub-clinical, with few negative effects on the rodent. It has been suggested that
infection can result in decreased size, reduced fertility and increased mortality, but
this is dependent on host genetics and virus strain (Vitullo et al., 1987; Vitullo and
Merani, 1988; Borremans et al., 2011; Zapata and Salvato, 2013). The majority
of the time, arenavirus infection of the host species will present as asymptomatic,
with high viral titres present in body fluids, including urine, faeces, blood and
saliva (Zapata and Salvato, 2013; Salazar-Bravo et al., 2002). This mediates the
horizontal transmission of arenaviruses throughout the rodent population, by close
physical contact, inhalation of aerosolised body fluids and bites (Tagliapietra et al.,
2009; Sarute and Ross, 2017; Milazzo et al., 2011). Arenaviruses can also be
vertically transmitted, which has been proposed to be a factor for establishing
chronic infections (Skinner and Knight, 1974; Tagliapietra et al., 2009; Milazzo et al.,
2011). It is thought that because the rodent pups are born with the infection, an
effective immune response is never mounted due to recognition of the viral antigens
as self, leading to a chronic, life-long infection (King et al., 2018).
Arenaviruses are proposed to persist in chronically-infected rodents during periods
of low rodent population density (Mariën et al., 2020a; Milazzo et al., 2011). In
order to persist, the arenaviruses must not overrun the host because that could
lead to immune detection and viral clearance. Therefore, LCMV, in particular,
restricts its spread by cycling through periods of acute, productive infection and
persistent, non-productive infection (King et al., 2018). Using a cell-culture
model of persistent infection and fluorescent detection of single RNA molecules,
it was found that the LCMV-infected cells cycle through periods of active viral
replication and transcription and periods where viral RNA could no longer be
detected (King et al., 2018). This cyclical loss and accumulation of viral RNA
and viral antigens has also been shown in vivo (Francis and Southern, 1988).
How arenaviruses are able to regulate this is unknown, but several models have
been proposed involving defective interfering particles or replication-competent but
transcription-incompetent genomes (King et al., 2018). Specific residues have been
identified in different strains of LCMV, namely the Armstrong strain (LCMV-ARM)
and its derivative Clone-13 (LCMV-Cl13), which have been attributed to the
14
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establishment of either an acute (LCMV-ARM; F260 in GPC and K1079 in LP) or
persistent (LCMV-Cl13; L260 in GPC and Q1079 in LP) infection (Grande-Pérez
et al., 2016; Zapata and Salvato, 2013).
Arenavirus Transmission to Humans
Accidental exposure to humans and other mammals (including non-human primates)
can occur through; disturbance, aerosolisation and subsequent inhalation of rodent
excreta; ingestion of contaminated food or water; rodent bites; direct contamination
of blood during handling of infected bush meat; or ingestion of infected bush meat
(Ogbu et al., 2007; Sarute and Ross, 2017; Mariën et al., 2020b; Milazzo et al., 2011).
Transmission of arenaviruses from rodents to humans typically happens when the
rodents’ natural habitats have been disturbed by changes in agricultural practices or
extreme weather (Sarute and Ross, 2017; Charrel and de Lamballerie, 2010). The
disturbance in habitat leads to the establishment of new territories, which could
increase access to humans, their homes or their food stocks. During rainy seasons,
there is also a sudden increase in the rodent population, which leads to territory
expansion and increased contact with humans in addition to increased arenavirus
transmission within the rodent population (Tagliapietra et al., 2009; Sarute and
Ross, 2017). Furthermore, there is the potential for arenavirus infections in scientists
that handle the infected rodents in either the field or in a laboratory setting, and for
agricultural workers who can encounter infected rodents in the field (Ogbu et al.,
2007; Charrel and de Lamballerie, 2010).
Arenaviruses can also be transmitted between humans. Nosocomial transmission
is common with haemorrhagic fever-causing arenaviruses, posing a high risk
to healthcare workers (Milazzo et al., 2011; Kernéis et al., 2009). This was
demonstrated by the emergence of Lujo virus in 2008, which resulted in the death of
four of the five infections, four of which were healthcare workers (Briese et al.,
2009). Nosocomial transmission is common because of the high viral titre in
bodily fluids and the lack of proper preventative measures, including personal
protective equipment (PPE) and patient isolation (Ogbu et al., 2007; Sandige, 2018).
Arenaviruses, specifically LASV and LCMV, can also be vertically transmitted
between mother and fetus. LASV can result in a high mortality of both the mother
and the fetus, whereby mortality is higher for women infected in a later trimester
15
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(30 % as opposed to 7 % in the earlier trimester) and higher for fetuses infected
in an earlier trimester (92 % as opposed to 75 % in the later trimester) (Ogbu
et al., 2007; Price et al., 1988). There is also a 100 % fatality rate in neonates
(Ogbu et al., 2007; Price et al., 1988). There is a high concentration of LASV in the
fetal and placenta tissues and it is thought that this is the result of a lack of MHC
presentation by these tissues, so the mother’s immune system cannot attack these
infected cells (Ogbu et al., 2007). LCMV infection in pregnant women can often be
passed transplacentally to the fetus, causing fetal death and significant congenital
deformities (Bonthius, 2012; Wright et al., 1997; Barton and Hyndman, 2000; Barton
and Mets, 2001). It has even been shown that there can be sexual transmission of
arenaviruses, including LASV and LCMV, due to the persistence of the virus in
semen for many months after symptoms have disappeared (Raabe et al., 2017a;
Ogbu et al., 2007; Trapecar et al., 2018). Finally, LCMV can also be transmitted
between humans through organ transplantation; the recipient can become infected if
the organ donor was asymptomatically infected with LCMV (Sarute and Ross, 2017;
Fischer et al., 2006). The recipient receives immunosuppressive therapy in order to
prevent transplant rejection, rendering the recipient vulnerable to a haemorrhagic
fever-style LCMV infection (Peters, 2006; Fischer et al., 2006). Typically, in LCMV
infections derived from organ transplantation, the fatality rate is very high, as is
transplant rejection (Fischer et al., 2006).
1.1.5 Geographical Distribution
Arenaviruses are present in distinct geographical regions and rarely establish
infections outside these regions. This is because the geographical distribution
of the arenaviruses is limited to the range of the host rodent and unless a new
rodent territory is established, then the arenavirus will not persist outside that
range. Broadly speaking, Old World arenaviruses are located in Africa, while New
World arenaviruses are found predominantly in South America, with the clade D
arenaviruses being found in North America. LCMV has a worldwide distribution
due to the worldwide distribution of its rodent host, Mus musculus. Some recently
discovered Old World arenaviruses were identified in Asia, suggesting another
location of arenavirus distribution. A map showing the geographic distribution
of the arenaviruses has been shown in figure 1.3. The geographic distribution of
16
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each mammarenavirus species has also been listed in table 1.2.
New World Arenaviruses – A  New World Arenaviruses – B New World Arenaviruses – C
New World Arenaviruses – D Old World Arenaviruses
Figure 1.3: Geographic Distribution of the Mammarenaviruses by Country.
Members of the Old World group of mammarenaviruses (pink) are predominantly found
in African countries, with some species endemic in China. Members of the New World
group of mammarenaviruses (blue) are predominantly found in South American countries,
with some species endemic in the USA. This figure was created using information from
(Radoshitzky et al., 2015; Fehling et al., 2012; Sarute and Ross, 2017; Li et al., 2015; Maes
et al., 2018; Howley and Knipe, 2020).
Whilst arenavirus distribution rarely exceeds that of the rodent host, the distribution
of arenaviruses does not necessarily cover the entirety of the rodent host distribution
(Gryseels et al., 2017). For example, the rodent host Mastomys natalensis has a very
broad distribution spanning sub-Saharan Africa, yet LASV infections have not been
detected beyond the east of Nigeria (Gryseels et al., 2017). Furthermore, there are
other arenaviruses which infect Mastomys natalensis but the regions occupied by
these arenaviruses do not overlap (Gryseels et al., 2017). This is proposed to be due
to the actual rodent host being a sub-taxon of the species level of rodent (Gryseels
et al., 2017).
1.1.6 Pathogenesis and Disease
Humans generally acquire mammarenavirus infections through close contact with
excreta from or directly with an infected rodent. Infections can also be transmitted
directly between humans, either in nosocomial settings, during pregnancy or
through organ donation. The severity of arenavirus infections in humans ranges
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from asymptomatic infections to highly fatal haemorrhagic fever. The primary
mammarenaviruses responsible for causing human disease include Old World
mammarenaviruses LCMV and LASV and New World clade B mammarenaviruses
JUNV, Machupo virus (MACV), Chapare virus (CHPV), Guanarito virus (GTOV)
and Sabiá virus (SBAV).
LCMV and Meningitis
In immunocompetent adults, LCMV generally causes asymptomatic infections, or
can result in mild "flu-like" symptoms (Lapošová et al., 2013). Occasionally, LCMV
infection can result in aseptic meningitis and meningoencephalitis, with symptoms
that include a fever, headache, stiff neck, nausea, confusion and motor-sensory
abnormalities. However, LCMV rarely causes fatality in immunocompetent adults
(Lapošová et al., 2013; Shao et al., 2015).
In immunocompromised individuals or developing fetuses, LCMV infection can
result in serious disease, which carries high morbidity and high fatality rates (McLay
et al., 2014). If an LCMV infection is acquired during pregnancy, it often severely
affects the fetus, resulting in fetal death or severe, permanent visual and neurological
defects (Shao et al., 2015; Labudova et al., 2009). Patients are also at risk of LCMV
infection through organ donation, due to being temporarily immunosuppressed.
LCMV infection in organ recipients can result in graft dysfunction, encephalopathy,
multi-system organ failure and death (Goldsmith et al., 2013).
Old World Haemorrhagic Fevers
LASV is endemic in West Africa and causes approximately 300,000 infections
annually, with a mortality rate of 1 % (Rojek et al., 2007). Roughly 80 % of LASV
infections result in mild symptoms, including a slight fever, malaise and headache,
and are undiagnosed. However, 20 % of LASV infections can progress to the
development of Lassa fever, a highly fatal haemorrhagic fever, which is characterised
by a high fever, "flu-like" symptoms, respiratory distress, oedema, shock, seizures,
mucosal bleeding, multi-system organ failure, coma and death (Shao et al., 2015;
Goncalves et al., 2013). The liver is commonly affected in LASV infection, resulting
in hepatitis (Shao et al., 2015; McCormick et al., 1986a).
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A percentage of LASV survivors also experience neurological symptoms after
recovery, including tremors and encephalitis (Shao et al., 2015). On average,
approximately 30 % of LASV survivors experience sudden, spontaneous deafness
in one or both ears, which is thought to be the result of lesions in the inner
ear that could occur during the course of the disease (Cummins, 1990; Mateer
et al., 2018b; Okokhere et al., 2009). It remains to be determined whether the
lesions occur as a result of direct viral damage or through immune cell-mediated
damage (Cummins, 1990; Mateer et al., 2018b; Li et al., 2020). Ophthalmic
manifestations have also been shown to occur during the course of Lassa fever,
including conjunctivitis, conjunctival oedema, uveitis, and in poorer prognosis cases,
subconjunctival haemorrhage (Li et al., 2020). Studies using guinea pigs as models
for LASV infection revealed the presence of LASV RNA and antigens in the eye,
and the initiation of an inflammatory response in the eye during acute disease
(Gary et al., 2019). Ophthalmic disease has also presented in Lassa fever survivors,
including cataract formation (18 %), retinal disease (13 %) and glaucoma (6 %),
which can result in vision impairment and blindness (Li et al., 2020).
In 2008, there was the emergence of LUJV, another Old World mammarenavirus
which caused haemorrhagic fever (Briese et al., 2009). Whilst there were only five
cases of LUJV infection, it caused a severe haemorrhagic fever that resulted in death
for 4 out of the 5 cases (Briese et al., 2009). The symptoms of Lujo haemorrhagic
fever resembled those of Lassa fever, although bleeding was not prominent. Death
from Lujo haemorrhagic fever was associated with rapid deterioration, neurological
symptoms, respiratory distress and circulatory collapse (Shao et al., 2015; Sizikova
et al., 2017).
New World Haemorrhagic Fevers
Five New World mammarenaviruses (JUNV, MACV, CHPV, GTOV and SBAV),
all classified within clade B, cause haemorrhagic fever in humans (Martinez et al.,
2013; Wolff et al., 2013a). JUNV is endemic in Argentina and infection can
cause a mild illness, with "flu-like" symptoms and petechial haemorrhage, or
a severe haemorrhagic fever, which results in severe shock, seizures, coma and
death (Wolff et al., 2013b). Haemorrhagic fevers caused by MACV, CHPV,
GTOV and SBAV have many different symptoms, including "flu-like" symptoms,
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mucosal petechial haemorrhage, conjunctivitis, haematuria, respiratory distress,
haemorrhaging and necrosis in the liver and gastrointestinal system, coma and shock
(McLay et al., 2014). Unlike LASV, haemorrhagic fevers caused by the New World
mammarenaviruses rarely include hepatitis as a symptom, but typically include
neurological complications (Shao et al., 2015; McLay et al., 2014)
1.1.7 Therapeutic and Preventative Measures
There are a few measures available for the treatment or prevention of arenavirus
infection, but they have limited efficacy and potential toxic side effects. These
measures also require correct and rapid diagnosis early in infection, which may not
be possible if the patient is unaware of infection until severe symptom development.
One of the most important strategies available to manage symptoms of haemorrhagic
fever is supportive therapy (Howley and Knipe, 2020). This involves rest, sedation,
hydration, pain relief and avoidance of intramuscular injections and blood-thinning
drugs such as aspirin. Platelet transfusions and replacement of blood clotting factors
can help relieve some symptoms of haemorrhagic fever (Howley and Knipe, 2020).
The early stages of arenavirus haemorrhagic fever correspond with low viraemia and
therefore minimal spread. However, later stages present higher viraemia, posing a
risk for nosocomial spread, especially to hospital staff treating patients with severe
haemorrhagic fever (Carey et al., 1972). Exposure to the virus is most dangerous
during parenteral (intramuscular, intravenous and sub-cutaneous) administration of
treatment. Other than that, PPE can help protect against aerosols and bodily fluids.
Another way to limit spread is to monitor for fever development in the patients’ close
contacts for 3 weeks. The patients’ bodily fluids should also be evaluated for viral
infectivity before release. Furthermore, advice can be given to the patient to use
contraceptive methods to prevent spread through sexual transmission.
Potential Treatments
To date, there are no licensed treatments available for arenavirus infections.
Therapies that are used include the nucleoside analog ribavirin and antibody
therapy, but these are not licensed due to toxic side effects. The efficacy of these
treatments also relies on being administered early in infection, requiring correct and
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rapid diagnosis, which is difficult in areas that are endemic for other diseases that
present with similar symptoms (such as malaria, influenza, dengue, yellow fever and
Ebola virus disease) (Raabe and Koehler, 2017b).
Ribavirin is therapeutically effective against several arenaviruses in both cell culture
and arenavirus haemorrhagic fever animal models, and it has lowered morbidity
and mortality when given to humans with Lassa fever (Jahrling et al., 1980;
Kenyon et al., 1986a; Kilgore et al., 1997; Sayler et al., 2014; Shtanko et al.,
2010). However, ribavirin has optimal efficacy through intravenous delivery, which
should typically be avoided for haemorrhagic fever patients. Furthermore, ribavirin
poorly penetrates the cerebrospinal fluid (CSF), reducing its efficacy targeting the
arenaviruses replicating in the central nervous system (CNS). Ribavirin also presents
several serious side effects, including anaemia, liver damage and congenital disorders,
exacerbating symptoms of arenavirus infection (McCormick et al., 1986b; Shao et al.,
2019; Howley and Knipe, 2020). The mechanism of action of ribavirin is poorly
understood, but it is thought to target multiple arenavirus lifecycle stages (Parker,
2005). Ribavirin remains the choice of therapeutic agent for the treatment of poor
prognosis Lassa fever, and has also been shown to be effective in humans infected
with JUNV, MACV and SBAV (Enria and Maiztegui, 1994; Barry et al., 1995;
Kilgore et al., 1997). Prophylactic treatment with ribavirin is able to delay (when
administered for 7-10 days) or even prevent (when administered for 14 days) the
onset of acute disease in guinea pigs infected with PICV, LASV or JUNV, but its
inability to penetrate the CSF meant JUNV was able to enter and replicate within
the CNS and cause fatal encephalitis (Lucia et al., 1989; Shtanko et al., 2010; Kenyon
et al., 1986a). Prophylactic therapy with ribavirin is successfully used to treat the
close contacts of an infected patient, if they present with fever.
Several other anti-arenaviral compounds have been identified using in vitro
high-throughput screening, but they have yet to be clinically trialled for their
efficacy and safety in vivo (Mills et al., 1994). These compounds target multiple
arenavirus lifecycle stages, including GPC fusion (ST-193; (Larson et al., 2008))
and RNA replication and transcription (targeting the RdRp; favipiravir; (Gowen
et al., 2013; Furuta et al., 2017; Mendenhall et al., 2011; Safronetz et al., 2015)).
Two types of drug can be identified in anti-arenaviral compound screens; direct
acting antivirals (DAAs), which target the virus specifically, or host-targeting
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antivirals (HTAs), which reduce availability or functionality of host machinery to
the virus. The DAAs are typically well tolerated by the host, with few side-effects,
but targeting the virus directly can trigger evolution and selection of resistant
viral variants. Favipiravir (T-705; 6-fluoro-3-hydroxy-2-pyrazinecarboxamide) is a
selective inhibitor of multiple viral polymerases (including arenaviruses), due to the
high conservation of the viral polymerase active site (Furuta et al., 2017). The
compound becomes phosphoribosylated in the cell, whereby it is recognised as a
substrate by the viral polymerase and inhibits the RdRp activity. Favipiravir has
shown in vitro inhibition of JUNV, GTOV, MACV, LASV, TCRV and PICV (Furuta
et al., 2017; Mendenhall et al., 2011; Gowen et al., 2013; Safronetz et al., 2015). On
the other hand, HTAs do not present such an evolutionary pressure on the virus and
can potentially be effective for multiple arenaviruses, but they can have serious side
effects on the host. PF429242 is a small molecule inhibitor of host SKI-1/S1P, which
successfully prevented the arenavirus GPC processing and was able to inhibit LCMV
and LASV infection in vitro (Kunz et al., 2002; Pasquato et al., 2012; Rodrigo et al.,
2012; Rojek et al., 2008a; Urata and Yasuda, 2015).
An alternative treatment to antiviral compounds is to use convalescent plasma.
This method has been successful in the treatment of JUNV infections, reducing
the mortality rate from 15-30 % to 1-2 % when the treatment was administered
within the first 8 days (Enria et al., 1984; Maiztegui et al., 1979). However, this
treatment can result in a self-limited neurological syndrome that develops 3-6 weeks
after treatment and includes symptoms of fever, headache, tremor and cranial nerve
palsies (Howley and Knipe, 2020). Animal studies have also shown that antibody
therapy could also be effective for the treatment of LCMV, LASV, MACV, GTOV
(Baldridge and Buchmeier, 1992; Baldridge et al., 1997; Whitmer et al., 2018; Cross
et al., 2016; Jahrling et al., 1984,b; Eddy et al., 1975; Kenyon et al., 1986b). However,
antibody therapy requires a high concentration of virus-specific antibodies, which
can be difficult to acquire (Maiztegui et al., 1979; Djomand et al., 2014). It also
poses a problem in endemic regions where HIV-1 and malaria are also prevalent
(Maiztegui et al., 1979; Djomand et al., 2014).
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Arenavirus Vaccines
The only vaccine that has been successfully developed for the arenaviruses is Candid
#1, which is extremely effective against JUNV. The Candid #1 strain was generated
through serial passage of the JUNV XJ strain. After demonstrating the safety and
efficacy in pre-clinical studies of guinea pigs and rhesus monkeys (McKee, Jr. et al.,
1992), the vaccine was successfully trialled in agricultural workers in areas endemic
for JUNV in Argentina (Maiztegui et al., 1998). Candid #1 has been licensed, but
only for use in Argentina. There are some concerns about the limited understanding
of the mechanisms behind attenuation of the Candid #1 strain and the potential
development of virulent strains (Enria and Barrera Oro, 2002).
Due to the high morbidity, mortality and a large population at risk, LASV has
been placed on the revised list of diseases considered to be a priority for vaccine
development by the World Health Organisation (Bausch et al., 2004; Sewlall et al.,
2014). However, the vaccine has to be inexpensive, highly effective, stable at
multiple temperatures and user-friendly. Many LASV live-attenuated vaccines are in
pre-clinical trials in non-human primates (Howley and Knipe, 2020). One vaccine,
based on a measles virus vector, showed sufficient antibody-based protection in
human clinical trials (Raju et al., 1990). The recombinant VSV (rVSV)-based LASV
vaccine, where the G protein of VSV is replaced with the LASV GPC, has also shown
promising development but there are some safety concerns (Geisbert et al., 2005;
Safronetz et al., 2010; Huttner et al., 2017). Another live-attenuated LASV vaccine
showing promise in pre-clinical development is ML29, which is a reassortant virus
comprising the L segment from the non-pathogenic MOPV and the S segment from
LASV (Carrion et al., 2007; Lukashevich et al., 2005).
1.2 The Structure of Arenavirus Virions
Arenavirus virions are generally spherical or pleomorphic, with sizes ranging between
40 nm to 300 nm in diameter (Murphy et al., 1969, 1970) although with a mean
diameter of typically between 80 nm and 150 nm (Dalton et al., 1968; Mannweiler
and Lehmann-Grube, 1973; Murphy and Whitfield, 1975; Neuman et al., 2005;
Hetzel et al., 2013; Li et al., 2016). Mammarenaviruses are enveloped with a
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A B
Figure 1.4: Schematic of the Mammarenavirus Virion.
(A)The genomic segments are tightly encapsidated by the nucleocapsid protein (NP; light
blue) and coupled with the viral RNA-dependent RNA polymerase (LP; yellow) to form
the ribonucleoprotein (RNP) complex. The Z matrix protein (ZP; orange) oligomerises
to form a matrix layer on the inner side of the viral envelope. Glycoprotein spikes (GPC;
teal) embed the viral envelope, present in a trimeric organisation. This figure was created
using BioRender. (B) Cryo-electron microscopic image of purified arenavirus virions. The
viral membrane can be seen, with surface projections corresponding to the GPC. The
interior density is too disordered to identify RNP complexes. The scale bar indicates 100
nm. The images were obtained from (Salvato et al., 2011).
host cell-derived membrane, which is studded with randomly distributed surface
projections that are spaced approximately 90 nm apart and are approximately
5-10 nm long (Murphy et al., 1970; Howard and Young, 1984; Li et al., 2016).
Furthermore, there is an additional density beneath the membrane, proposed to be
a layer formed of the ZP (Li et al., 2016; Hetzel et al., 2013). The viruses also
appear to contain homogeneous, electron-dense granules, which are approximately
20-25 nm in diameter (Young and Howard, 1983). These granules were proposed
to be ribosomes derived from the host cell, due to sharing similar density and
sedimentation characteristics. Furthermore, 28S and 18S ribosomal RNAs were
present within virus preparations (Murphy et al., 1970; Pedersen and Konigshofer,
1976). However, the inclusion of ribosomes within arenavirus virions has been
subject to dispute, with the suggestion that the granule-containing viruses represent
non-infectious viruses (Müller et al., 1983). It has also been proposed that the
putative viral-associated ribosomes differ structurally and biochemically from host
cell-associated ribosomes (Dalton et al., 1968; Mannweiler and Lehmann-Grube,
1973).
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1.3 Introduction to the Viral Genome
All arenaviruses have a segmented, negative-sense RNA genome present
in the virions (virus-associated RNA; vRNA). For the mammarenaviruses,
reptarenaviruses and hartmaniviruses, the genome is divided into two segments,
whereas the antennavirus genome is divided into three segments. In the
mammarenaviruses and reptarenaviruses, the two segments are termed small (S;
approximately 3.5 kb) and large (L; approximately 7.2 kb) and direct the expression
of four viral proteins; the nucleocapsid protein (NP) and the glycoprotein complex
(GPC) from the S segment and the L polymerase (LP) and the Z-matrix protein
(ZP) from the L segment (figure 1.5A). The hartmanivirus genome is similar, except
the L segment does not encode for the Z-matrix protein (figure 1.5A). The three
antennavirus genome segments are termed small (S), medium (M) and large (L) and
direct expression of the NP, GPC and LP, respectively (figure 1.5A). Additionally,
the antennavirus M segment directs expression of a protein with an unknown
function. With the exception of the hartmanivirus L segment and the antennavirus
S and L segments, the arenavirus genomic segments utilise an ambisense coding
strategy (figure 1.5B), which means that proteins are expressed from both the
vRNA and the positive-sense replicate (complementary RNA; cRNA), strand. For
the mammarenavirus and reptarenavirus S segment, the messenger RNA (mRNA)
transcribed from the vRNA encodes NP, whereas the mRNA transcribed from
the cRNA encodes GPC (figure 1.5). Similarly, for their L segment, the mRNA
transcribed from the vRNA encodes LP, whereas the mRNA transcribed from the
cRNA encodes ZP (figure 1.5). The antennavirus M segment expresses its GPC
from the vRNA and the unknown protein from the cRNA.
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Figure 1.5: Schematic of the Arenavirus Genomes and the RNA Synthesis
Strategy.
(A) The genomic segments (vRNA; S and L) of mammarenaviruses and reptarenaviruses
direct the expression of four viral proteins; the nucleocapsid protein (NP) and
the glycoprotein complex (GPC) from the S segment and the RNA-dependent
RNA-polymerase (LP) and the Z-matrix protein (ZP) from the L segment. The vRNA is
flanked by untranslated regions (UTR) and the viral genes are separated by the intergenic
region (IGR), which is proposed to form a stem loop structure. The hartmanivirus
genomic segments (vRNA; S and L) direct the expression of three viral proteins; NP
and GPC from the S segment and LP from the L segment. The antennavirus genomic
segments (vRNA; S, M and L) direct the expression of four viral proteins; NP from the S
segment, GPC and an unknown protein from the M segment and LP from the L segment.
The arenavirus genomic segments (mammarenavirus S and L, reptarenavirus S and L,
hartmanivirus S and antennavirus M) utilise an ambisense coding strategy (B). The genes
in blue (NP, LP, and the unknown) are transcribed into mRNA from the vRNA by the
arenavirus LP. Transcription is terminated by the signals in IGR, which form a stable stem
loop structure. The vRNA is replicated by the arenavirus LP to form a positive-sense
intermediate (cRNA). The genes in red (GPC and ZP) are then transcribed into mRNA
from the cRNA by the arenavirus LP. This figure was created using BioRender.
The open reading frames in the mammarenavirus and reptarenavirus segments are
non-overlapping and they are separated by the intergenic region (IGR). The IGR is
predicted to fold into a stable stem loop, the structure of which acts as a transcription
termination signal for the LP. Transcription termination is thought to be mediated
by a structural motif as opposed to sequence motifs due to termination occurring at
multiple sequences present throughout the IGR stem (Meyer et al., 2002). Although
all arenaviruses contain IGR sequences, there is no conservation of either sequence
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or predicted structure, except between isolates of the same arenavirus. Some
arenaviruses, such as TCRV and MOPV, even contain an IGR that is predicted
to fold into two distinct stem loop structures (Meyer et al., 2002). The molecular
switch for replication and transcription mediated by the LP is not known, although
the transcription termination signal is ignored when the LP is replicating, allowing
complete replication of the genome.
The 3’ and 5’ termini of the vRNA and cRNA contain untranslated regions (UTRs)
that are present upstream and downstream of the viral protein open reading frames.
Whilst the lengths, sequences and predicted structures of the UTRs do not appear
conserved throughout the Arenaviridae family, the terminal 19 nucleotides are
completely conserved and are complementary between the 3’ and 5’ UTRs. The
complementarity of the terminal nucleotides is responsible for the formation of
partially double-stranded RNA secondary structure, known as a panhandle, driven
by non-covalent inter-terminal interactions, leading to pseudo-circularisation of the
segment (figure 1.4A). These terminal nucleotides are also proposed to contain the
vRNA (3’) and cRNA (5’ complement) promoters for LP and mutations within
this region cannot be tolerated by the mini-genome assay (Perez and de la Torre,
2003a). For several arenaviruses, it has also been reported that there is an additional,
non-templated G residue that is present at the 5’ end of the vRNA (Garcin and
Kolakofsky, 1990, 1992).
1.4 Introduction to the Viral Proteins
1.4.1 Nucleocapsid Protein
The nucleocapsid protein (NP) is responsible for encapsidating the RNA segments in
a complex known as the ribonucleoprotein (RNP). The RNP is composed of multiple
copies of the NP, lining up along the RNA segment, in association with the LP. The
functions of the NP within the RNP are to form a scaffold that acts as the functional
template for RNA synthesis by the LP and to assist ZP-mediated recruitment of the
segments into newly formed viral particles (Iwasaki et al., 2015; Ortiz-Riano et al.,
2011). Furthermore, the NP is proposed to have additional functions modulating
the host cell response to infection, including counteracting the host interferon (IFN)
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and apoptotic responses and recruiting cellular factors to promote the viral lifecycle
(Martínez-Sobrido et al., 2006, 2009; Zhou et al., 2010; Pythoud et al., 2012; Baird
et al., 2013; Wolff et al., 2013b; Reynard et al., 2014; Knopp et al., 2015; Loureiro
et al., 2018; Shao et al., 2018).
Structure of Nucleocapsid Protein
The crystal structures of NPs from LASV, LCMV, JUNV, TCRV and MOPV have
been solved by several groups (figure 1.6), either as full-length structures (Qi et al.,
2010; Brunotte et al., 2011a; Hastie et al., 2011b) or as individual N-terminal and
C-terminal domains (Hastie et al., 2011a,b; Zhang et al., 2013; Jiang et al., 2013;
West et al., 2014; Yekwa et al., 2017). The N-terminal and C-terminal domains
are connected by an unstructured, flexible linker, the site of which was initially
suggested as the groove responsible for binding genomic RNA (Qi et al., 2010).
However, when the structure of the N-terminal domain was solved in complex
with single-stranded RNA, the genomic RNA binding site was proposed to be
located in a deep cavity present in the N-terminal domain (Hastie et al., 2011b)
(figure 1.6B). This N-terminal domain site was previously suggested to bind host
7-methylguanosine (M7G) cap structures but mutations of the residues proposed to
bind the cap structures resulted in an impairment of cRNA synthesis, rather than
viral transcription (Qi et al., 2010; Brunotte et al., 2011a). Furthermore, attempts to
co-crystallise LASV NP with the M7G cap or isolate LASV NP with cap-conjugated
beads failed (Hastie et al., 2011b).
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Figure 1.6: Structure of the Arenavirus Nucleocapsid Protein (A) The overall
structure of the full-length Lassa virus nucleocapsid protein (LASV NP - FL; purple; PDB:
3MWP) shown as a cartoon with its partially transparent surface, reveals the N-terminal
domain and C-terminal domain. (B) The N-terminal domain of the LASV NP (LASV;
purple; PDB: 3T5N) has been shown as a cartoon, with partially transparent surface
overlay, and as a solid surface, with RNA present in the deep, basic groove. (C) The
C-terminal domains of the LCMV NP (LCMV; pink; PDB: 4O6H), the Junín virus NP
(JUNV; green; PDB: 4K7E), the Mopeia virus NP (MOPV; blue; PDB: 5LRP) and the
Tacaribe virus NP (TCRV; red; PDB: 4GVE) have been shown as cartoons, overlaid with
a partially transparent surface. This figure was created using UCSF Chimera X.
The N-terminal domain is composed primarily of α-helices, which form "head" and
"body" regions (Hastie et al., 2011b) (figure 1.6B). Between these regions is a deep
cavity, which contains positively-charged residues that are thought to bind the
negatively-charged sugar-phosphate backbone of single-stranded RNA (Hastie et al.,
2011b). The comparison of full-length, RNA-free LASV NP and the RNA-bound,
N-terminal domain of LASV NP revealed striking structural rearrangements that
are suggested to represent a gating mechanism that regulates RNA binding (Hastie
et al., 2011b). In the RNA-free structure, α-helices 5 and 6, and their connecting
loop, block access to the RNA-binding crevice, which is stabilised by interactions
with the C-terminal domain (Hastie et al., 2011b). In the RNA-bound structure,
α-helix 5 is shortened to terminate before the RNA-binding crevice and α-helix 6
and the connecting loop are shifted away from the crevice (Hastie et al., 2011b).
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This permits access to the crevice, where residues in the loop and the crevice can
interact with the RNA (Hastie et al., 2011b).
The C-terminal domain is composed of a mixture of β-sheets and α-helices (Hastie
et al., 2011a; Qi et al., 2010; Brunotte et al., 2011b) (figure 1.6C). The five-stranded
β-sheet contains one anti-parallel strand and is surrounded by six α-helices, which
are connected by flexible loops (Hastie et al., 2011a). A zinc atom is coordinated by
residues present in the second β-strand, the sixth α-helix and the long, basic loop
which connects the fifth and sixth α-helices (Hastie et al., 2011a). The structure
of the C-terminal domain revealed a structural similarity with the characteristic
fold of exonucleases within the DEDD superfamily (Qi et al., 2010; Hastie et al.,
2011a). Exonucleases are enzymes that catalyse the cleavage of phosphodiester
bonds between nucleotides at either the 3’ or 5’ end of the nucleotide chain. Members
of the DEDD superfamily are characterised by Asp-Glu-Asp-Asp catalytic residues
in the active site, in addition to a neighbouring histidine or tyrosine, which further
sub-divides the superfamily (DEDDh and DEDDy) (Zuo and Deutscher, 2001).
The substrate for the exonuclease activity of the arenavirus NPs was identified as
double-stranded RNA (dsRNA), which is digested in a 3’-5’ direction (Hastie et al.,
2011a).
The higher-order structure of the NP within the RNP has not been fully understood.
Trimerisation of the NP is thought to occur, but this has not been proposed to
be involved with RNP formation because purified NP trimers are not associated
with RNA (Pattis and May, 2020; Brunotte et al., 2011a; Hastie et al., 2011b;
Lennartz et al., 2013; Qi et al., 2010). Currently, it is thought that NP forms
trimers during viral transcription in order to prevent RNA binding and maintain a
store of NP (Hastie et al., 2011b; Pattis and May, 2020). Upon RNA replication,
an unknown signal disassembles the NP trimer, shifting the C-terminal domain
away from the N-terminal domain and opening up the RNA-binding crevice to
enable the NP to bind newly synthesised genomic RNA (Hastie et al., 2011b; Pattis
and May, 2020). Structural analysis on the arenavirus RNPs has been limited,
although low-resolution electron microscopic studies on the RNPs within PICV
has revealed some structural understanding (Young and Howard, 1983) (figure 1.7).
This study proposed that the RNPs were flexible filaments, composed of a linear
array of multiple globular subunits, which were 4-5 nm in diameter (Young and
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Howard, 1983) (figure 1.7). These subunits folded through many intermediate
helical structures, ranging from flexible arrangements to increasingly structured
arrangements, with an increasing number of NPs per turn. These filaments ranged
between 12 and 15 nm in diameter and presented as a circular configuration
(Young and Howard, 1983) (figure 1.7). Recently, studies have been performed on
bacterially-expressed recombinant MOPV NP revealing RNP-like structures and a
heptameric organisation of the NP, the diameter of which agrees with the previously
seen RNPs (preliminary unpublished data) (Papageorgiou et al., 2020). However,
there is still little structural data to offer insight into the organisation of the NPs in
the RNP complex.
Figure 1.7: Electron Microscopy Reveals the Structural Organisation of the
Ribonucleoprotein Complexes Virus particles were purified, lysed by osmotic shock
and then negatively-stained with 2 % phosphotungstic acid, which released complexes that
were 12-15 nm in diameter. Higher order structures, including twisting and super-coiling,
were observed and had a diameter of 20 nm (arrows in (a) and (d)). Scale bars have been
included and represent 100 nm in (a), (c) and (d) and 200 nm in (b). This figure was
obtained from (Young and Howard, 1983).
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Functions of Nucleocapsid Protein
In addition to encapsidating the genomic RNA, the NP has functions within the
viral lifecycle and modulating the host cell environment, which have been described
in more detail.
Formation of Replication-Transcription Complexes
One of the functions attributed to the NP is the formation of discrete sites
of arenavirus RNA synthesis. These sites are called replication-transcription
complexes (RTCs) and are thought to be the site of vRNA and cRNA replication
and transcription (Baird et al., 2013). RTCs are associated with a cytosolic
membrane, phosphatidylinositol-4-phosphate (PI4P) and several host proteins
including translation initiation factors, ribosomal proteins and stress granule protein
G3BP1 (Baird et al., 2013) (figure 1.8). The sites have not been associated
with any membrane-bound organelles and appear to export any viral mRNAs for
translation (Baird et al., 2013). The NP is thought to be the driving force for the
formation of RTCs because immunofluorescence analysis of cells transfected with a
NP-expressing plasmid reveal the characteristic discrete puncta seen in infected cells
(Baird et al., 2013; Knopp et al., 2015) (figure 1.8 rN PI4P). It has been proposed
that the establishment of these sites involves NP residue T206, which appears
to be transiently phosphorylated. Mutating T206 to a residue that cannot be
phosphorylated (T206A) changes NP distribution from discrete puncta to a disperse
cytoplasmic diffusion and recombinant LCMV containing this mutation cannot be
recovered from a reverse genetics system (Knopp et al., 2015). Mutating T206 to a
phosphomimetic residue (T206E), thereby simulating constitutive phosphorylation,
results in a phenotype reminiscent of WT NP and mutant NP T206A, showing both
discrete puncta and a diffuse cytoplasmic distribution (Knopp et al., 2015). The NP
is thought to drive the formation of RTCs either through aggregation or interaction
with cellular proteins (Baird et al., 2013). Whilst this is not yet fully understood,
the colocalisation of PI4P with NP at the RTCs could be the key to the formation
of these sites. PI4P promotes membrane dynamics and the recruitment of cellular
proteins involved with vesicular budding and has been implicated in membrane
remodelling for other viruses (Baird et al., 2013). Further studies are required to
understand NP interactions necessary for the formation of RTCs in addition to the
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role of phosphorylation in these interactions.
Figure 1.8: Co-localisation of Host Cell Components with Arenavirus NP
in Replication-Transcription Complexes Vero cells were infected with Tacaribe
virus (TCRV) and then fixed using 4 % paraformaldehyde, permeabilised using 0.1
% Triton-X-100 and stained with antibodies raised against the following proteins:
phosphatidylinositol-4-phosphate (PI4P), small ribosomal subunit protein S6 (S6), large
ribosomal protein L10a (L10), eIF4G (4G), eIF4A (4A) and eIF4E (4E) and Ras-GAP SH3
domain binding protein (G3BP) (all then stained with a secondary antibody conjugated
to a 488 nm fluorophore; green). The TCRV NP was stained with an antibody conjugated
to a 568 nm fluorophore (red). Co-localisation between the staining can be seen in each
image in distinct puncta and the fluorescence intensities, which are spatially correlated.
Co-localisation was also seen when recombinant NP was transfected into the cells (rN
PI4P). This figure was obtained from (Baird et al., 2013).
Recruitment of Translation Initiation Factors
Within RTCs, the NP is proposed to have an additional function to interact
with and recruit translation initiation factors, although this is variable between
mammarenaviruses. Studies on Old World mammarenavirus LCMV shows that
the NP colocalises with all three of the eIF4F components, but does not
co-immunoprecipitate with any of them (Knopp et al., 2015). This suggests that the
eIF4F complex is recruited to the RTCs in LCMV-infected cells, potentially through
NP interactions, but the LCMV NP does not interact strongly with or replace any
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of the eIF4F components (Knopp et al., 2015). For New World mammarenaviruses
JUNV, TCRV and PICV, it has been proposed that the NP replaces the cap-binding
protein of the eIF4F complex, eIF4E. Studies have shown that the NP from these
viruses colocalises and co-immunoprecipitates with eIF4A and eIF4G in infected
cells (Linero et al., 2013). These viruses can also not complete their lifecycle in cells
that have expression of eIF4A or eIF4G knocked down by siRNA or pharmacological
inhibition (Linero et al., 2013). However, there is no colocalisation or interaction
between eIF4E and NP and the inhibition or siRNA knock-down of eIF4E does not
affect infection by JUNV, TCRV or PICV. Furthermore, unlike LASV NP (Hastie
et al., 2011a), the NPs from JUNV, TCRV and PICV were all retained by M7G
cap-conjugated beads (Linero et al., 2013). This suggests an alternative interaction
between New World mammarenavirus NPs and the eIF4F complex and highlights
the need for further investigation into the structure of New World mammarenavirus
NPs, potentially in complex with M7G caps. Modulation of the Host Cell Immune
Response
Prior to the structure of the C-terminal domain being solved, an immunosuppressive
function was attributed to the NP, specifically to residues within the C-terminal
domain (Martínez-Sobrido et al., 2006, 2007, 2009). Viral replication can result
in the generation of dsRNA, which is a well-known pathogen-associated molecular
pattern (PAMP) (Hastie et al., 2011b). The detection of PAMPs in the host
cytoplasm by pattern recognition receptors (PRRs), such as retinoic acid-inducible
gene I (RIG-I) or melanoma differentiation-associated protein 5 (MDA5), can trigger
the interferon (IFN) response (Papageorgiou et al., 2020) (figure 1.9). This leads
to the expression of interferon-stimulated genes (ISGs) and the establishment of an
anti-viral environment in the infected cell and neighbouring cells (Yekwa et al., 2019)
(figure 1.9). It has been proposed that the arenavirus NP exonuclease functions
to cleave any dsRNA intermediates resulting from viral replication, in order to
prevent detection and initiation of the IFN response (Reynard et al., 2014; Shao
et al., 2018; Zhou et al., 2010) (figure 1.9). Mutational analysis of residues involved
in, and proximal to, the LASV exonuclease active site (D389, E391, D466, D533,
H528, G392, and R492), in addition to residues which disturb the zinc coordination
(E399, C506, H509, and C529), disrupted the exonuclease activity and the ability
to suppress the IFN response (Hastie et al., 2011a). Furthermore, mutational
34
CHAPTER 1. INTRODUCTION TO THE ARENAVIRUSES
analysis of residues D382 and G385 in LCMV NP (corresponds to D389 and G392
in LASV NP) showed these residues, which were later attributed to exonuclease
active site residues, were critical for anti-IFN activity (Martínez-Sobrido et al.,
2009). Finally, attempts to rescue viruses (PICV, LASV or LCMV) with a mutant
NP deficient of exonuclease activity either failed or significantly impaired viral
replication (Martínez-Sobrido et al., 2009; Huang et al., 2015; Carnec et al., 2011).
Figure 1.9: Inhibition of Steps in the Innate Immune Response by the
Arenavirus Nucleocapsid Protein The diagram shows the signalling pathways for type
I interferon (IFN) induction. Arenavirus non-poly-adenylated RNA and double-stranded
RNA species are detected by RIG-I and MDA5. The arenavirus NP inhibits this detection
and signalling by degrading the RNA species and possibly through binding to RIG-I
directly. Arenavirus ZP also binds directly to RIG-I and MDA5 to prevent the activation
of the mitochondrial antiviral signalling (MAVS) protein. The arenavirus NP also inhibits
later stages of induction, through binding to IKK-epsilon and preventing activation of
IFN-responsive factor 3 (IRF3) and through blocking activation of NF-κB, which is
activated through detection of the arenavirus GPC by Toll-like receptors (TLRs). This
figure was obtained from (Meyer and Ly, 2016).
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Despite strict conservation of the exonuclease domain amongst arenaviruses, and
many arenaviruses exhibiting anti-IFN activity, cells infected with non-pathogenic
viruses TCRV and MOPV induce a strong IFN response (Martínez-Sobrido et al.,
2007; Pannetier et al., 2004). This suggests a potential link between anti-IFN
activity and viral pathogenesis, but also suggests that NP exonuclease activity may
be conserved for an additional role in the viral lifecycle (Martínez-Sobrido et al.,
2007; Yekwa et al., 2019). Recently, there has been a proposal that the arenavirus
exonuclease activity may be necessary for genome editing (Yekwa et al., 2019).
The Coronaviridae family is the only other viral family which has 3’-5’ exonuclease
activity in a viral protein (nsp14) (Minskaia et al., 2006; Bouvet et al., 2012).
During the coronavirus lifecycle, nsp14 functions to remove mismatched bases from
the RNA genome, maintaining genomic fidelity and stability (Bouvet et al., 2012;
Eckerle et al., 2010; Denison et al., 2011; Ferron et al., 2018). Other studies have
shown nsp14 has additional functions involved in immunosuppression (Becares et al.,
2016). The exonuclease domains of the arenavirus NP and the coronavirus nsp14
are structurally similar, suggesting a potential additional role of genome editing for
the arenavirus NP (Yekwa et al., 2019). The study proposed that the arenavirus
NP exonuclease domain was able to cleave dsRNA which had a single mismatched
nucleotide (3’), which could possibly represent the NP checking the quality of the
UTRs forming the panhandle (Yekwa et al., 2019).
There are also other interactions between the arenavirus NP and various mediators
of the host cellular immune response. When PRRs, such as RIG-I, MDA5 and
dsRNA-detector protein kinase R (PKR), are activated by the presence of PAMPs,
several pathways can be induced in order to mount an anti-viral IFN response.
Activated RIG-I and MDA5 signal through IκB kinase (IKK) complexes to induce
phosphorylation and nuclear translocation of interferon regulatory factor 3 (IRF3)
and NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) (figure
1.9). These activated transcription factors then induce expression of IFN-β, IFN-α
and cytokines. Activated PKR can also phosphorylate and activate NF-κB to
induce IFN expression, in addition to phosphorylation and inactivation of eIF2-α,
preventing cap-dependent translation. Arenavirus NPs interact with many of these
cellular proteins to interfere with the induction of the IFN pathway.
LCMV NP is able to block the nuclear translocation of both transcriptional
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activators of IFN expression, IRF3 and NF-κB (Martínez-Sobrido et al., 2006) (figure
1.9). Which proteins are targeted specifically to prevent IRF3 activation has not
been fully elucidated, although LCMV NP has been shown to interact specifically
with the kinase domain in IKKε, which would block its auto-catalytic activity and
subsequent IRF3 activation (Pythoud et al., 2012) (figure 1.9). It is further proposed
that the LCMV NP sequesters IKKε from its cellular binding partner MAVS, due to
a lack of colocalisation between IKKε and MAVS in presence of LCMV NP (Pythoud
et al., 2012). LCMV NP has also been shown to interact with RIG-I and MDA-5,
which could be another way by which the NP prevents induction of the IRF3 and
NF-κB pathways (Zhou et al., 2010). However, IKKε, RIG-I and MDA-5 have not
been identified in other studies exploring the NP interactome by mass spectrometry
(King et al., 2017; Loureiro et al., 2018).
One of these studies revealed that both JUNV NP and LCMV NP interacted with
activated PKR, but the phosphorylation and activation of eIF2-α was only prevented
in JUNV infection (King et al., 2017). This suggested that JUNV NP was able
to specifically block the downstream interactions of PKR activation (King et al.,
2017). The other study showed LCMV NP, LASV NP and JUNV NP appeared
to interact with DDX3 and require DDX3 for completion of the viral lifecycle
(Loureiro et al., 2018). DDX3 is an RNA helicase that is involved with transcription,
translation and nuclear export of RNA, stress granule assembly and activation of
IFN-β expression (Loureiro et al., 2018). It is thought DDX3 could be recruited
in early infection to assist viral RNA replication because mini-genome replication
is reduced in cells depleted of DDX3 (Loureiro et al., 2018). However, it was also
proposed to be required in LCMV-infected cells for an IFN-inhibitory effect later in
infection (Loureiro et al., 2018).
The interactions between the arenavirus NP and host cellular proteins involved in
innate immune pathways have not yet been fully understood, although it appears
the NP may sequester, divert or prevent the activity of multiple proteins at
multiple levels. The mechanisms by which the IFN response is suppressed, or
potentially promoted, appear to be different for viruses within the Old World group
as opposed to the New World group and could also be related to viral pathogenesis.
Finally, these interactions could also differ based on which cell type is the primary
target of arenavirus infection. Immune cells, including macrophages, dendritic cells
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and natural killer cells, which are initially targeted in LASV infection, and IFN
suppression in these cell types is tightly linked with subsequent disease prognosis
(Pannetier et al., 2011; Huang et al., 2015). If an IFN response is established in
early LASV infection, there is a much higher chance of survival. Alternatively,
being able to oppose the IFN response may enable the virus to infect immune cells;
non-pathogenic MOPV cannot negate the IFN response and also cannot establish
productive infection in macrophages (Pannetier et al., 2004). This, however, differs
to highly pathogenic New World arenaviruses (Huang et al., 2015). These differences
may also be related to the ZP (Huang et al., 2015).
Modulation of Host Cell Apoptosis
Another proposed function of the NP involves the modulation of host cell apoptosis.
Apoptosis is programmed cell death and can be induced through extrinsic (activation
of tumour-necrosis factor [TNF] receptors) or intrinsic (cytochrome c release from
the mitochondrial membrane) pathways (Wolff et al., 2016; Ashkenazi and Dixit,
1998; Granville and Gottlieb, 2002). The induction of these pathways results in
the proteolytic activation of initiator caspases (2, 8, 9, 10 and 12) and effector
caspases (3, 6, 7 and 14) (Wolff et al., 2013b; Nuñez et al., 1998). Caspases are
cysteine-dependent aspartate-specific proteases; initiator caspases are responsible
for cleaving and activating effector caspases, while effector caspases proteolytically
degrade many cellular proteins to initiate cell death (Wolff et al., 2013b; Nuñez
et al., 1998). Viral infection generates multiple stress signals in the cell, including
production of reactive oxygen species, alterations of Ca2+ signalling and generation
of PAMPs, all of which can induce apoptosis (Meyer and Groseth, 2018). Viruses
have a complicated relationship with apoptosis; it can either be beneficial to the
viral lifecycle, assisting with viral release, or it can be inhibitory to the viral
lifecycle, sequestering necessary host cell factors and shortening the available time
for completion of the lifecycle (Wolff et al., 2016).
Many studies have been performed to understand how arenaviruses are affected
by, and interact with, components of the cellular apoptosis pathways (Meyer and
Groseth, 2018). One particular study, trying to understand the multi-functionality
of the JUNV NP within the host cell, found that the NP was cleaved in infected
and transfected cells (Wolff et al., 2013b). This led to the identification of caspase
cleavage motifs within the NP sequence and the proposal that the JUNV NP acted as
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a decoy substrate for the caspases, diverting the caspases away from their targets so
they fail to activate apoptosis (Wolff et al., 2013b). The NP cleavage products were
also present within mature virions, so whether the NP caspase motifs were required
to prevent apoptosis or to result in cleaved NP was not fully determined. Apoptosis
induction was reduced in JUNV-infected cells, especially in comparison to the cells
infected with non-pathogenic TCRV, which mounted an effective apoptosis response,
potentially due to the NP lacking one of the caspase motifs and subsequently not
being cleaved (Wolff et al., 2013b, 2016; Kolokoltsova et al., 2014). The activation
of caspase 3 was also shown to be reduced in presence of JUNV NP but not affected
by the presence of TCRV NP (Wolff et al., 2013b). Furthermore, TCRV replication
and growth was not affected by a strong induction of apoptosis (Wolff et al., 2016).
The differences in these two viruses in response to apoptosis induction may be
related to pathogenesis, although further work is required to understand this. The
presence of cleaved NP in mature virions of PICV and LASV also suggests other
arenaviruses may utilise the conserved caspase motifs as a means for NP cleavage
or for modulation of host cell apoptosis (Harnish et al., 1981; Clegg and Lloyd,
1983; Young et al., 1987). It has been observed that LCMV and LASV do not
appear to induce apoptosis in cell culture, and the caspase motifs are conserved,
strongly suggesting the NP could be involved with subverting the apoptotic response
(Pythoud et al., 2012; Baize et al., 2004; Wolff et al., 2013b).
1.4.2 L Polymerase
The arenavirus L polymerase (LP), is a multi-domain protein that mediates
transcription and replication of the genome. This is achieved through the LP’s
RNA-dependent RNA polymerase (RdRp) domain. However, the LP has additional
functions because residues that are essential for correct LASV LP function have been
identified both within and outside the RdRp domain (Lelke et al., 2010; Lehmann
et al., 2014; Hass et al., 2008). Unlike the well-characterised influenza polymerase
complex, sequence analysis of the LASV LP did not identify distinguishable RNA
helicase or RNA capping functions (Vieth et al., 2004).
The structures of the LPs from LASV and Machupo virus (MACV) were recently
solved to sub-4 Å resolution using cryo-electron microscopy and single-particle
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reconstruction (Peng et al., 2020) (figure 1.10). The LASV and MACV LPs
were structurally similar to each other, to bunyavirus La Crosse orthobunyavirus
(LACV) and to the polymerase complexes of influenza virus (Peng et al., 2020).
The LP is composed of a single polypeptide chain, which is organised into
three structural domains; the N-terminal endonuclease-containing domain (PA-like
region), the central RdRp-containing domain (RdRp region) and the C-terminal
cap-binding domain (PB2-like region) (figure 1.10A and C). The N-terminal and
C-terminal domains, after cleavage at specific positions, are able to functionally
trans-complement each other (Brunotte et al., 2011b). These LASV and MACV LP
structures supported previous EM examination of the MACV LP, which showed a
core domain that was surrounded with appendages (Kranzusch and Whelan, 2012;
Kranzusch et al., 2010).
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Figure 1.10: Structure of the LASV and MACV L Polymerases The three
domains of the L polymerase (LP) has been schematically depicted for the LASV
LP (A) and the MACV LP (C), showing the N-terminal PA-like region, the central
RNA-dependent RNA-polymerase (RdRp) (PB1-like) region and the C-terminal PB2-like
region. The regions that have not been structurally resolved yet are depicted as lighter
colours with dashed outlines. The structures of the LASV (B) and MACV (C) LPs have
been shown as a cartoon, with the different domains coloured the same as the schematic
in (A) and (C). This figure was obtained from (Peng et al., 2020).
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The N-terminal (PA-like) region contains the endonuclease region, which has been
shown to share high structural homology between members of the Arenaviridae
family (including California Academy of Sciences virus (CASV), a member
of the Reptarenavirus genus), in addition to other bunyaviruses (from the
Peribunyaviridae, Hantaviridae and Phenuiviridae families) and the orthomyxovirus
influenza A virus (figure 1.11). The endonuclease region has a two-lobed structure;
the first lobe comprises α-helices that form a helix bundle, whereas the second lobe
is composed of a β-sheet and an α-helix (Olschewski et al., 2020). The second lobe
also contains the PD(E/D)K endonuclease active site residues, which co-ordinate two
divalent metal ions (Olschewski et al., 2020). Other viral polymerase endonucleases
utilise an additional histidine residue in the first lobe to co-ordinate the first metal
ion in the active site (figure 1.11C; His+). Arenavirus endonucleases do not contain
this histidine residue, instead possessing a glutamate or aspartate residue that is
involved with the co-ordination of the second metal ion (figure 1.11B; His-). Whilst
the arenavirus endonuclease region had the structural conformation of the active
site of enzymatically-active endonucleases from other viruses, the absence of the
histidine residue (His-) reduces its in vitro endonuclease activity (Vogel et al.,
2019; Olschewski et al., 2020). Biochemical analysis of the LASV LP N-terminal
region showed it was unable to cleave RNA (Reguera et al., 2016; Vogel et al.,
2019). The functional activity of the arenavirus endonuclease domain remains to be
elucidated, but it has been proposed that there may be another component, as of
yet unidentified, required to enable endonuclease activity (Vogel et al., 2019).
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Figure 1.11: Structure of the Endonuclease Domains from Viral Polymerases
(A) The structures of the endonuclease domains from multiple viral polymerases have been
shown as cartoons for lymphocytic choriomeningitis virus (LCMV; PDB: 3JSB), Lassa
virus (LASV; PDB: 5J1P), Pichindé virus (PICV; PDB: 4I1T), California Academy of
Sciences virus (CASV; PDB: 5MV0), La Crosse virus (LACV; PDB: 2XI5), Hantaan virus
(HTNV; PDB: 5IZE), Andes virus (ANDV; PDB: 5HSB), Toscana virus (TOSV; PDB:
6QVV) and influenza A virus (IAV; PDB: 2W69). Comparable structural elements have
been coloured the same and divalent cations have been shown as red spheres. (B and C)
The structures of the endonuclease active site have been overlaid for the His- endonucleases
(LCMV, LASV, PICV, and CASV) and His+ endonucleases (LACV, HTNV, ANDV, and
TOSV) and the active site residue side chains have been shown as sticks. The cations
(Me1 and Me2) have been shown as spheres, and colour matched to either the His- or
His+ model. This figure was obtained from (Olschewski et al., 2020).
The C-terminal PB2-like region only had 30 % of its structure solved in the
monomeric structures of LASV LP and MACV LP, suggesting inherent flexibility.
The region of the C-terminal domain that remains unresolved in these structures
is proposed to contain the putative cap-binding domain (Lehmann et al., 2014;
Rosenthal et al., 2017; Peng et al., 2020). Mutational analysis of the LASV LP found
that mutation of conserved residues within the C-terminus affected transcription but
not replication, suggesting the C-terminus has a role in cap-snatching (Lelke et al.,
2010; Olschewski et al., 2020). Structural determination of the LP C-terminal region
of CASV (Rosenthal et al., 2017) also showed structural similarity with the influenza
virus PB2 cap-binding domain (Olschewski et al., 2020) (figure 1.12).
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Figure 1.12: Structural Comparison of the Cap-Binding Domains from a
Reptarenavirus and Influenza A Virus The crystal structure of the C-terminal
domain of the L polymerase (LP) of California Academy of Sciences virus (CASV; PDB
5MUZ) has been shown with the structure of the cap-binding domain within PB2 from
influenza A virus PB2 (IAV; PDB 2VQZ). Both structures have been depicted as cartoon,
with comparable structures coloured the same, and the proposed cap-binding residues
have been shown as sticks. The (m7G) cap structure has been shown with IAV PB2 and
has been depicted as black lines. This figure was obtained from (Olschewski et al., 2020).
The central RdRp region of the arenavirus LP contains the typical motifs that are
conserved amongst most viral polymerases (Peng et al., 2020; Poch et al., 1989). One
specific motif (the finger-tip) has been unresolved in the other viral polymerases,
until the LP is solved in complex with 5’vRNA sequences, in which case the finger-tip
is stabilised and the structure can be resolved. However, in the LASV and MACV
LPs, the finger-tip motif is highly ordered and the structure could be resolved. It is
thought that the finger-tip motif is stabilised through interactions with the core lobe
in the PA-like region (Peng et al., 2020). The arenavirus RdRp active site therefore
appears "switched on" and does not require 5’ vRNA activation like the other viral
polymerases (Peng et al., 2020). This supports other biochemical analyses where
LASV and MACV demonstrated both replicase and transcriptase activities in the
presence of 3’ vRNA, but only replicase activities in presence of 5’ vRNA (Kranzusch
et al., 2010; Pyle and Whelan, 2019; Peng et al., 2020). This is unlike other viral
polymerases, which experience improved replication and transcription in presence of
5’ vRNA (Peng et al., 2020). This may be a unique feature to the arenaviruses, due
to the presence of the core lobe stabilising residues, which are conserved between
44
CHAPTER 1. INTRODUCTION TO THE ARENAVIRUSES
the arenaviruses but not in other viral families (Peng et al., 2020).
The MACV LP was also solved in complex with the 3’ vRNA and the ZP (Peng et al.,
2021) (figure 1.13). This revealed that the 3’ vRNA bound in a highly positively
charged groove found between the head lobe of the PA-like region and the thumb
of the RdRp, which was comparable to the binding of 3’ vRNA by the LACV LP
and the influenza polymerase (Peng et al., 2021). Furthermore, this structure gives
insight to understanding the mechanism behind the ZP’s regulation of LP activity.
Previously, residues in the RdRp region (H1189 and D1329) of the TCRV LP were
shown to be essential for ZP-LP interaction (Wilda et al., 2008). Here, the residues
were mapped to the entrance site of the RNA, suggesting that the ZP could limit
replication and transcription through occluding this entrance (Peng et al., 2020,
2021).
Figure 1.13: Structure of the MACV LP in Complex with 3’ vRNA and ZP
The Machupo virus (MACV) LP has been shown in complex with 3’ vRNA and the MACV
ZP (PDB: 7ELC; (Peng et al., 2021)). The MACV LP (purple) has been shown as its
transparent surface, the 3’ vRNA has been shown as sticks, coloured to corresponding
nucleotides, and the MACV ZP (orange) has been shown as a cartoon, overlaid with its
transparent surface. The 3’ vRNA is bound in a deep groove found in between the PA-like
region and the RdRp region. The groove (indicated by a dashed red line), which forms
the entrance site of nucleotide chains, appears to be blocked by the ZP. This figure was
created using UCSF Chimera X.
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1.4.3 Glycoprotein Complex
The glycoprotein complex (GPC) is present on the viral surface and has a trimeric
organisation (Schlie et al., 2010a). GPC is translated as a single polypeptide and
is later proteolytically processed into the mature tripartite GPC, comprising GP1
(approx. 44 kilodalton (kDa)), GP2 (approx. 35 kDa) and the stable signal peptide
(SSP; approx. 5 kDa) (figure 1.14; inset) (Burri et al., 2012a; Hastie and Saphire,
2018).
Figure 1.14: Post-Processing of the Arenavirus Glycoprotein Complex
(Inset)The glycoprotein complex (GPC) is composed of the stable signal peptide (SSP),
GP1 and GP2. The transmembrane domain of GP2 has been indicated (TM), as have the
cleavage sites of signal peptidase and SKI-1/S1P. Translation of the GPC mRNA is halted
when the SSP is recognised by the signal recognition particle (SRP). The SRP binds to
the SRP receptor in the endoplasmic reticulum (ER) membrane and translation resumes
through a translocon into the ER lumen. Signal peptidase cleaves the SSP from the rest of
the GPC and the SSP becomes embedded in the membrane through two transmembrane
domains and the addition of an N-terminal myristic acid (myr). Translation of the
GPC mRNA continues and the GP2 TM domain embeds the GPC in the membrane,
in association with the SSP. The GPC is later proteolytically processed by SKI-1/S1P.
The mature tripartite complex (SSP, GP1 and GP2) then trimerises to form the trimeric
GPC spike. This figure was created using BioRender and information from the following
citations (Burri et al., 2012b; Pasquato et al., 2018).
Translation of the GPC mRNA is redirected to the endoplasmic reticulum (ER)
when the ribosome reaches the SSP (Nunberg and York, 2012) (figure 1.14). Signal
peptidase cleaves the SSP from the GPC, but the SSP unusually remains associated
with the GPC (Nunberg and York, 2012; York et al., 2004). The SSP is different
to most conventional signal peptides; it is significantly longer (58 amino acids as
opposed to 18-30 amino acids) and has two hydrophobic regions, instead of one
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(von Heijne, 1985; Froeschke et al., 2003; Eichler et al., 2003; York et al., 2004).
The arenavirus SSP also has a conserved myristoylation motif (GX3(S/T) where X
is any amino acid), which directs the covalent attachment of a myristoyl group to
the second glycine residue of the SSP, anchoring it to the membrane (York et al.,
2004; York and Nunberg, 2016). The hydrophobic regions, which are separated by
a single positively-charged lysine residue (K33), are thought to cross the membrane
in an anti-parallel fashion (Froeschke et al., 2003; Agnihothram et al., 2007). The
K33 residue is proposed to interact with the GP2 ectodomain in the ER lumen
and is important for pH-mediated GP2 fusion; it is thought that K33 has roles
in stabilising the metastable glycoprotein prior to membrane fusion (Nunberg and
York, 2012; York and Nunberg, 2006, 2009). The C-terminal tail of the SSP of JUNV
(residue C57) interacts with residues in the GP2 cytoplasmic tail (H447, H449, C455,
H485, H459, C467, and C469) to form a zinc-binding domain (Agnihothram et al.,
2007; York and Nunberg, 2007; Briknarová et al., 2011). The arenavirus SSP is also
thought to mask the GPC’s ER retention motif, permitting progression to the Golgi,
for subsequent processing and trafficking to the plasma membrane (Agnihothram
et al., 2006).
The immature GPC is translated as a transmembrane protein, embedded in the
ER membrane (figure 1.14). Post-translationally, the GPC is subject to extensive
N-glycosylation (Burri et al., 2012a). Whilst specific N-glycosylation sites are not
necessarily conserved between arenaviruses, particularly on GP1, a high proportion
of the sites are actively used by the arenavirus GPCs (LASV GPC uses all the
predicted N-glycosylation sites and LCMV GPC requires eight out of nine sites)
(Eichler et al., 2006; Bonhomme et al., 2011). Some of the N-glycosylation sites
are necessary for the correct proteolytic processing of the GPC, whereby mutation
of these sites results in the trafficking of uncleaved GPC to the plasma membrane
(Eichler et al., 2006). However, it has not been fully elucidated on whether these
mutations affect the tertiary/quaternary structure, which prevents enzyme cleavage,
or whether the N glycosylation sites are required for enzyme activity (Burri et al.,
2012a). Furthermore, it is thought that glycosylation plays a role in masking the
glycoprotein from the host humoral immune response, forming a glycan shield that
prevents access of the antibodies to the viral glycoprotein (Hastie and Saphire, 2018;
Sommerstein et al., 2015; Igonet et al., 2011). The arenavirus GPC is proteolytically
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processed by the proprotein convertase, subtilisin kexin isozyme-1/site-1 protease
(SKI-1/S1P) (figure 1.14) (Lenz et al., 2001; Beyer et al., 2003). Cleavage by
SKI-1/S1P occurs at the conserved consensus motif (RXΦX, where X is any amino
acid except cysteine and Φ is any hydrophobic residue) in the GPC and results
in the formation of the GP1 and GP2 subunits, which remain non-covalently
associated (Burri et al., 2012b,a). The cleavage motif appears to play a role in which
intracellular compartment the arenavirus glycoprotein is cleaved, whereby the LASV
"RRLL" motif directs cleavage in the ER/cis Golgi and the LCMV "RRLA" motif
directs cleavage in the late Golgi (figure 1.14) (Lenz et al., 2001; Burri et al., 2012b;
Wright, 1990).
The structures of the pre-fusion GPCs of the LCMV, LASV and UHV have
been solved by either x-ray crystallography (LCMV and LASV) (figure 1.16) or
tomographic reconstruction (LASV and UHV) (figure 1.15) (Hastie et al., 2016a,
2017; Li et al., 2016; Hetzel et al., 2013). The tomographic reconstruction of
the LASV glycoproteins on chemically fixed virions revealed "spikes" on the viral
membrane, which had a trimeric organisation and were approximately 10 nm
in width and 9 nm in height (figure 1.15) (Li et al., 2016). There were also
"legs" connecting the spikes to the membrane, which were spaced 4 nm apart and
were thought to correspond to the GP2 domain (figure 1.15) (Li et al., 2016).
Furthermore, there was electron density corresponding to the GP2 intra-viral tails
(figure 1.15) (Li et al., 2016). In comparison to the tomographic reconstruction of
the LASV GPC, the "spike" structures present on the UHV membrane were similar
in size (11 nm in width and 10 nm in height) and were also trimeric (Hetzel et al.,
2013). However, comparison of the glycoprotein of UHV with that of LASV and
EBOV showed that the UHV GPC had a much higher structural homology with
EBOV GPs than with LASV, suggesting an evolutionary history involving filoviruses
(Li et al., 2016; Gallaher et al., 2001).
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Figure 1.15: Comparison of the LASV GPC at pH 7 and pH 5 The tomographic
reconstructions of the LASV GPC (from fixed virions; EMD: 3290) at pH 7 (A) and LASV
GPC (from virus-like particles; EMD: 3293) at pH 5, with lysosomal associated membrane
protein (LAMP1) (B). The crystal structure of the Lassa virus GPC (LASV; PDB: 5VK2;
yellow) has been shown as a cartoon and was docked into the tomographic reconstruction
of the LASV GPC at pH 7 (C) and the LASV GPC at pH 5 (D). The histidine triad,
which is proposed to be responsible for binding secondary receptor, has been shown as
sticks and coloured red. This figure was created using UCSF Chimera X.
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In order to solve the structure of the pre-fusion GPCs of LCMV and LASV by
x-ray crystallography, mutations had to be introduced to stabilise the interactions
between the GP1 and GP2 domains. The crystal structure of the LASV GPC
aligned well with both the crystal structure of the LCMV GPC and the tomographic
reconstruction of LASV (figures 1.15 and 1.16A and B)) (Hastie et al., 2017; Hastie
and Saphire, 2018). While the tomographic reconstruction of the LASV GPC
provided information on how native GPCs presented on the virion surface, albeit in
a chemically fixed conformation, the crystal structures provided further information
on the interactions between the GP1 and GP2 domains as well as positioning of
residues required for receptor binding and regions exposed to antibody recognition
(figure 1.16) (Hastie et al., 2016a, 2017).
Figure 1.16: Structure of the Arenavirus Glycoprotein Complex The overall
structures of the full-length LCMV (A; PDB: 5INE; purple) and Lassa virus (B; LASV;
PDB: 5VK2; yellow) have been shown as a cartoon with the GP1 domains shown as light
purple (LCMV) and yellow (LASV) and the GP2 domains shown as dark purple (LCMV)
and orange (LASV). (C) The LCMV GP1 domain (PDB: 5INE; light purple) overlaid
with the GP1 domains (solved without the GP2 domain) of LASV (PDB: 4ZJF; blue) and
New World mammarenaviruses Junín virus (JUNV; PDB: 5EN2; green) and Machupo
virus (MACV; PDB: 2WFO; pink), showing a high structural homology. This figure was
created using UCSF Chimera X.
The GP1 (amino acids 59-265) domain mediates attachment to the host cell receptor.
The domain can be divided into three structural features; the N-terminal β-strand,
the upper "β-sheet" face and the lower "helix-loop" face (figure 1.16C) (Hastie et al.,
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2016a). The upper "β-sheet" face is composed of a six-stranded, anti-parallel β-sheet
and is highly glycosylated, contributing to the glycan shield (Hastie et al., 2016a).
The lower "helix-loop" face has five α-helices and three extended loops (Hastie et al.,
2016a). The N-terminal β-strand extends from GP1 to interact with GP2 and form
a three-stranded, anti-parallel β-sheet (Hastie et al., 2016a).
Structures of the GP1 domain of many arenaviruses has been solved, either
independently (Bowden et al., 2009; Cohen-Dvashi et al., 2015, 2018; Israeli et al.,
2017; Shimon et al., 2017; Pryce et al., 2018) or in complex with their receptor
(Abraham et al., 2010), antibody fragments (Mahmutovic et al., 2015; Zeltina
et al., 2017; Clark et al., 2018) or GP2 (Hastie et al., 2016a, 2017). There is a
high structural homology shared by these GP1 domains, all of which contain the
characteristic α/β fold (figure 1.16C). Differences can be attributed to the inherent
flexibility in the loops (Hastie et al., 2016a; Pryce et al., 2018). The biggest
differences were seen comparing LCMV GP1 (in complex with GP2) and LASV
GP1 (independent of GP2). Here, the N- and C termini, which were orientated
towards GP2 in LCMV, were orientated in the opposite direction in LASV (Hastie
et al., 2016a). Furthermore, two α-helices (α-1 and α-2) present in the LCMV
GP1 formed a single α-helix in LASV, which was perpendicular to the rest of the
GP1 structure (Hastie et al., 2016a). The third α-helix of the helix-loop face was
also positioned 45° away from the position of α-3 in LCMV (Hastie et al., 2016a).
These striking differences cannot be attributed to the absence of GP2, because of
similarities between LCMV GP1 (-GP2) and LCMV GP1 (+GP2), nor can it be
attributed to pH differences because of the similarities seen between MACV GP1
(at pH 5.5) and JUNV GP1 (at pH 8), despite these GP1 domains sharing a lower
sequence homology (20 %) than LCMV and LASV GP1 domains share (63 %)
(Hastie et al., 2016a). The GP1 domain of WWAV was solved in both pH 7 and pH
5.5 and there were no conformational changes (Pryce et al., 2018).
The host cell receptor of Old World arenaviruses is α-dystroglycan (α-DG), although
additional secondary receptors have been identified; LASV requires lysosomal
associated membrane protein (LAMP1) (Jae et al., 2014) and LUJV requires
neutrophilin-2 (Raaben et al., 2017). Five residues (136, 153, 155, 190 and 260), all
present within the GP1 subunit, have now been identified as critical for binding to
α-DG, although their exact functions have yet to be clarified (Hastie et al., 2016a).
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Residues Ser153 and Leu260 are present in the lower helix-loop face of GP1 (Hastie
et al., 2016a) and confer high affinity binding to α-DG and the establishment of viral
persistence (Smelt et al., 2001; Teng et al., 1996; Sevilla et al., 2000). Binding to
α-DG cannot be mediated by GP1 alone, suggesting there are some factors mediated
by the complete GPC necessary for the conformation or orientation of GP1 (Hastie
et al., 2016a). This additional interaction between the LASV GPC and LAMP1
necessitates a histidine triad (H92, H93 and H230) present in the LASV GP1 domain
(Cohen-Dvashi et al., 2015). The histidine triad is present within the β-sheet face
and appears in the centre of the GPC spike in the tomographic reconstruction,
when it is overlaid with the LASV GPC crystal structure (figure 1.15). The
structure of the LASV GPC, at pH 5, and in complex with LAMP1, has also been
shown (figure 1.15B). Although the histidine triad is conserved between LASV and
LCMV (Armstrong strain), LAMP1 has not been shown as a requirement for LCMV
infection (Jae et al., 2014). However, recombinant viruses bearing mutations in the
histidine triad residues fail to rescue, suggesting a potential role of stability for the
histidine triad, or additional, as of yet unidentified, receptor for LCMV (Hastie
et al., 2016a).
The GP2 (266-498 aa) domain directs membrane fusion between the viral and the
host cell membranes in order to release the RNPs into the cytoplasm. The structure
of the GP2 domain has been solved (figure 1.17), by x-ray crystallography, in both
pre-fusion (Hastie et al., 2016a, 2017) and post-fusion forms (Igonet et al., 2011;
Zhang et al., 2019; Shulman et al., 2019; Parsy et al., 2013; Koellhoffer et al., 2014).
The structure of GP2 can be divided into three regions; an N-terminal α-helix, a
C-terminal α-helix and a "T loop" region which connects the two α-helices (Igonet
et al., 2011; Parsy et al., 2013).
GP2 is considered a class I viral fusion protein (Eschli et al., 2006), although it has
features of all three classes of fusion protein. It is considered a class I fusion protein
because it requires proteolytic processing in order to release the fusion peptide and
it has α-helices which form the class I characteristic six-helix bundle post fusion,
although the orientation of these α-helices in arenavirus GPC is contrary to that
of the other class I fusion GPCs. The LASV GP2 subunit is thought to have both
an N-terminal fusion peptide (termed F1; commonly seen in class I viral fusion
proteins) and an internal fusion loop (termed F2; seen in Ebola virus GP, and all
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Figure 1.17: Comparison of Pre- and Post-Fusion Forms of LCMV GP2 The
pre-fusion form of LCMV GP1 shows heptad repeat (HR) 1 is present as four segments
(HR1a-d; yellow), which are connected to the α-helical HR2 by the T-loop, present as two
anti-parallel β-strands (pink). The post-fusion form of GP2 (which has been shown as
trimeric, forming the characteristic six-helix bundle of class I viral fusion proteins) reveals
that HR1a-d form a single α-helix, which is connected to the α-helical HR2 by the T-loop,
which is now present as an α-helix. This figure was obtained from (Hastie et al., 2016a).
class II and III viral fusion proteins) (Klewitz et al., 2007; Hastie et al., 2016a).
F1 and F2 are highly conserved across the arenavirus family (Hastie et al., 2016a).
In the LCMV GP2 structure, the F1 N-terminal peptide is partly helical and is
present at the GP1-GP2 interface, while the F2 fusion loop is a connecting loop of
two anti-parallel β-strands (Hastie et al., 2016a). The arenavirus GP2 also contains
two heptad repeats (HR). There are huge conformational changes in these regions
when the pre- and post-fusion forms of GP2 are compared (figure 1.17). Post-fusion,
the HRs form the individual N- and C-terminal helices, connected by the "T loop",
which also has an α-helical structure. The two HRs come together, with the other
two protomers, to form the anti-parallel six-helix bundle commonly seen in class I
viral fusion proteins (Hastie et al., 2016a). In the pre-fusion GP2 structure, HR1 is
present as four segments (HR1a-d), which form helices except for HR1b, which is
present as an extended loop. The "T loop" is present as two anti-parallel β-strands
in the pre-fusion form (Hastie et al., 2016a). There are also glycosylation sites on
the T loop, suggesting the glycan shield extends beyond GP1 (Hastie et al., 2016a).
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1.4.4 Z Matrix Protein
The Z matrix protein (ZP) is the smallest of the arenavirus proteins, comprising
between 90 and 99 amino acids with an approximate molecular weight of 11 kDa.
Despite its small size, the true multi-functionality of the arenavirus proteins is
reflected with the ZP. A critical role of the ZP is to act as the viral matrix protein,
forming a matrix layer on the inner side of the viral envelope and linking the
glycoprotein spikes with the packaged RNP complexes. The ZP is also responsible
for the recruitment and packaging of all the viral components into newly formed
viruses. Furthermore, ZP recruits host cell machinery to promote viral budding
from the host plasma membrane. The ZP also has multiple interactions with other
host cell proteins, including eIF4E and promyelocytic leukaemia protein (PML), as
well as playing a role in IFN antagonism.
Structure of the Z Matrix Protein
The structure of the ZP has been determined by nuclear magnetic resonance (NMR)
and x-ray crystallography (figure 1.18) (Volpon et al., 2010; Hastie et al., 2016b).
The ZP has three domains: the N-terminal domain, the central domain and the
C-terminal domain. The N- and C-terminal domains are both highly flexible
(figure 1.18C) (Hastie et al., 2016b). The second glycine residue of the ZP, present
in the N-terminal domain, is myristoylated, which permits membrane anchorage
and potentially initiates oligomerisation (Strecker et al., 2006; Capul et al., 2007;
Loureiro et al., 2011). The N-terminal domain also contains conserved basic residues,
thought to further assist membrane association through interaction with the acidic
phospholipids (Fehling et al., 2012). The N-terminal myristoylation is conserved
between Old World and New World mammarenaviruses and it is critical for the
ZP-GP(SSP) interaction (Capul et al., 2007). Mutation of this residue to alanine
or treatment of WT ZP with myristic acid analogues has been shown to alter the
intracellular distribution of ZP and affect the structure of ZP (Strecker et al., 2006),
as well as reducing interaction with the GP, although whether this reduction is due
to altered localisation or altered structure is not yet known (Fehling et al., 2012).
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Figure 1.18: Structure of the Arenavirus Z Matrix Protein The crystal structure
of the RING domain of the LASV Z matrix protein (ZP) has been shown as a cartoon (A;
PDB: 5I72; blue). The NMR reconstruction of the RING domain of LASV ZP has also
been shown as a cartoon (B; PDB: 2M1S; pink). The two zinc ions which are coordinated
by the RING domain have been shown as green spheres and the residues which coordinate
them (C31, C34, C50 and C53 form one coordination site and C44, H47, C64 and C67 form
the other site; cysteine residues has been shown in yellow whereas histidine residues have
been shown in orange) have been shown as sticks. (C) shows the schematic organisation
of the ZP and all the 10 structures solved by NMR, showing the flexibility of the N- and
C-terminal domains. This figure was created using UCSF Chimera X.
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Within the central domain of ZP is a 60-amino acid RING domain, which contains
the characteristic features typically seen with RING domain including a conserved
Cys3HisCys4 motif that co-ordinates two zinc cations at two co-ordination sites,
referred to as site I and site II (figure 1.18A and B). The RING domain comprises a
single α-helix, two anti-parallel β-strands and two loops, with the zinc-coordination
sites present on the α-helix (Hastie et al., 2016b). The RING domain, especially
site I, is important for the self-assembly of ZP because expression of the RING
domain alone is sufficient to drive the formation of spherical cytoplasmic structures
(Kentsis et al., 2001, 2002a,b). X-ray crystallographic analysis of ZP showed a
dodecameric organisation within crystals and it has been proposed that this is also
the organisation within virions (Hastie et al., 2016b). The RING domain is also
similar to the globular type of zinc-binding domains, which are known to interact
with proteins, as opposed to a zinc-finger domain which interacts with nucleic acids
(Fehling et al., 2012).
The C-terminal domain contains many late-domain motifs that are conserved
amongst the Old World and New World arenaviruses. Late-domain motifs are
tetra-peptide motifs (either "P[T/S]AP", "PPxY", or "YxxL" where x is any amino
acid), which mediate interactions between the viral protein and proteins of the
endosomal sorting complexes required for transport (ESCRT) (Fehling et al., 2012).
The Old World arenaviruses typically contain "PPxY" motifs and occasionally a
"P[T/S]AP" motif. The New World arenaviruses do not contain "PPxY" motifs,
but they do generally contain the "P[T/S]AP" motif, except for New World clade
A arenaviruses, which have overlapping "PSAP" and "APPY" ("PPPY"-like) motifs
that are similar to the overlapping late domains of VP40 from Ebola virus (Fehling
et al., 2012). It is thought that the "PPxY" motif mediates binding with Nedd4-like
ubiquitin ligases, although direct interactions have yet to be shown. The "P[T/S]AP"
motif binds tumour susceptibility gene 101 (Tsg101), which in turn recruits ESCRT1
(Martin-Serrano et al., 2001). Many of the arenaviruses, both Old World and New
World, also contain a "YxxL" motif located in the RING domain, which is able to
bind Alix/AIP1 to form multi-vesicular bodies and interact with Tsg101 to recruit
ESCRT1 (Strack et al., 2003). There are a couple of exceptions to this; LUJV
contains another "YxxL" motif in the C-terminal domain instead of a "PPPY" motif
and TCRV contains an "ASAP" motif instead of the "P[T/S]AP" motif. The "ASAP"
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and "YxxL" motifs in TCRV were not required for ZP-mediated budding, indicating
a different mechanism for budding (Urata et al., 2009). TCRV ZP-mediated budding
was also weak and not enhanced by replacement of the "ASAP" motif with a
"P[T/S]AP" motif, but it was enhanced by presence of the TCRV NP, which also
contains a "YxxL" motif and mutation of the NP "YxxL" motif blocks ZP-mediated
virus-like particle (VLP) release (Groseth et al., 2010).
Functions of the Z Matrix Protein
The ZP has several functions in the arenavirus life cycle including regulating
synthesis of viral RNA, recruitment of viral components for assembly and cellular
components to direct budding and interaction with host cell proteins to promote
viral translation and inhibit host cell apoptosis.
The ZP is thought to be responsible for halting viral replication and transcription to
begin the formation of the viral assembly complexes and initiate viral budding from
the host cell membrane. In a dose-dependent manner, ZP has an inhibitory effect
on replication and transcription in mini-genome assays (López et al., 2001; Cornu
and de la Torre, 2001). It has been observed that the ZP (of TCRV) can directly
interact with the LP (Jaòcamo et al., 2003). There are two putative Z-binding sites
on the LP, one at the N-terminus of the LP and one within the RNA polymerase
domain (Wilda et al., 2008). The residues identified as important for the ability
of ZP to inhibit viral RNA synthesis are thought to be the residues required for
LP binding. The RING domain is essential for inhibition of RNA synthesis, in
addition to residues that coordinate the zinc cations and a conserved tryptophan
residue within the RING domain (Loureiro et al., 2011; Capul et al., 2011; Cornu
and de la Torre, 2002). The direct interaction between the LP and ZP inhibits the
catalytic activity of the L polymerase (Kranzusch and Whelan, 2011) but does not
affect its ability to bind viral RNA, which would be important for packaging of the
viral genome and recruitment of LP into newly synthesised virions (Fehling et al.,
2012). Furthermore, ZP interaction with the NP is thought to further inhibit LP
RNA synthesis activities (Fehling et al., 2012).
The ZP is also responsible for the recruitment of each viral component to the site of
assembly. The LP is recruited through direct binding as discussed above. The RING
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domain of the ZP is also important for interaction with the NP because mutation
of the RING domain abolishes the incorporation of NP into ZP-induced VLPs
(Casabona et al., 2009). Furthermore, for MOPV, it is thought that the ZP-NP
interaction is mediated by both proteins interacting with Alix/AIP1 (Shtanko et al.,
2011). The ZP-NP interaction has been proposed to play a predominant role in
recruiting the genomic RNP complexes into newly synthesised virions (Fehling et al.,
2012). Finally, the interaction between ZP and the GPC is thought to be mediated
through the myristoylation of residues within the N terminal domain of the ZP
and the SSP of the GPC. The interaction of the ZP with all the viral proteins is
a principal role, due to a lack of direct interaction between NP and the GP. ZP
therefore acts as a bridge between the NP and GP, whereby cells only expressing
GPC and NP show no colocalisation between the two and no incorporation of NP in
GP-directed VLPs, but expression of ZP shows colocalisation of GPC and NP and
the NP is incorporated into VLPs (Schlie et al., 2010b).
The ZP also recruits the ESCRT complex components to the viral assembly site,
in order to catalyse the budding of the newly synthesised viruses from the host
cell membrane (Fehling et al., 2012). There are four ESCRT protein complexes
(ESCRT-0, ESCRT-I, ESCRT-II, ESCRT-III) that associate with additional factors
including the ATPase Vps4 and adaptor protein Alix/AIP1 (ALG-2-interacting
protein 1). The ESCRT complexes typically initiate recruitment of ubiquitinated
cargoes to endosomes (ESCRT-0) and direct membrane budding (ESCRT-I and -II)
and membrane scission (ESCRT-III) to release vesicles into multi-vesicular bodies
(Wollert et al., 2009). Vps4 assists this process by disassembling ESCRT-III from
the membrane after scission (Fehling et al., 2012). Interaction between the ZP
"P[T/S]AP" motif and ESCRT-I complex member Tsg101 enables recruitment of the
ESCRT complexes to the viral assembly site (Martin-Serrano et al., 2001). The ZP
"YxxL" motif also recruits ESCRT complexes through interactions with Alix/AIP1,
which binds Tsg101 (of ESCRT-I) and components of ESCRT-III (Strack et al.,
2003). Finally, the ZP "PPxY" motifs recruit ESCRT complexes through interactions
with Nedd4(Neuronal precursor cell-expressed developmentally down-regulated
4)-like E3 ubiquitin ligases, which are involved with the ubiquitination enzyme
cascade of proteins (Fehling et al., 2012). The ESCRT complexes often recruit
proteins through ubiquitination, offering a suggestion for why the ZP would interact
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with Nedd4-like E3 ubiquitin ligases. It has been observed that the LASV ZP can
directly bind Nedd4 and Nedd4-like ubiquitin ligases, an interaction that requires the
"PPxY" motif, but the role of these proteins and of ubiquitination in virus budding
has not been fully elucidated (Fehling et al., 2012).
The ZP has also been shown to interact with multiple host cellular proteins,
including PML, ribosomal P proteins, eukaryotic translation initiation factor 4E
(eIF4E) and the proline-rich homeodomain protein (PRH) (Fehling et al., 2012).
PML has roles in apoptosis and the immune response. It has been shown that during
LCMV infection, and when the ZP (of LASV and LCMV) is solely expressed, PML
is relocalised from the nucleus to the cytoplasm where it forms large bodies that
colocalise with ZP (Borden et al., 1998a). This interaction has been suggested
to help arenaviruses evade host cell apoptosis or the innate immune responses
(Fehling et al., 2012). Ribosomal P proteins (P0, P1, P2) are components of
the large subunit of the ribosome. In infected cells, LCMV ZP has been shown
to colocalise with P0, P1 and P2 in the nucleus but it does not result in their
redistribution, rather the down-regulation of P1 and P2 expression, which is thought
to affect ribosome function (Borden et al., 1998b). However, the expression of P0
is not down-regulated by Z, which instead binds directly to P0 and potentially
incorporates P0, and possibly ribosomes, into new virions (Borden et al., 1998b).
It is thought that ZP may recruit P0 for processing activities, such as excision
repair and endonuclease activity, that may be required for viral genomic replication
(Fehling et al., 2012). eIF4E assists host ribosomal binding of mRNA M7G caps
to initiate cap-dependent translation. Direct binding between the ZP (LCMV and
LASV) and eIF4E has been shown and this interaction results in conformational
changes within the eIF4E cap-binding site, which therefore limits eIF4E-dependent
protein synthesis (Volpon et al., 2010). This could result in a reduction of translation
of regulators of the immune response or potentially promote translation of viral
mRNAs, with the suggestion that the NP replaces the eIF4E cap-binding function.
PRH is a transcription factor necessary for early development of the brain, thyroid
and liver, as well as regeneration of the liver cells following damage or disease. The
expression of PRH was found to be significantly reduced in hepatic cell lines following
infection with the highly pathogenic LCMV-WE strain but not after infection with
the LCMV-ARM strain, which is considered to have reduced pathogenicity (Djavani
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et al., 2005). Proliferation of hepatocytes is also induced in rhesus macaques infected
with LCMV-WE but not when infected with LCMV-ARM (Lukashevich et al.,
2004). It is proposed that the down-regulation of PRH reduces the anti-proliferative
effects of PRH, which promotes cell division, therefore supporting viral infection,
but results in higher pathogenicity because the liver cells cannot be regenerated. It
has been shown that the RING domain of the LCMV ZP can directly interact with
PRH (Djavani et al., 2005; Topcu et al., 1999) leading to the suggestion that ZP
mediates the down-regulation of PRH but this has not been fully elucidated and
other viral proteins may play a role.
Finally, it has also been shown that the ZP, of New World arenaviruses TCRV,
GTOV, JUNV, MACV and SBAV, assists the NP in antagonism of the IFN response.
This occurs through an interaction between the ZP and RIG-I (Fan et al., 2010).
This interaction is thought to disrupt the interaction between RIG-I and MAVS,
which is essential in the signalling cascade that leads to the production of IFN-β
(Fan et al., 2010). The LASV and LCMV ZPs are not thought to antagonise the
IFN response because their ZPs do not interact with RIG-I.
1.5 Introduction to the Arenavirus Lifecycle
The mammarenaviruses follow a similar lifecycle (figure 1.19). Initially, the
mammarenavirus GPC binds a cellular receptor on the plasma membrane and the
virus enter the cell through receptor-mediated endocytosis. Following acidification
of the endosome, the GPC mediates viral and host membrane fusion for release of
the RNPs into the host cytoplasm. The vRNA is then transcribed and replicated
(to form the cRNA, which is also transcribed and replicated), in the host cytoplasm,
by the LP. The mRNAs of the viral proteins are translated by host ribosomes in the
cytoplasm, except for the GPC, which is translated into the endoplasmic reticulum
(ER) and matures through the Golgi apparatus (GA) towards the plasma membrane
(figure 1.14). All the viral proteins assemble at the host plasma membrane and host
complexes are recruited to drive budding from the membrane and formation of a
new virion.
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Figure 1.19: Schematic of the Mammarenavirus Lifecycle.
The mammarenavirus attaches to its host cell receptor (1) and is internalised through
an endocytic pathway (2). The internalised endosome becomes increasingly acidic (3),
inducing host and viral membranes to fuse and release the ribonucleoproteins (RNPs)
(4). The viral polymerase (LP) then transcribes (5) the nucleocapsid protein (NP) and
L polymerase (LP) genes and replicates (6) the vRNA to form the cRNA (6). The
cRNA is then bound by the LP, to transcribe (7) the glycoprotein (GPC) and Z matrix
protein (ZP) genes and replicate the cRNA to produce more vRNA copies (8). The
viral mRNAs are translated (9) and the NP, LP and genome segments assemble to form
ribonucleoprotein complexes. The GPC is processed in the rough endoplasmic reticulum
and Golgi apparatus. The Z matrix protein (ZP) recruits the RNPs and GPCs to the
plasma membrane for assembly (10) and budding (11). This figure was created using
BioRender.
1.5.1 Entry
Arenaviruses enter host cells through receptor-mediated endocytosis, but Old World
and New World (clade B specifically) mammarenaviruses adopt different entry
mechanisms, and utilise different receptors. The entry pathway and receptor of
New World clade A mammarenaviruses have not yet been identified, whilst it has
been shown that New World clade C mammarenaviruses (Oliveros virus and Latino
virus) utilise the same receptor and entry pathway as Old World mammarenaviruses
(Rojek et al., 2007, 2008b; Nunberg and York, 2012).
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Figure 1.20: The Different Entry Pathways of Different Mammarenaviruses.
(A) shows a schematic of the different entry pathways of mammarenaviruses. Old World
mammarenaviruses (and New World clade C) typically enter cells after binding to host
cell membrane protein α-dystroglycan (α-DG), except for Lujo virus (LUJV), which
binds neuropilin 2 (NRP-2). Old World mammarenaviruses are then internalised into
the host cell in an endocytic mechanism that involves the formation of multi-vesicular
bodies, which mature into late endosomes, in a Rab5- and Rab7-independent manner.
The decrease in pH induces structural changes in the GPC that mediates membrane
fusion and release of the ribonucleoprotein complexes (RNPs). For LUJV and Lassa virus
(LASV), the reduction in pH induces a receptor switch (to tetraspanin CD63 for LUJV
and lysosome associated membrane protein 1 [LAMP1] for LASV), which is necessary to
mediate membrane fusion and RNP release. New World (clade B) mammarenaviruses
bind transferrin receptor 1 (TfR1) and enter the host cell through clathrin-mediated
endocytosis. The virions are initially delivered to early endosomes and then to late
endosomes, in a Rab5 and Rab7-dependent manner. The pH decrease induces GPC
structural changes, which direct host and viral membrane fusion and RNP release. This
figure was obtained from (Stott et al., 2020). (B andC) show electron microscopy evidence
of LCMV (B) and JUNV (C) entering cells. LCMV (labelled with 10 nm gold particles)
was found associated with smooth (B1) and clathrin-coated (B2) structures (Quirin et al.,
2008). JUNV was shown to internalise through clathrin-coated structures (C 1 and 2)
(Martinez et al., 2007).
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Cellular Entry of Old World Mammarenaviruses
The cellular receptor for many Old World (including LCMV and LASV) and New
World clade C mammarenaviruses has been identified as α-dystroglycan (α-DG),
which is a widely-expressed cell surface protein that is highly conserved and found on
many cell types (Cao, 1998; Kunz et al., 2002). α-DG forms part of the dystroglycan
complex that connects the extracellular matrix (ECM) to the cytoskeleton (Rojek
et al., 2007). α-DG is extensively post-translationally modified and O-glycosylation
of α-DG was found to be critical for arenavirus entry (Kunz, 2009; Rojek et al.,
2007) (figure 1.20A). Specifically, successful arenavirus infection was dependent on
the addition of the negatively-charged matriglycan sugar to α-DG, which is mediated
through like-acetylglucosaminyltransferase (LARGE)-directed glycosylation (York
and Nunberg, 2009; Rojek et al., 2010; Kunz, 2009; Rojek et al., 2007). Furthermore,
during arenavirus infection, the GPC disrupts the LARGE-mediated modification
of α-DG, which reduces the presence of functional α-DG at the cell surface (Kunz,
2009). There is an extremely high binding affinity between the GPC and α-DG (Cao,
1998; Smelt et al., 2001; Sevilla et al., 2000; Kunz et al., 2001, 2005) and therefore
it is thought that the down-regulation of the expression of functional α-DG at the
cell surface assists viral exit and prevents re-infection of the same cell (Kunz, 2009).
Interestingly, a second essential entry receptor, lysosomal associated membrane
protein (LAMP1), has been identified for LASV infection (Jae et al., 2014;
Cohen-Dvashi et al., 2015). LAMP1 is found intracellularly in late endosomes and
lysosomes. It is thought that through dissociating from α-DG and interacting with
LAMP1, the LASV GPC can mediate membrane fusion and RNP escape into the
cytoplasm in less acidic endosomes (Hulseberg et al., 2018) (figure 1.20A). Through
switching receptors to LAMP1, LASV therefore avoids trafficking to increasingly
acidic endosomes, which may be inactivate virions before fusion (Torriani et al., 2017;
Hulseberg et al., 2018). LCMV has not been shown to require LAMP1 for infection,
suggesting differences in cellular receptors and entry pathways even between the Old
World mammarenaviruses (Jae et al., 2014). Furthermore, there have been several
other entry factors that have been identified for LASV, including receptor tyrosine
kinases Axl and Tyro3/Dtk, and C-type lectins Dendritic Cell-Specific Intercellular
adhesion molecule-3-Grabbing Non-integrin (DC-SIGN) and LSECtin (Goncalves
et al., 2013). These entry factors have been proposed to function as alternative
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receptors for LASV cellular entry in the absence of functional α-DG (Fedeli et al.,
2017; Herrador et al., 2019; Goncalves et al., 2013).
LUJV does not utilise the same entry receptors as LCMV, LASV and other Old
World mammarenaviruses, or the New World mammarenaviruses. Instead, the
LUJV GPC binds neuropilin 2 (NRP2) and has the tetraspanin CD63 as a secondary
entry receptor, performing a similar receptor switch as LASV in the late endosome
(Raaben et al., 2017) (figure 1.20A).
α-DG-mediated internalisation of Old World mammarenaviruses, specifically LCMV
and LASV, is thought to involve macropinocytosis (Iwasaki et al., 2014; Oppliger
et al., 2016) (figure 1.20A). These viruses are able to enter cells in a way that is
dependent on sodium-hydrogen exchangers (critical in macropinocytosis) and actin
remodelling, but independent of clathrin, dynamin-2, Arf6, calveolae, lipid rafts,
Rab5 and Rab7 (Iwasaki et al., 2014; Oppliger et al., 2016; Shao et al., 2015). The
viruses are internalised initially into a multivesicular endosome, and the receptor
(and attached virion) is then delivered to the late endosome, which involves ESCRT
complexes (Pasqual et al., 2011; Fedeli et al., 2018). It is unknown whether the
virus GPCs hijack a natural trafficking, degradation or recycling pathway of α-DG or
whether the interaction between the virus GPCs and α-DG induces a novel endocytic
route (Boulant et al., 2015). Interestingly, electron microscopy of LCMV entry
showed LCMV particles were internalised into smooth vesicles, but a small number
of virions were found internalised into clathrin-coated vesicles, suggesting there could
potentially be a different entry pathway or use of alternative entry receptors (Quirin
et al., 2008) (figure 1.20B).
Cellular Entry of New World Mammarenaviruses
The cellular receptor of New World clade B mammarenaviruses was identified as
the transferrin receptor-1 (TfR1) (Radoshitzky et al., 2007, 2008). Pathogenic
New World clade B mammarenaviruses (such as JUNV and MACV) are able to
bind human TfR1, whereas TCRV, AMPV and CPXV, are apathogenic to humans
because the GPC is unable to bind human TfR1 (Shao et al., 2015). However, these
viruses are able to bind rodent orthologs of the transferrin receptor, permitting entry
into their hosts’ cells (Shao et al., 2015). Furthermore, some of these viruses are
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able to bind multiple TfR1 orthologs, including JUNV, which can bind the feline
TfR1 ortholog (Martinez et al., 2013). This poses a threat because apathogenic
viruses could be selected, or mutate, to successfully bind human TfR1, potentially
enabling human infection (Fedeli et al., 2018; Abraham et al., 2009). Other cellular
factors have also been identified as necessary for JUNV entry, including C-type
lectins DC-SIGN and L-SIGN (Martinez et al., 2013).
The New World clade B mammarenaviruses enter cells through clathrin-mediated
endocytosis into early endosomes, following the normal internalisation and recycling
pathway of TfR1 (Radoshitzky et al., 2007) (figure 1.20A). However, the optimal pH
for JUNV GPC membrane fusion is less than 5.5, meaning fusion cannot occur in
the early endosomes, where the pH is approximately 6. JUNV GPC is proposed
to prevent TfR1 recycling and instead redirect it to the late endosomes (in a
Rab7-dependent manner), where the virus can direct membrane fusion at the lower
pH (McLay et al., 2014). Electron microscopy has confirmed the entry pathway
through clathrin-mediated endocytosis through observation of JUNV associated with
clathrin-coated vesicles (Martinez et al., 2007) (figure 1.20B).
1.5.2 Replication and Gene Transcription
After fusion of the viral and late endosome membranes, the S and L vRNAs, which
are present as the RNP complexes, are released into the host cytoplasm (figure 1.19
4). The input vRNA is then transcribed and replicated by the virion-associated
LP (Wallat et al., 2014) (figure 1.19 5-6). The RNA synthetic activities of the LP
is dependent on several structures and sequences present in the arenavirus vRNA,
including the IGR, promoter sequences in the 3’ and 5’ UTRs, the double-stranded
pan-handle structure formed by the 3’ and 5’ UTRs and a non-templated G residue
present at the 5’ end of the vRNA. Mini-genome assays have shown that NP and
LP are the minimal viral trans-acting factors that are required for the transcription
and replication of the arenavirus genome (of LCMV, LASV, JUNV, TCRV and
PICV) (Hass et al., 2004; Albariño et al., 2009; López et al., 2001; Lan et al.,
2009). Oligomerisation of the LCMV LP has also been shown to be important for
its activity (Salvato, 1993). The arenavirus ZP has an dose-dependent inhibitory
effect on transcription and replication of the arenavirus genomes (specifically LCMV,
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LASV and TCRV) (Cornu and de la Torre, 2001, 2002; Cornu et al., 2004; Hass et al.,
2004; López et al., 2001).
Initially, the NP and LP genes are transcribed from the vRNA. Sequencing of
the NP and LP mRNAs showed the presence of non-viral sequences at the 5’
end of the mRNA (Raju et al., 1990; Meyer and Southern, 1993; Polyak et al.,
1995). This suggested that the LP utilises its endonuclease activity to cleave
a short 5’-M7G-capped primer from host cellular mRNAs (Lelke et al., 2010;
Howley and Knipe, 2020). This is a mechanism shared by other viruses, including
bunyaviruses and orthomyxoviruses (Olschewski et al., 2020). However, the in vitro
endonuclease activity of LASV and LCMV LP is much lower than the other viral
endonucleases (Reguera et al., 2016). Mini-genome assays have shown residues in
the endonuclease region are essential for in vivo viral transcription but not for
replication (Reguera et al., 2016). This 5’-M7G-capped primer is able to prime
viral mRNA synthesis. The IGR functions as a bona fide transcription termination
signal for LP (Pinschewer et al., 2005). The LP transcribes capped viral mRNAs,
which are non-polyadenylated (Meyer et al., 2002). The cap assists the ribosome in
recognising, and therefore translating, the viral mRNAs. It was proposed that the
LASV NP replaces the cap-binding activity of eIF4E in the translation-initiation
complex (Qi et al., 2010), although Hastie et al. showed that mutations in the
proposed cap-binding site did not reduce levels of viral mRNA and the LASV NP
was unable to pull down the cap-structure (Hastie et al., 2011b). The NPs from
Junín, Tacaribe, and Pichindé mammarenaviruses have also not been shown to have
a direct interaction with the cap-structure (Olschewski et al., 2020).
Following the increase in NP and LP expression, the LP switches from its
transcriptase activity to its replicase activity. Arenavirus promoter sequences are
present in the 3’ UTRs of the vRNA and the cRNA. The 3’ and 5’ UTRs are
complementary, which is necessary for the formation of the panhandle structure. The
sequence and the structure of the UTR promoters has been shown to be important
for promoter activity in LCMV, LASV and MACV (Hass et al., 2006; Perez and de la
Torre, 2003a). There is a non-templated G residue at the 5’ ends of the vRNAs and
cRNAs, which is the result of a prime-and-realign mechanism that is used to initiate
LP replication (Garcin and Kolakofsky, 1990, 1992; Radoshitzky et al., 2011; Vogel
et al., 2019). The arenavirus LP (and other viral polymerases) initiate de novo
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RNA synthesis with GTP and therefore initiation of RNA replication has to start
at an internal templated C residue (Howley and Knipe, 2020). Once the initial
phosphodiester bond has been formed, LP and this uncapped primer slips back on
the vRNA template and realigns with position 1 at the 3’ end of the vRNA, and
continues RNA replication, incorporating the non-templated G residue at the 5’ end
of the newly synthesised RNA (Howley and Knipe, 2020). In order to keep the
length of the genomic vRNA constant, the LP terminates replication by removal of
the last base at the 3’ end of the newly synthesised RNA.
In the replicase mode, the LP synthesises RNA molecules that are different to the
mRNAs synthesised in the transcriptase mode. During replication, the LP reads
through the IGR termination signals to produce a complete complementary copy
of the vRNA, called the complementary RNA (cRNA). This cRNA is full-length,
uncapped and encapsidated by the NP, unlike mRNAs. This intermediate cRNA,
which is positive-sense, then acts as a template for the synthesis of mRNAs of
the GPC and ZP and negative-sense vRNA copies (figure 1.19 7-8). Initially,
the low expression levels of the ZP promotes LP transcription and replication
(Kranzusch and Whelan, 2011, 2012). Increasing ZP expression levels then have
a dose-dependent inhibitory effect on LP transcription and replication (Perez et al.,
2003b; Stinebaugh et al., 1966). The ZP has been proposed to directly interact with
the LP in order to lock it in a catalytically-inactive state (Kranzusch and Whelan,
2011, 2012). This is thought to promote progression onto the assembly and budding
stages of the viral lifecycle.
1.5.3 Assembly and Exit
The assembly and exit of the newly-synthesised arenavirus virions requires
the ZP and the GPC (figure 1.19 10-11). The GPC is translated into
the endoplasmic reticulum (ER) and proteolytically processed in the ER/Golgi
apparatus (GA) lumen by signal peptidase and SKI-1/SIP1, into the trimeric,
tripartite SSP/GP1/GP2 complex, which is directed to the plasma membrane (figure
1.14) (Lenz et al., 2000, 2001; Pinschewer et al., 2003). The ZP is also targeted to
the plasma membrane, through myristoylation of its second glycine residue, which
is thought to initiate ZP oligomerisation (Perez et al., 2004; Strecker et al., 2003).
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The ZP recruits all of the viral proteins to the assembly site through interactions
with the LP (Kranzusch and Whelan, 2011), the NP (Shimojima et al., 2012)
and the GPC (Capul et al., 2007; Urata et al., 2006). The ZPs (of LASV and
LCMV) have been shown to drive virion budding from the plasma membrane,
through recruitment of cellular ESCRT complexes using its late-budding motifs
("PTAP" and/or "PPPY") (Perez et al., 2003b; Stinebaugh et al., 1966; Freed, 2002).
Arenavirus virions also package the cellular cargo receptor endoplasmic reticulum
(ER)-Golgi intermediate compartment 53-kDa protein (ERGIC-53), which interacts
with the GPC and localises to the assembly site. This has been shown to be required
for infectivity of the progeny virions (Klaus et al., 2013).
Whilst the predominant method of arenavirus budding occurs through the action
of ZP-mediated recruitment of host cellular ESCRT complexes, some arenaviruses
lack the necessary late motifs (TCRV) or ZP entirely. It has been shown that
the late motifs of TCRV ZP are not required for ZP-mediated budding and their
replacement with other arenavirus ZP motifs did not enhance budding, suggesting
alternative methods (Urata et al., 2009). Whilst budding mediated by the TCRV
ZP was weak, budding was enhanced by the presence of the TCRV NP. The TCRV
NP contains a "YxxL" late motif and mutation of this motif blocks VLP release
(Groseth et al., 2010). This suggests that the budding activity of the ZP can be
replaced by motifs that can be present in the NP. Similarly, reptarenaviruses lack late
domain motifs in the ZP, but budding is thought to be achieved through a conserved
"PPPY" late motif in the NP and other late domain-like motifs present in the NP
C-terminal domain (Stenglein et al., 2012). Furthermore, viruses in the Hantaviridae
family of the Bunyavirales order do not encode a ZP-like protein and instead
utilise late-domain motifs located within the Gn cytoplasmic tail to direct budding
(Strandin et al., 2013). The lack of ZP in hartmaniviruses and antennaviruses
suggests alternative budding methods are employed for their exit. Furthermore,
the presence of a conserved "P[Y/F]PHYP" stretch in the hartmanivirus GP2
cytoplasmic tail has indicated that hartmanivirus budding is mediated through
binding between GP2 and apoptosis-linked gene 2 (ALG-2), which then bridges
Alix and the ESCRT-I complex (Hepojoki et al., 2018). The budding activities of
the antennaviruses has not yet been well described.
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1.6 Project Aims
The work presented in this thesis aimed to develop molecular tools in order to
further the understanding of arenavirus infection, arenavirus RNP complexes and
arenavirus GPC entry spikes. This thesis focused on two biosafety level 2 classified
arenaviruses; LCMV as a representative of the Old World mammarenaviruses and
PICV as a representative of the New World mammarenaviruses. Study of these
viruses can be extrapolated to biosafety level 4 classified arenaviruses, which are
responsible for severe human morbidity and mortality. Three main objectives were
established for this project:
1. Generation of LCMV NP antisera for its use as an arenavirus detection tool.
LCMV NP was purified for the generation of a polyclonal antibody, which was
subsequently used to investigate intracellular localisation of the NP during
arenaviral infection and to develop a focus-forming assay for the titration of
LCMV, using fluorescence microscopy.
2. Development of a reverse genetics system designed to recover infectious LCMV.
This system was used to generate high titre stocks of LCMV for subsequent
structural examination. This system was also engineered to investigate the
incorporation of eGFP into the S segment and the fusion of the 6xHis tag
to the C-terminus of the NP, permitting the development of high-throughput
screening methods and structural examination of the arenavirus RNP, using
fluorescence and electron microscopy.
3. Structural examination of the PICV and LCMV GPCs by cryo-electron
tomography. Sub-tomogram averaging was subsequently performed to permit
structural investigation into the differences between glycoprotein complex
(GPC) spikes of New World (PICV) and Old World (LCMV) arenaviruses.
In summary, the aim of this project was to generate an LCMV NP antibody, which
enabled the optimisation of the LCMV reverse genetics system. The LCMV NP
antibody can be used for easy identification of successful infection and further
investigation into the cellular localisation of the NP during the viral lifecycle. The
LCMV reverse genetics system permits mutational analysis of the viral proteins, as
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well as the incorporation of fluorescent tags or purification tags for high throughput
screening assays or structural investigation into arenavirus RNPs. Both the tools
developed here permitted the generation of high titre LCMV stocks for the structural
examination of the GPC spike and comparison to the PICV GPC spike. The study
of the GPC spikes from both Old World and New World mammarenaviruses can
potentially provide explanations for differences in arenavirus entry and highlight






The LCMV NP open reading frame (ORF) was supplied in pMK-RQ and it was
sub-cloned into the pET28a(+)-His-SUMO expression vector for bacterial expression
and protein purification.
The LCMV (strain: Armstrong; clone 13 derivative) S and L segment sequences
(GenBank accession numbers: DQ361065 and DQ361066 for S and L respectively)
were synthesised by GENEWIZ in the pUC57 vector. The NP and LP support
plasmids were made by sub-cloning the NP and LP ORFs from pUC57-S and
pUC57-L into a pUC57 vector.
2.1.2 Bacterial Cell Strains
The Escherichia coli (E. coli) DH5-α strain was used for plasmid amplification,
unless otherwise specified. For bacterial expression of LCMV NP, a range of E.
coli expression strains were used, as described in table 2.1. All E. coli strains were
produced in house by Susan Matthews.
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Name Manufacturer Genotype
BL21-Gold(DE3)pLysS Agilent Technologies E. coli B F- ompT hsdS(rB-mB-) dcm+ TetR gal
λ(DE3) endA Hte [pLysS CamR]
BL21-Star(DE3)pLysS Invitrogen E. coli F- ompT hsdSB(rB-mB-) gal dcmrne131
λ(DE3) [pLysS CamR]
BL21-Rosetta(DE3)pLysS Millipore E. coli F- ompT hsdSB(rB-mB-) TetR gal dcm
λ(DE3) [pLysSRARE CamR]
BL21-Rosetta 2(DE3)pLysS Millipore E. coli F- ompT hsdSB(rB-mB-) TetR gal dcm
λ(DE3) [pLysSRARE2 CamR]
BL21-CodonPlus(DE3)-RIPL Agilent Technologies E. coli B F- ompT hsdS(rB-mB-) dcm TetR gal
λ(DE3) endA Hte [argU proL CamR] [argU ileY
leuW Strep/SpecR]
Lemo21(DE3) New England Biolabs fhuA2 [lon] ompT gal λ(DE3) [dcm]
∆hsdS/pLemo(CamR)
Table 2.1: Table of Bacterial Expression Strains
2.1.3 Mammalian Cell Lines
The cell lines used in this work include Baby Hamster Kidney 21 (BHK) cells,
BSR-T7 cells, SH-SY5Y cells, A549 cells, Vero cells, VeroE6 cells and SW13
cells. BHK-21 cells were isolated from kidney tissue of Syrian golden hamsters
(Mesocricetus auratus) (Stoker and Macpherson, 1964). BSR-T7 cells were derived
from the BHK-21 cell line and have been stably transformed to constitutively
express T7 RNA polymerase (T7P; (Buchholz et al., 1999)). BSR-T7 cells were also
additionally supplemented with G418 (1 mg/mL) every other passage to maintain
the T7P plasmid. SH-SY5Y cells were sub-cloned from an original cell line called
SK-N-SH, which was derived from the bone marrow of a four-year-old female with
neuroblastoma (Biedler and Schachner, 1978). A549 cells are derived from human
adenocarcinomic alveolar basal epithelial cells, which were cultured from a tumour
from a 58-year-old male (Giard et al., 1973). Vero cells originated from epithelial
cells isolated from the kidney tissue of the African Green Monkey (Cercopithecus
aethiops). Vero-E6 cells were kindly provided by Professor Roger Hewson (Public
Health England, UK) and originate from the Vero76 clone, which itself is a clone of
the original Vero cell line (Ammerman et al., 2008). SW13 cells have been derived
from human adrenocortical carcinoma (Leibovitz et al., 1973).
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2.1.4 Virus Strains
Clone-13 (LCMV-Cl13), which derived from the parent Armstrong strain of LCMV
(LCMV-ARM), was isolated from the spleen tissue of a mouse that was persistently
infected with LCMV-ARM from birth (Ahmed et al., 1984) and was the strain chosen
in the design of the LCMV rescue system described here. There are 15 nucleotide
differences between the genomes of the LCMV-ARM and LCMV-Cl13 strains (6 in
the S segment and 9 in the L segment) but only 2 of these result in coding changes.
Typically, the LCMV-ARM strain is associated with acute infections and strong
immune responses whereas the LCMV-Cl13 strain is associated with persistent
infections and immunosuppression (Zapata and Salvato, 2013). This difference in
persistence between LCMV-ARM and LCMV-Cl13 has been attributed to the two
coding changes; F260L in the GPC and K1079Q in the LP (Grande-Pérez et al.,
2016; Zapata and Salvato, 2013).
The P18 strain of Cali mammarenavirus (previously known as Pichindé virus; PICV)
was used in these experiments, kindly provided by Professor Roger Hewson (Public
Health England, UK).
2.1.5 Antibodies
The antibodies used for western blotting analysis (WB), immunofluorescence
analysis (IF) and focus forming assays (FFA) have been detailed in table 2.2.
Antibody Species Dilution (v/v) Label Company
Anti-LCMV NP Sheep WB (1:1000) IF (1:500)
FFA (1:1000)
N/A Antibody Applications
Anti-HAZV NP Sheep WB (1:3000) IF (1:500) N/A Alta Bioscience
Anti-GAPDH Mouse WB (1:7500) N/A Cell Signalling Technologies
Anti-β-Actin Rabbit WB (1:5000) N/A abcam
Anti-6xHis Tag Mouse WB (1:1000) N/A ThermoFisher Scientific
Anti-GFP (B-2) Mouse WB (1:1000) IF (1:250) N/A Santa Cruz Biotechnology
Anti-Goat IgG Donkey WB (1:10000) IRDye 800CW LI-COR Biosciences
Anti-Mouse IgG Donkey WB (1:10000) IRDye 680RD LI-COR Biosciences
Anti-Rabbit IgG Donkey WB (1:10000) IRDye 800CW LI-COR Biosciences
Anti-Sheep IgG Donkey IF (1:1000) Alexa Fluor 594 Cell Signalling Technologies
Anti-Mouse IgG Chicken IF (1:1000) Alexa Fluor 488 Cell Signalling Technologies
Anti-Sheep IgG Donkey FFA (1:500) Horseradish Peroxidase Sigma-Aldrich
Table 2.2: Table of Antibodies
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2.2 Molecular Biology
2.2.1 Polymerase Chain Reaction (PCR)
PCR was used for the amplification of the ORFs and to introduce flanking restriction
enzyme sites to permit ligation with a complementary vector. The LCMV NP
ORF, from plasmid pMK-RQ and the pUC57-S plasmid, the LCMV L polymerase
ORF, the eGFP-P2A ORF and the pUC57 plasmid were all amplified by PCR. The
oligonucleotide primers that were used in the reaction have been described in table
2.3.
Primer Name Primer Sequence (5’ - 3’)
LCMV NP Forward ACCAAGGATCCATGTCCTTGTCTAAGGAAGTTAAGAGCTTCCAATGG
LCMV NP Reverse TATAATCTCGAGTCAGGGAGGCCCAGAGG
NP ORF Forward CAGAAGCTAGCAAGATCCTAGGCATTTGATTG
NP ORF Reverse GAAGTCTCGAGTAGTCTTAGAGTGTCACAACATTTG
LP ORF Forward CAGAAGCTAGCAACTAGGCTTTTTGATGCGC







Insert eGFP Forward CGGCCGCATGTCCTTGTCTAAG
Insert eGFP Reverse CCCATGGCTTGTTGCTCAATGG
XhoI Forward CAGGGAAGCCTCGAGGGAGTATGAAG
XhoI Reverse GTCATTTCAACATCGATAAGCTTAATG
Table 2.3: Table of Oligonucleotide Primers
PCR was performed in a volume of 50 µL and contained; 50 ng template DNA, 10
mM dNTPs, 10 µM forward primer, 10 µM reverse primer, 1X Q5 Reaction Buffer
and 1 U Q5 High Fidelity DNA Polymerase (Q5 High Fidelity Kit; New England
Biolabs). PCR cycling was performed in a thermocycler (ProFlexTM) using the
following conditions; 98 ℃ for 30 seconds, then 25 cycles of; 98 ℃ for 10 seconds,
an annealing temperature for 30 seconds, then 72 ℃ for 30 seconds/kb, followed by
a final extension step at 72 ℃ for 2 minutes. The optimal annealing temperature
for the primers was determined by using a temperature gradient, ranging from 50
℃ to 70 ℃.
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Insertions, substitutions and deletions were also carried out using PCR and
the primers were designed according to the manufacturer’s instructions (Q5
Site-Directed Mutagenesis Kit, New England Biolabs). Here, PCR was performed in
a total volume of 25 µL, using a mastermix which contains the Q5 Reaction Buffer,
the Q5 Hot Start High-Fidelity DNA Polymerase, 10 mM dNTPs and 2 mM (final
concentration) Mg2+ to which the following was added; 10 µM forward primer, 10
µM reverse primer and 25 ng template DNA. The PCR cycling conditions were the
same as above. Following PCR amplification, 1 µL of the PCR mix was treated with
kinase, DpnI and ligase, for 5 minutes, to re-circularise the mutated vector, which
was then transformed into E. coli DH5-α.
2.2.2 Restriction Digest
Restriction digests were performed either to generate sticky ends for ligating PCR
products into new vectors or as a diagnostic digest. 1 µg of the DNA sample was
mixed with 1 U of each restriction enzyme and the appropriate enzyme buffers. This
reaction was incubated for a minimum of 1 hour at 37 ℃. The enzymes were then
either heat-inactivated (according to the manufacturer’s instructions) or removed
using the Monarch DNA Gel Extraction Kit or the Monarch PCR and DNA Cleanup
Kit.
2.2.3 Agarose Gel Electrophoresis
In order to examine diagnostic restriction digests or to purify DNA samples through
gel extraction, DNA samples were separated by agarose gel electrophoresis. The
DNA samples were mixed with 1X gel loading dye (New England Biolabs) and were
loaded on to a 1 % agarose gel (made in 1X TAE buffer [40 mM Tris-acetate, 1 mM
EDTA; TAE] and stained with SYBRTM Safe DNA Stain [Thermo Fisher Scientific,
diluted 10,000-fold]). Hyperladder I (Bioline) was loaded alongside the DNA samples
as a molecular marker. The agarose gel was run at 100 V for 1 hour in 1X TAE
buffer. DNA was visualised using blue light trans-illumination.
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2.2.4 Ligation
When the amplified PCR product needed to be ligated with a vector, the amplified
cDNA was first treated with 10 U of DpnI enzyme, incubated in CutSmart buffer
for 1 hour at 37 ℃. DpnI cleaved any methylated template DNA which was present
in the reaction, in order to prevent the original template DNA being transformed
into bacteria instead of the ligated product.
After the restriction enzyme digest, DpnI treatment and DNA clean up, the vector
and the PCR insert were mixed at a 1:5 ratio. On ice, T4 DNA ligase buffer (New
England Biolabs) and 20 U T4 DNA ligase (New England Biolabs) were added and
gently mixed. The reaction was incubated at room temperature for 10 minutes then
heat-inactivated at 65 ℃.
2.2.5 Transformation
E. coli DH5-α were used for the amplification of plasmid DNA. 50 µL of bacterial
cells was mixed with 50 ng DNA and incubated on ice for 30 minutes. The cells
were heat-shocked at 42 ℃ for 45 seconds, before incubating on ice for a further 5
minutes. 950 µL (LB) media was added to the cells, which were incubated for 1 hour
at 37 ℃, with shaking. 100 µL of this was plated on to an LB agar plate containing
the appropriate antibiotic (100 µg/mL ampicillin or 50 µg/mL kanamycin) and was
incubated at 37℃ overnight.
2.2.6 DNA Amplification
A single bacterial colony was used to inoculate 50 mL (small-scale), 100 mL
(large-scale; high copy number plasmid) or 200 mL (large-scale; low copy number
plasmid) LB media, which had appropriate antibiotic selection. This was incubated
overnight at 37 ℃, with shaking. The bacterial cells were pelleted by centrifugation
at 4000 x g at 4 ℃ for 30 minutes. Plasmid DNA was extracted using QIAprep
Spin Miniprep Kit (QIAGEN) or QIAGEN Plasmid Midi or Maxi Kits (QIAGEN),
following the manufacturer’s instructions. DNA concentration and purity was
determined by spectrophotometry using a NanoDrop 1000 (Thermo Scientific) and
was confirmed as correct through Sanger sequencing, performed by GENEWIZ.
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2.3 Protein Expression and Purification
2.3.1 IPTG Induction
The pET28a(+)-His-SUMO-LCMV NP expression vector was transformed into
BL21-DE3 E. coli variants (table 2.1), using the method described in section 2.2.5.
Single colonies were used to inoculate 10 mL LB media, with selection antibiotic
kanamycin added, and this was incubated overnight at 37 ℃, with shaking. The
overnight culture was then used to inoculate 1 L 2YT media (0.5 % NaCl, 1.6
% tryptone, 1 % yeast extract), which was incubated at 37 ℃ with shaking at
180 RPM until the optical density, measured at a wavelength of 600 nm (OD 600)
reached 0.6-0.8. A sample of the uninduced sample was taken and then 500 mM
isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to the media to induce
T7P expression of LCMV NP. The induced culture was incubated at 37 ℃, with
shaking. After incubation for 24 hours, the culture was harvested and centrifuged at
4000 x g for 30 minutes at 4 ℃. The pellet was resuspended in lysis buffer (500 mM
NaCl, 20 mM Tris-HCl [pH 6.8], 20 mM MgCl2, 20 mM imidazole, 1 % Triton-X-100,
0.5 % NP40, 0.5 % Tween-20, 10 % glycerol, 0.1 mM phenylmethylsulfonyl fluoride
(PMSF), 0.1 mM Tris(2-carboxyethyl)phosphine hydrochloride (TCEP-HCl), 0.1 %
[w/v] lysozyme from chicken egg white (Sigma-Aldrich), 1 U/mL DNase, 1 U/mL
RNase) and incubated on ice for 30 minutes. The resuspension was then sonicated
using a Soniprep 150 to complete cell lysis. Sonication was performed on ice using 10
microns amplitude for 10 seconds, with 50 seconds in between cycles, for a total of 30
cycles. A whole cell lysate sample was taken and the remainder was centrifuged at
40,000 x g for 30 minutes. The supernatant was taken into a new tube and contained
the soluble fraction of the bacterial cells. The pellet was resuspended in resuspension
buffer (400 mM NaCl, 20 mM Tris-HCl [pH 6.8]) and contained the insoluble portion
of the bacterial cells. All samples were then prepared for SDS-PAGE analysis, which
has been described in section 2.4.1.
Lemo21(DE3) cells (New England Biolabs) were also transformed with the
pET28a(+)-His-SUMO-LCMV NP expression vector, in an attempt to improve
solubility. Single colonies were picked to inoculate 10 mL LB media, with selection
antibiotics kanamycin and chloramphenicol added, and this was incubated overnight
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at 37 ℃, with shaking. 1 mL of the overnight culture was then used to inoculate
100 mL 2YT media, which was incubated at 37 ℃ with shaking at 180 RPM,
until OD600 reached 0.6-0.8. At this point, an uninduced sample was taken and
the culture was divided into 10 mL, where 500 mM IPTG and L-rhamnose (Sigma
Aldrich), concentration ranging from 0 µM - 2000 µM, were added. The samples
were incubated at 37 ℃, with shaking, for 24 hours and the soluble and insoluble
fractions were harvested in the same manner as above.
2.3.2 Autoinduction
The pET28a(+)-His-SUMO-LCMV NP expression vector was transformed into
Rosetta strain and expression was induced by autoinduction, the method of which
was previously described by (Studier, 2005). Briefly, 10 mL of an overnight culture
was added to 1 L autoinduction media (42 mM Na2HPO4, 22 mM KH2PO4, 2
% tryptone, 0.5 % NaCl and 0.5 % yeast extract) supplemented with 0.22 µm
filter-sterilised 60 % glycerol (final concentration; 0.6 %), 10 % glucose (final
concentration; 0.05 %), 8 % lactose (final concentration; 0.2 %) and kanamycin
and was incubated for 60 hours at 18 ℃ with shaking at 150 RPM. Samples were
harvested as described in section 2.3.1.
2.3.3 Immobilised Metal Affinity Chromatography
Before applying the soluble fraction to the nickel (Ni2+) resin, it was filtered through
a 0.45 µM filter and the resin was equilibrated with binding buffer (500 mM NaCl, 20
mM Tris-HCl; pH 7 and 20 mM imidazole). It was then applied to 5 mL HisTrapTM
High Performance (GE Healthcare) Ni2+ resin column at 4 ℃ and the flowthrough
was collected. The Ni2+ resin was washed with increasing concentrations of imidazole
(ranging from 20 mM to 100 mM), in 500 mM NaCl and 20 mM Tris-HCl; pH 7
buffer, before elution at 500 mM imidazole. The Ni2+ resin was then washed in 1 M
imidazole (500 mM NaCl and 20 mM Tris-HCl; pH 7) to remove any bound proteins,
before final water washes and storage in 20 % ethanol. The imidazole concentration
was reduced by overnight dialysis in 500 mM NaCl and 20 mM Tris-HCl; pH 7, and
the 6xHis-SUMO tag was removed using 1 U/mL ULP1.
For further purification, the dialysed/cleaved elution was once again applied to a
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clean 5 mL HisTrapTM High Performance (GE Healthcare) column and the flow
through was collected, which contained untagged LCMV NP. The Ni2+ resin was
then washed with a 20 mM imidazole (500 mM NaCl and 20 mM Tris-HCl; pH 7)
buffer and in 1 M imidazole (500 mM NaCl and 20 mM Tris-HCl; pH 7) to remove
other bound proteins. Samples were collected throughout and were prepared for
SDS-PAGE analysis, as described in section 2.4.1.
2.3.4 Ion-Exchange Chromatography
Ion-exchange chromatography (IEC) was performed on SP sepharose resin (GE
Healthcare), which was loaded into a glass column and washed with 5 M NaOH
and ddH2O. The resin was equilibrated by 3 cycles of alternate washes (5 column
volumes) of low salt buffer (50 mM NaCl, 20 mM Tris; pH 7) and high salt buffer (1
M NaCl, 20 mM Tris; pH 7), before a final wash with 10 column volumes low salt
buffer. The flowthrough collected from the HisTrap HP column, containing LCMV
NP, was diluted, in low salt buffer, to reduce the NaCl concentration from 500 mM
to 50 mM. The diluted LCMV NP was then passed over the SP sepharose resin
by gravity flow. The resin was subsequently washed with increasing concentrations
of salt (50 mM-1 M) and constant 20 mM Tris, at pH 7. Samples were collected
throughout and were prepared for SDS-PAGE analysis, as described in section 2.4.1.
The IEC fractions containing the highest concentration of LCMV NP were
pooled and concentrated to 0.5 mg/mL, using a 10 kDa molecular weight cut-off
concentrator (Amicon). This was then analysed by SDS-PAGE (described in 2.4.1)
and Coomassie staining (described in section 2.4.2). Purity (>85 %) was confirmed
by densitometry using ImageJ software.
2.3.5 Size-Exclusion Chromatography
Size-exclusion chromatography (SEC) was performed on a HiLoad 26/600 Superdex
prep grade column (GE Healthcare), which had previously been equilibrated with
filtered and degassed equilibration buffer (500 mM NaCl and 20 mM Tris-HCl; pH
7). The flowthrough collected from the HisTrap HP column, containing LCMV NP,
was concentrated to 5 mL using a 10 kDa molecular weight cut-off concentrator
(Amicon). This was injected onto the column using an ÄKTA prime and a flow rate
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of 0.5 mL/min. After the void volume (120 mL), 3 mL fractions were collected and
the absorbance at 280 nM (mAU) was measured. Fractions containing the highest
concentration of LCMV NP were pooled, concentrated to 1 mg/mL and analysed
by SDS-PAGE analysis (as described in 2.4.1).
2.3.6 Generation of the LCMV NP antisera
α-LCMV NP antibody was generated by immunising a sheep with 4x 200 mg
inoculations of purified LCMV NP (Antibody Applications). Serum was collected
pre-inoculation and post-1, -2, -3 inoculations and verified as reactive to the original
sample through enzyme-linked immunosorbent assays (ELISA) analysis. α-LCMV
NP serum was clarified by centrifugation at 4000 x g for 20 minutes at 4 ℃ to
remove debris, aliquoted to avoid repeated freeze-thaw cycles and stored at -20 ℃.
Subsequent western blotting and immunofluorescence assays were performed using
clarified serum collected from the post-3 inoculation.
2.4 Protein Analysis Techniques
2.4.1 SDS Polyacrylamide Gel Electrophoresis
Proteins were resolved by sodium dodecyl-sulphate polyacrylamide gel
electrophoresis (SDS-PAGE). Samples were prepared with 4X lithium dodecyl
sulphate (LDS; made in house) and 10X dithiothreitol (DTT) (both final
concentration at 1X) and denatured by heating at 95 ℃ for 5 minutes. The samples
were loaded onto 12 % SDS PAGE resolving gels, which were overlaid with 5 %
stacking gels. The gels were run at 180 V for 1 hour, or until the loading dye front
has run off the gel, in 1X SDS-PAGE running buffer (25 mM Tris, 192 mM glycine,
0.1 % [w/v] SDS).
2.4.2 Coomassie Staining and Silver Staining
The proteins resolved by the SDS-PAGE gels were fixed using a fixative solution (40
% [v/v] ethanol, 10 % [v/v] acetic acid). This was incubated at room temperature
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for 1 hour and the gel was then washed using water and stained using the Colloidal
Coomassie G-250 stain (2 % [v/v] phosphoric acid, 10 % [w/v] ammonium sulphate,
0.1 % [w/v] Coomassie Brilliant Blue G-250 dye). The gel was stained overnight at
room temperature. Resolution was improved by destaining the gel overnight in 1 %
acetic acid.
To improve sensitivity of the protein staining, silver staining was performed instead
using the ProteoSilverTM Kit (Sigma-Aldrich). The gel was stained following the
manufacturer’s protocol.
2.4.3 Western Blotting
In order to detect specific proteins using antibodies, proteins resolved by SDS-PAGE
were transferred to a polyvinylidene fluoride (PVDF) membrane. The membrane
was first activated in 100 % methanol and then washed in TOWBIN (22 mM Tris,
192 mM glycine, 20 % methanol). The SDS-PAGE gel was also washed in TOWBIN
and the filter papers were soaked in TOWBIN before assembly. The transfer was
performed at 15 V for 1 hour, using the Trans-Blot semi-dry cell (Bio-Rad). After
transfer, the membrane was briefly rinsed in 1X PBS-T (1X PBS supplemented
with 0.1 % tween-20) before being incubated in Odyssey blocking buffer (PBS)
(Licor; diluted 1 : 1 with 1X PBS), for 1 hour rocking. Subsequently, the blocking
buffer was removed and the membrane was stained with the primary antibodies
(made in 1:4 [blocking buffer:PBS-T]; for antibody concentrations, see table 2.2)
for 1 hour rocking. The membrane was washed three times (5 minutes each) in 1X
PBS-T, and then rocked for 1 hour with secondary antibody (made in 1:4 [blocking
buffer:PBS-T]; for antibody concentrations, see table 2.2). The secondary antibody
is reactive to the species of the primary antibody and is conjugated to fluorescent
dyes, either IRDye 680RD or IRDye 800CW. The membrane was washed three times
(5 minutes each) in 1X PBS-T before a final wash in 1X PBS (5 minutes) and then
a rinse in UltraPure Distilled Water (Thermo Fisher Scientific). The membrane was
dried and visualised on the Licor Odyssey Sa Infrared imaging system.
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2.5 Cell Culture
2.5.1 Continuous Cell Culture
All cell lines were incubated in a humidified environment, at 37 ℃ with 5 %
CO2. The cell lines were maintained in high-glucose Dulbecco’s modified Eagle
medium (DMEM; Sigma-Aldrich), supplemented with 10 % heat-inactivated foetal
bovine serum (FBS), 100 µg of streptomycin/mL and 100 U of penicillin/mL
(complete media). The absence of mycoplasma contamination was confirmed using
MycoAlertTM (Lonza).
Cells were routinely passaged when confluence was reached. Media was washed
from the cells using 1X PBS. The cells were detached from the flask by adding 1X
Trypsin-EDTA solution (Sigma-Aldrich) and incubating at 37 ℃ for 3-5 minutes.
2.5.2 Freezing and Thawing Cells
All cell lines were stored in liquid nitrogen. In order to freeze cells, the cells were
washed with 1X PBS and trypsinised as in section 2.5.1. The cell suspension was
then centrifuged at 500 x g for 5 minutes. The cell pellet was resuspended in a
solution containing 40 % FBS, 10 % dimethyl sulfoxide (DMSO) and 50 % DMEM.
The resuspension was then aliquoted into cryo-vials and frozen at a controlled rate
(approximately -1 ℃/min) using a Corning CoolCell alcohol-free freezing container.
The frozen cells were then transferred to liquid nitrogen.
Frozen cells would be thawed rapidly at 37 ℃. The defrosted cell suspension would
then be centrifuged at 500 x g for 5 minutes. The pellet would be resuspended in
complete media and transferred to a T-25 flask and incubated overnight. When
confluency was reached, the cells would be transferred to a T-75 flask and then
eventually to a T-175 flask.
2.5.3 Mammalian Cell Lysis
Cell lysates were collected by removing the complete media, washing the cells once in
1X PBS and then adding 1X radioimmunoprecipitation assay (RIPA) buffer (50 mM
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Tris-HCl pH 7.5, 150 mM NaCl, 1 % (v/v) NP40 alternative, 0.5 % (w/v) sodium
deoxycholate and 0.1 % sodium dodecyl sulphate (SDS; w/v)), supplemented with
1X cOmpleteTM, Mini, EDTA-free Protease I inhibitor cocktail (Sigma-Aldrich).
This was incubated on ice for 20 minutes before collecting and transferring the cell
lysate to a 1.5 mL eppendorf. The lysate was centrifuged at 13,000 x g for 10 minutes
and the supernatant was stored at -20 ℃.
2.6 Virological Techniques for LCMV
2.6.1 LCMV Infection and Propagation
In order to infect cells with LCMV, the cells were seeded the previous day to a density
which would provide 60-70 % confluency. The cells were washed with 1X PBS and
after PBS removal, LCMV clarified supernatant was added in serum-free DMEM
(SFM) at a specified multiplicity of infection (MOI). The cells were incubated at
37 ℃, with regular manual rocking, for one hour, to allow LCMV to adsorb to
the cells. The LCMV clarified supernatant was then removed and replaced with
DMEM containing 2 % FBS and incubated for the necessary time before harvesting
the supernatant or the cell lysate. Mock infections were carried out in the same
manner, but using SFM only instead of LCMV clarified supernatant.
In order to propagate LCMV, T175 flasks were seeded with 5 x 106 BHK-21 cells.
The following day, the cells were washed with 1X PBS and infected with LCMV at an
MOI of 0.001. After 1 hour incubation, the media was replaced with 15 mL DMEM
containing 2 % FBS and incubated for 72 hours. At this point, the supernatant
was collected and clarified by centrifugation at 4000 x g for 15 minutes at 4 ℃. The
clarified supernatant was aliquoted into cryo-vials and stored at -80 ℃.
2.6.2 LCMV Purification for Electron Microscopy
12x vented T175 cm2 flasks were seeded with 5x106 BHK-21 cells at least 24 hours
before infection. When the BHK-21 cells were approximately 80-90 % confluent,
the cells were washed twice with 1x PBS and then LCMV, at a MOI of 0.001, was
allowed to adsorb for 1 hour in serum free media at 37 ℃. LCMV was removed after
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the adsorption time and replaced with 15 mL complete media. The infection was
allowed to proceed for approximately 65 hours and was regularly rocked to move
the media around. The supernatant was collected and centrifuged for 30 minutes
at 4000 x g at 4 ℃. The supernatant was then filtered through a 0.45 µm filter and
centrifuged again for 30 minutes at 4000 x g at 4 ℃. The supernatant was then
transferred to ultra-centrifuge tubes and 8 mL 20 % sucrose (supplemented with 1X
cOmpleteTM, Mini, EDTA-free Protease I inhibitor cocktail (Sigma-Aldrich)) was
underlayed. The tubes were balanced and then centrifuged for 3 hours at 90,000 x g
at 4 ℃. The sucrose cushion and supernatant were removed after centrifugation and
the pellet was air-dried for 5 minutes, upside down on tissue. 15 µL resuspension
buffer (0.1X PBS + 0.1 mM MgCl2 + 0.1 mM CaCl2 + 1X cOmpleteTM, Mini,
EDTA-free Protease I inhibitor cocktail (Sigma-Aldrich)) was added to the virus
pellet and the ultra-centrifuge tubes were covered with two layers of parafilm, before
incubating on a rocker overnight at 4 ℃. The resuspended pellet was collected the
following morning and aliquots were flash-frozen using liquid nitrogen and then
stored at -80 ℃. Samples were taken for western blotting analysis (section 2.4.3),
plaque assay (section 2.6.4) and negative-stain EM (section 2.10.1). For preparation
of cryo-EM grids (section 2.10.2), aliquots were removed from -80 ℃ storage and
defrosted on ice.
2.6.3 Titre Determination by Crystal Violet Plaque Assay
Crystal violet plaque assays were attempted to determine the titre of the LCMV
stocks. The crystal violet plaque assay protocol was adapted from (Ziegler et al.,
2016). VeroE6 cells were seeded in six-well plates at 1 x 105 and the following day
were infected with serially diluted LCMV (10-fold). LCMV was allowed to adsorb
to the cells for 90 minutes at 37 ℃ and then the cells were overlaid with 1.4 %
agarose, mixed at a 1 : 1 ratio with complete media (final agarose concentration
was 0.7 %). The cells were incubated for 4 days, at which point they were fixed with
2.5 % formaldehyde diluted in 3X PBS. The agarose was removed and the cells were
stained with 0.1 % crystal violet in 2.1 % ethanol.
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2.6.4 Titre Determination by Focus Forming Assay
The titre of LCMV stocks was successfully determined using focus forming assays.
Six-well plates were seeded with 5 x 105 BHK-21 cells and incubated overnight.
The following day, the cells were infected with serial dilutions of LCMV (10-fold)
and incubated for 1 hour, allowing LCMV to adsorb to the cells. The dilutions
were removed from the cells, which were then overlaid with methylcellulose (1.6 %
mixed 1 : 1 with complete media; final concentration of methylcellulose 0.8 %) and
incubated for 3 days. After incubation, the overlay was removed and the cells were
washed with 1X PBS. 4 % formaldehyde (made in 1X PBS) was added and the
cells were fixed for 15 minutes. The 4 % formaldehyde was removed and the cells
were washed twice with 1X PBS. The cells were then permeabilised by adding 0.5 %
Triton-X-100 (made in 1X PBS) and incubating for 15 minutes at room temperature,
with rocking. The cells were then washed twice with 1X PBS and blocked using 0.5
% FBS (made in 1X PBS) which was incubated for 1 hour at room temperature,
with rocking. The blocking buffer was removed and the cells were washed twice
with 1X PBS. The cells were then stained with anti-LCMV NP (for dilution, see
table 2.2), made in 0.5 % FBS containing 0.1 % tween-20. After 2 hours incubation,
the antibody solution was removed and the cells were washed three times in 1X
PBS. The cells were then stained for 1 hour at room temperature with an anti-sheep
secondary antibody (for dilution, see table 2.2), which was either conjugated to a
fluorophore (568 nm) or to horseradish peroxidase (HRP).
For the fluorophore-conjugated secondary antibody staining, the cells were washed
five times with 1X PBS and left in the final wash. The entire well was then imaged
at 4X magnification using the EVOS FL 2 automated microscope. Foci were counted
as individual regions of more than one cell that were fluorescing brighter than the
background.
For the HRP-conjugated secondary antibody staining, the cells were washed five
times with 1X PBS. 4-Chloro-1-naphthol (4C1N; Sigma) was made previously, by
dissolving 1 tablet in 10 mL 100 % methanol, which was then stored at -20 ℃. On
the day, 4C1N was diluted 1 : 10 in 1X PBS and 30 µL hydrogen peroxide was
added to 10 mL. 200-500 µL was then added to the cells, which were incubated for
15 minutes or until purple foci had appeared. The wells were imaged and the foci
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were counted. Titre was calculated using the following equation:
V irus titre (ffu/mL) = average number of foci
dilution factor ∗ volume (mL)
2.7 Virological Techniques for PICV
2.7.1 PICV Infection and Propagation
In order to infect cells with PICV, the cells were seeded the previous day to a density
which would provide 60-70 % confluency. The cells were washed with 1X PBS and
after PBS removal, PICV clarified supernatant was added in serum-free DMEM
(SFM) at a specified multiplicity of infection (MOI). The cells were incubated at
37 ℃, with regular manual rocking, for one hour, to allow PICV to adsorb to
the cells. The PICV clarified supernatant was then removed and replaced with
DMEM containing 2 % FBS incubated for the necessary time before harvesting the
supernatant or the cell lysate. Mock infections were carried out in the same manner,
but using SFM only instead of PICV clarified supernatant.
In order to propagate PICV, T175 flasks were seeded with 5 x 106 BHK-21 cells.
The following day, the cells were washed with 1X PBS and infected with PICV at an
MOI of 0.001. After 1 hour incubation, the media was replaced with 15 mL DMEM
containing 2 % FBS and incubated for 72 hours. At this point, the supernatant
was collected and clarified by centrifugation at 4000 x g for 15 minutes at 4 ℃. The
clarified supernatant was aliquoted into cryo-vials and stored at -80 ℃.
2.7.2 PICV Purification for Electron Microscopy
12x vented T175 cm2 flasks were seeded with 1x107 BHK-21 cells at least 24 hours
before infection. When the BHK-21 cells were approximately 80-90 % confluent,
the cells were washed twice with 1x PBS and then PICV, at a MOI of 0.001, was
allowed to adsorb for 1 hour in serum free media (rocking at 37 ℃). PICV was
removed after the adsorption time and replaced with 15 mL DMEM containing 2
% FBS and 0.01 % DEAE. The infection was allowed to proceed for 72 hours and
was regularly rocked to move the media around. The supernatant was collected and
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centrifuged for 30 minutes at 4000 x g at 4 ℃. The supernatant was then filtered
through a 0.45 µm filter and centrifuged again for 30 minutes at 4000 x g at 4 ℃. The
supernatant was then transferred to ultra-centrifuge tubes and 8 mL 30 % sucrose
(supplemented with 1X cOmpleteTM, Mini, EDTA-free Protease I inhibitor cocktail
(Sigma-Aldrich)) was underlayed. The tubes were balanced and then centrifuged
for 3 hours at 150,000 x g and at 4 ℃. The sucrose cushion and supernatant were
removed after centrifugation and the pellet was air-dried for 5 minutes, upside down
on tissue. 15 µL resuspension buffer (0.2X PBS + 0.1 mMMgCl2 + 0.1 mM CaCl21X
cOmpleteTM, Mini, EDTA-free Protease I inhibitor cocktail (Sigma-Aldrich)) was
added to the virus pellet and the ultra-centrifuge tubes were covered with two layers
of parafilm, before incubating on a rocker overnight at 4 ℃. The resuspended pellet
was collected the following morning and samples were taken for western blotting
analysis (section 2.4.3), plaque assay (section 2.7.3) and negative-stain EM (section
2.10.1). The remainder of the resuspended pellet was immediately taken to make
cryo-EM grids (section 2.10.2).
2.7.3 Titre Determination by Crystal Violet Plaque Assay
In order to titre PICV stocks, vero cells were seeded in 12-well plates at 2 x 105
and the following day were infected with serially diluted PICV (10-fold). PICV was
allowed to adsorb to the cells for 1 hour at 37 ℃ and then the cells were overlaid
with 2.4 % agarose, mixed at a 1 : 1 ratio with complete media (final agarose
concentration was 1.2 %). The cells were then incubated for 6 days, at which point
they were fixed with 4 % formaldehyde, which was added directly to the overlay.
The overlay was removed, the cells were washed twice with 1X PBS and then stained
with 2.5 % crystal violet in 20 % ethanol. The stain was incubated for 15 minutes,
after which it was removed and the cells were washed with water, dried and imaged.
The plaques were counted and titre was calculated using the following equation:
V irus titre (pfu/mL) = average number of plaques
dilution factor ∗ volume (mL)
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2.8 Reverse Genetics
2.8.1 Design of Plasmids
Plasmids pUC57-S and pUC57-L were synthesised by GENEWIZ, as described in
section 2.1.1. The plasmids were designed according to previous papers (Sánchez
and de la Torre, 2006; Flatz et al., 2006). The segments were flanked by the T7
RNA polymerase (T7P) promoter sequence at the 5’ end of the segment and the T7P
terminator sequence at the 3’ end. This permitted permits the intracellular synthesis
of cRNA species from the plasmids by T7P. The T7P promoter was truncated,
leaving a single G residue at the 3’ end of the promoter sequence, which permits the
generation of S and L RNA species (vRNA and cRNA) containing the characteristic
non-templated G residue at the 5’ end. Immediately upstream of the T7P terminator
is the hepatitis delta virus (HDV) ribozyme sequence. This sequence self-cleaves
to generate the hairpin sequence found at 3’-termini of arenavirus RNA species.
An extra C residue was added to the 3’ end of the ribozyme sequence to improve
self-processing (Perrotta and Been, 1991; Sánchez and de la Torre, 2006).
Plasmids pUC57-NP and pUC57-LP were synthesised using PCR to sub-clone the
NP ORF and the LP ORF into the pUC57 vector using complementary flanking
restriction sites. The primers used in the PCR have been described in table
2.3 (NP ORF Forward; NP ORF Reverse; LP ORF Forward; LP ORF Reverse;
pUC57 Promoter; pUC57 Terminator). These fragments were then digested with
the restriction enzymes (section 2.2.2) and ligated (section 2.2.4) with one another
(NP ORF with the pUC57 vector and LP ORF with the pUC57 vector). The ligation
mix was transformed into DH5-α bacterial cells (section 2.2.5) and successful ligation
colonies were picked for plasmid amplification (section 2.2.6).
2.8.2 Transfection
BSR-T7 cells were seeded in 6-well plates (CytoOne) at a seeding density of 2x105
cells/well. The following day, 1.6 µg of pUC57-S, 1.6 µg of pUC57-NP, 2.8 µg
pUC57-L, 2 µg of pUC57-LP and 0.6 µg of a pUC57-T7 was added to 200 µL
OptiMEM media, followed by 2.5 µl/µg TransIT-LT1 transfection reagent (Mirus)
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and this was incubated for 30 minutes at room temperature. This was then diluted
in 800 µl OptiMEM and added to cells. At 19 hour post transfection (hpt), the
media was removed and replaced with 1 mL of DMEM supplemented with 2 %
FBS. At 120 hpt, the supernatant was removed and clarified by centrifugation at
4000 x g for 5 min. The clarified supernatant was used to infect BHK-21 cells, seeded
the previous day at 2x105 cells/well in 6-well plates (CytoOne). All infections were
carried out as described in section 2.6.1.
2.8.3 Incorporation of a Silent Mutation
In order to confirm that LCMV was being recovered from the transfection of the
rLCMV-WT rescue system plasmids, a single nucleotide mutation was introduced
into plasmid pUC57-S using PCR. The primers used in the PCR have been described
in table 2.3 (XhoI Forward; XhoI Reverse). This mutation created a new XhoI
restriction site in the S segment, allowing the identification of the mutated S
segment in rLCMV-XhoI. The transfection was carried out as described in section
2.8.2, replacing pUC57-S with pUC57-S-XhoI. The supernatant was harvested from
the BHK-21 cells at 96 hpi and was used to infect a fresh set of BHK-21 cells,
which had been seeded the previous day. The supernatant from this infection was
then harvested at 96 hpi and RNA was extracted from the supernatant using the
QIAamp Viral RNA Mini Kit (QIAGEN), following the manufacturer’s protocol.
The extracted RNA was then converted to DNA and amplified by PCR, using the
OneTaq One-Step reverse-transcription PCR (RT-PCR) Kit (New England Biolabs),
following the manufacturer’s protocol. S segment-specific primers were used and
have been described in table 2.3 (S-Segment Forward; S-Segment Reverse). The
amplified DNA was then digested with XhoI (NEB), as described in section 2.2.2
before being analysed by agarose gel electrophoresis (section 2.2.3).
2.8.4 Incorporation of Enhanced Green Fluorescent
Protein
In order to generate rLCMV-eGFP, an eGFP-P2A ORF (GenBank accession
number: QFU20120.1) was ordered from GENEWIZ and sub-cloned from the
plasmid, using primers "eGFP Forward" and "eGFP Reverse" to introduce flanking
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restriction sites. These restriction sites were also introduced into the plasmid
pUC57-S (rLCMV-WT), using primers "Insert eGFP Forward" and "Insert eGFP
Reverse". The restriction sites were inserted in between the start codon of the
NP ORF and the 3’ end of the untranslated region (UTR) of the S segment. The
primers used in both reactions have been described in table 2.3. The eGFP ORF was
separated from the NP ORF by the porcine teschovirus 1 (PTV-1) 2A self-cleaving
peptide sequence (ATNFSLLKQAGDVEENPGP) (GenBank accession number:
MH358390). Transfection of the rLCMV rescue system plasmids was carried out as
described in section 2.8.2, replacing plasmid pUC57-S with plasmid pUC57-S-eGFP.
eGFP fluorescence in both transfected and infected cells was examined by the EVOS
FL 2 automated microscope (Thermo Scientific Invitrogen).
2.9 Confocal Microscopy Techniques
2.9.1 Fixing and Staining Cells
Glass coverslips were washed in 100 % ethanol and allowed to dry. The coverslips
were then placed into a 6-well plate (CytoOne) and washed once with 1X PBS prior
to cell seeding. The cells were left to adhere to the coverslips for a minimum of
18 hours before infection. Infection was allowed to proceed for 24 hours before the
cells were washed once in 1X PBS and then fixed using 4 % formaldehyde for a
minimum of 15 minutes at room temperature (all subsequent steps were performed
at room temperature). The 4 % formaldehyde was then removed and the fixed cells
were washed three times in 1X PBS. The 1X PBS was removed and the cells were
permeabilised by adding 0.5 % Triton-X-100 (made in 1X PBS) and incubating for
10 minutes, rocking. The permeabilisation buffer was then removed and the cells
were washed three times in 1X PBS before blocking using 2 % FBS (made in 1X
PBS) for 15 minutes, with rocking. The blocking buffer was removed and the cells
were then stained with primary antibodies (made in 2 % FBS; for concentrations,
see table 2.2) for 2 hours, with rocking. The cells were then washed three times
with 1X PBS before staining with secondary antibodies, conjugated to Alexa Fluor
fluorophores (made in 2 % FBS; for more detail, see table 2.2), for 1 hour rocking in
the dark. The cells were then washed five times in 1X PBS, before a final wash in
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ddH2O. The coverslips were then dabbed onto tissue to remove excess fluid before
being mounted onto microscope slides using ProLong Gold Antifade Mountant with
DAPI (ThermoFisher Scientific). The coverslips were then sealed with nail varnish
and mounting media was allowed to cure overnight in the dark.
2.9.2 Confocal Microscopes
Images were acquired using either the Zeiss LSM700 Inverted Microscope or the
Zeiss upright LSM880 Microscope. All the images required multicolour imaging and
in order to do this, individual fluorescent signals were acquired sequentially. Image
contrast and fluorescent signal were adjusted using Fiji software.
2.10 Electron Microscopy Techniques
2.10.1 Negative Stain Electron Microscopy
Purification of LCMV (section 2.6.2) and PICV (section 2.7.2) was deemed suitable
for cryo-EM after examination using negative-stain EM. Immediately prior to sample
application, carbon-coated electron microscopy grids were rendered hydrophilic by
glow discharge for 45 s using a PELCO easyGlow glow discharge system. 3 µL of the
sample, which was diluted 1:10, was then put onto the charged grids and incubated
at room temperature for 1 minute. Excess sample was then blotted and the grids
were washed three times in water droplets, and excess wash was blotted away each
time. The grids were then stained with 1 % uranyl acetate, which was immediately
blotted away and then reapplied, which was incubated for 1 minute. The stain was
blotted and the grids were allowed to air-dry before visualisation, using either the
JEOL 1400 transmission electron microscope or the FEI Tecnai T12 transmission
electron microscope (at a defocus of -1 µm - 5 µm).
2.10.2 Cryo-Electron Microscopy Grid Preparation
Purified virus samples were mixed 1:1 with 10 nm colloidal gold, which would
act as fiducial markers during the tomogram alignment (PICV; Protein A -
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10 nm Gold labelled, Aurion or LCMV; Protein A, Colloidal gold (10 nm),
Boster Immunoleader). The samples (3 µL) were then immediately applied to
glow-discharged (45 seconds) carbon-coated grids (PICV; QR 2/2, 400-mesh or
LCMV; QR 2/2, 200-mesh), which were kept at a pre-set temperature and high
humidity and then blotted (3.5 seconds) and rapidly plunged into liquid ethane
using the Leica EM GP automated grid plunge freezer (all procedures performed
here were with the help of either Dr Juan Fontana or Dr Daniel Maskell). Frozen
grids were then transferred to a pre-cooled grid container in liquid nitrogen and
stored in liquid nitrogen until imaging.
2.10.3 Cryo-Electron Microscopy and Tomography
Vitrified PICV EM grids were initially clipped, loaded and screened by the FEI
Titan Krios I (performed by facility managers Dr Rebecca Thompson and Dr Emma
Hesketh, Astbury Biostructure Laboratory Electron Microscopy Facility). Screening
was performed to assess the quality of the fiducial concentration and spread, virus
concentration and spread, ice formation or other contamination. Dr Juan Fontana
and Dr Emma Hesketh helped collect the images (pixel size = 4.7 Å).
With the help of Dr Juan Fontana and the Astbury Biostructure Facility staff,
cryo-ET on vitrified PICV grids was set up for an automated data collection on the
FEI Titan Krios II, using Tomography 4 software (FEI). Single axis tilt-series data
was collected at grid angles from -50° to +50°, with 2° increments. Projections were
collected at 53,000x magnification, with a -1 µm defocus and using the Volta phase
plate. The pixel size was 2.72 Å resulting in an electron dose of 1.8 e- per image.
The microscope alignments were performed by the Astbury Biostructure Facility
staff. With the help of Dr Juan Fontana and Dr Emma Hesketh, grid locations of
interest were specified manually and then autofocus and automated data collected
was performed by Tomography 4.
Vitrified LCMV EM grids were initially clipped, loaded and screened by the
FEI Titan Krios I (performed by facility manager Dr Daniel Maskell, Astbury
Biostructure Laboratory Electron Microscopy Facility). Screening was performed
by Dr Daniel Maskell to assess the quality of the fiducial concentration and spread,
virus concentration and spread, ice formation or other contamination.
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Dr Daniel Maskell also set up the automated data collection on the vitrified LCMV
EM grids, using the FEI Titan Krios II and Tomography 4 software (FEI). Single axis
tilt-series data was collected at grid angles from -60° to +60°, with 2° increments.
Projections were collected at 53,000x magnification, with a -1 µ defocus and using
the Volta phase plate. The pixel size was 2.72 Å resulting in an electron dose of 1.8 e-
per image. The microscope alignments were performed by the Astbury Biostructure
Facility staff.
2.10.4 Tomogram Reconstruction
Following the data collection, the tilt-series were imported into IMOD for
tomogram reconstruction using Etomo. All the PICV tilt-series were manually
reconstructed whereas the LCMV tilt-series were reconstructed using batch
tomogram reconstruction, in order to perform this as high-throughput.
The images firstly went through a pre-processing step to remove any outlying pixels
or artefacts and then each 2D projection of the tilt-series was roughly aligned. Gold
particles were then selected as fiducial markers to track through the tilt-series, detect
particle movement between the projections and refine the alignment. This was then
used by IMOD to reconstruct the 3D tomogram volume (Cope et al., 2011). The
images were then binned by a factor of 2, resulting in a final pixel size of 5.44 Å.
The images were then filtered using Gaussian Blur 3D in ImageJ. The tomogram
reconstructions were performed by A Shaw, with help from Dr Juan Fontana.
2.10.5 Sub-Tomogram Averaging
In an attempt to resolve the structure of the GPC from PICV and LCMV, STA
was performed using the Particle Estimation for Electron Tomography (PEET)
software (IMOD). PEET permits alignment, averaging and iterative refinement of
3D particles (Cope et al., 2011). The settings for PEET and the angles for the
iterations were decided according to previous work (Cope et al., 2011; Li et al.,
2016; Punch et al., 2018). All STA was performed by A Shaw, with assistance from
Dr Juan Fontana.
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Model Generation
In order to inform PEET of the positioning and size of the GPC spikes, with
respect to the viral membrane, a model was generated using 3dmod (IMOD). Briefly,
an object was created to define the centre of the virus and was increased in size
until it matched the viral membrane, and assuming the virus is near-spherical, the
object matched the viral membrane throughout the 3D volume. Then another
object was added to define the position where the GPC spikes meet the viral
membrane. Models were manually generated for all tomograms and spikeInit (PEET
programme, IMOD) was then utilised to create an initial orientation list (the initial
motive list), which makes the assumption that the spikes sit perpendicular to the
viral membrane.
Automated particle selection and refinement
The models and initial motive lists generated in section 2.10.5 provided information
for the STA by PEET. The spikes, as specified by the model, were then averaged and
roughly aligned. PEET was allowed to identify the optimal alignment of the spikes
by altering of the lateral spike location on the membrane (theta (forward/back
tilting) and psi (left/right tilting)) and the twist orientation of the particles
around the Y-axis (phi). The averages generated in this first run were then
C120-symmetrised to remove any specific features and used as the reference particle
for automatic particle alignment in the next run.
In order to improve the resolution of the GPC spike structures, further iterative
refinement steps were performed in PEET. For all the steps, the average from the
previous step was used as the reference for the following step in order to improve
and refine the alignment of the particles. Some of the PEET runs had a wide search
range and therefore a parameter was set to remove duplicate particles because when
the search range is wide, it can exceed the spacing between individual spikes. This
means some spikes can be erroneously averaged multiple times, which could lead to
an overestimation of resolution. PEET will identify these cases of duplication and
remove the particles from further averaging. The tolerance was set at 10 pixels apart
(or 5.44 nm) in 360°, which means any particles that are closer than this will be
considered duplicates. In the PEET runs, missing-wedge compensation was enabled
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to account for the data that was not collected (i.e. tilt angles greater than +50/+60°
and smaller than -50/-60°). In the initial runs, a broad search range was applied in
every direction to account for differences in predicted spike location. This was also
accounted for in the initial sub-tomogram volume, which was set to 40 voxels (~22
nm), with a large spherical mask of 30 pixels (~16 nm) until the initial average, and
size of the GPC spike, was determined.
In the next stage, a smaller spherical mask, which was centred on the glycoprotein
base, was used in order to identify evidence of three-fold (C3) symmetry. The
averages were then iteratively refined, beginning with a large search range (+/- 180°)
and reducing at each iteration in order to improve the alignment. The iterations
aimed to improve three angles of the GPC spike; phi (twisting around the Y-axis),
theta (forward/back tilting) and psi (left/right tilting).
The previous stage identified C3 symmetry (Li et al., 2016) and therefore the C3
symmetry was applied to those averages to provide the reference for this stage. The
average here was further refined with smaller searches in the spike orientation and
location, and an increase in the high and low frequency cut-offs, in order to only
focus on the high resolution information, which would improve the final resolution.
In order to calculate the final resolution, calcFSC (PEET) was used, using Fourier
shell correlation (FSC), which was cut-off at a threshold of 0.5. UCSF Chimera
(RBVI) was then used to created isosurface rendered 3D reconstructions of the
averaged density maps (Goddard et al., 2007), which could be overlaid with each
other, overlaid with the LASV density map (Li et al., 2016) or have rigid-body-fitting
of crystal structures (Hastie et al., 2016a) into the electron density. Electron density
map can be obtained from the Electron Microscopy Data Bank (EMDB) under
accession numbers: EMD-3290 for the LASV GPC spike (Li et al., 2016).
2.10.6 Electron Microscopes
The JEOL 1400 and FEI Tecnai T12 transmission electron microscopes (LaB6
electron source and 120 kV operating voltage) were used for negative-stain EM.
Tilt-series were collected on the FEI Titan Krios II electron microscope (X-FEG
electron source and 300 kV operating voltage).
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Production of LCMV NP Antisera
as an Arenavirus Detection Tool
3.1 Chapter Introduction
Currently, whilst there are many commercially available arenavirus NP antibodies,
their reliability to function in biological assays is questionable. Furthermore,
LCMV infection in cellular culture has also been reported to be non-cytolytic
(Abdel-Hakeem, 2019), making it difficult to detect and quantify infectivity of
LCMV through conventional crystal violet-based plaque assays, which rely on
cytopathic effect. Without these tools, the study of arenavirus biology is very
difficult, therefore the solution was to make a highly-specific antibody against LCMV
NP, which can be used to develop assays for LCMV titration.
Expression of recombinant proteins, followed by effective purification techniques,
allows the isolation of large quantities of high-quality proteins for their study in
basic research, therapeutics and biotechnology. Highly pure protein preparations
are often required to investigate the protein’s structure and function using structural
and biochemical approaches, but also to serve as starting material for production of
highly specific recognition molecules such as antibodies. The various expression and
purification methodologies are selected based upon the characteristics of the protein
of interest and the final purpose of its production.
A variety of recombinant protein expression systems exist, utilising prokaryotic cells,
eukaryotic cells or even cell-free systems. This chapter describes the large-scale
production of the LCMV nucleocapsid protein (NP) using a bacterial expression
system and its subsequent purification, resulting in a purity of >85 %. This LCMV
NP preparation was then used as an antigen to generate polyclonal antibodies.
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LCMV NP was chosen as the priming antigen for antibodies because of its abundance
in virally-infected cells, offering an easily identifiable indicator of successful infection.
This chapter also describes the validation of the resulting LCMV NP antisera, using
techniques including western blotting and immunofluorescence, and its subsequent
application in a focus forming assay to determine the titre of LCMV stocks.
3.1.1 Introduction of Recombinant Protein Expression
In order to express recombinant protein, it is first necessary to determine which
expression system to use. There are multiple expression systems available, some
of which use bacterial, yeast, insect or mammalian cells, and each of these
present several advantages and disadvantages (summarised in table 3.1). Which
expression system is chosen depends on the required yield and purity for the
downstream applications, in addition to the protein characteristics including
molecular mass, solubility and post-translational modifications such as glycosylation,
phosphorylation or disulphide bond formation.
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CHAPTER 3. GENERATION OF LCMV NP ANTISERA
3.1.2 Overview of Bacterial Expression of Recombinant
Proteins
Expression of recombinant proteins using the prokaryote Escherichia coli (E. coli)
has many advantages (Rosano and Ceccarelli, 2014; Demain and Vaishnav, 2009).
The bacterial protein expression system has been extremely well-characterised
genetically and large yields of recombinant protein can be rapidly generated, in
a relatively easy and inexpensive manner (Kaur et al., 2018). The system is also
easily scaled-up to significantly increase the yield of recombinant protein, without
increasing expense or time. However, bacterial expression systems are unable
to perform eukaryotic post-translational modifications, including disulphide bond
formation, phosphorylation and glycosylation. This can cause the degradation of
the recombinant protein by host proteases or an accumulation of the recombinant
protein in inclusion bodies, rendering the protein insoluble (Kaur et al., 2018; Rosano
and Ceccarelli, 2014). Bacterial expression systems also utilise an alternative codon
strategy, occasionally requiring recombinant proteins to be codon-optimised for
expression (Rosano and Ceccarelli, 2014). Despite these disadvantages, the bacterial
expression system was chosen for experiments in this chapter due to its simplicity,
affordability, the large yield of recombinant protein that can be attained and relative
ease of subsequent purification.
Introduction to Bacterial Expression Vectors
To produce the recombinant protein in a bacterial expression system, the gene of
interest needs to be cloned into an appropriate expression vector. There are many
bacterial expression vectors are available for protein expression in E. coli cells,
combining different replication origins (and thus copy numbers per cell), promoters,
antibiotic selection markers, multiple cloning sites, and the provision to add fusion
proteins or tags to the protein of interest. The pET bacterial expression vectors are
commonly used due to their high efficiency for protein production, with expressed
recombinant protein representing up to 50 % of the total bacterial cell protein
content (Rosano and Ceccarelli, 2014). Following transformation of the recombinant
protein into the bacterial cells, further optimisation of protein expression induction,
scaling up and purification is required.
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Experiments described in this chapter utilised the pET28a(+)-His SUMO vector,
which puts the recombinant protein under control of a bacteriophage T7 RNA
polymerase (T7P) promoter and a lac operator (Studier, 2005). This vector also adds
a six histidine (6xHis) residue tag and a small ubiquitin-related modifier (SUMO)
tag to the N-terminus of the recombinant protein. The 6xHis tag is added to aid
downstream purification, whereas the SUMO tag improves expression and solubility
of the protein. The efficient and specific removal of the 6xHis-SUMO tag is then
mediated by Ubiquitin-like-specific protease 1 (ULP1), which cleaves based on the
tertiary structure of the SUMO tag, reducing the chance of erroneous cleavage at
alternative sites (Marblestone et al., 2006; Malakhov et al., 2004).
Introduction to Bacterial Expression of Recombinant Protein
Some methods of induction of recombinant protein expression, such as
autoinduction, are reliant on the process of bacterial carbohydrate metabolism. E.
coli are able to switch metabolic processes dependent on the presence of glucose and
lactose (Jacob and Monod, 1961) and this can be exploited for recombinant protein
expression. In this chapter, BL21(DE3) E. coli strains were used for recombinant
protein expression. These strains have been genetically altered to encode extra
elements, such as the T7 bacteriophage RNA polymerase (T7P), which is present
in the chromosome under control of a lacUV5 promoter, and T7 lysozyme, which
is present in the pLys plasmid that has been stably transformed into these strains
(the genetic composition has been summarised in table 2.1) (Studier and Moffatt,
1986; Kaur et al., 2018).
There are several major regulatory elements to be aware of in this process. Firstly,
there is the T7P, which binds to a T7 promoter region to transcribe the gene encoding
the target protein. Next, there is the lac repressor, which is encoded by the lacI
gene and binds at lac operator sequences but the binding overlaps onto polymerase
promoter regions, preventing RNA polymerase and T7P transcription (Wagner et al.,
2008; Studier, 2005; Dubendorf and Studier, 1991). There is also the T7 lysozyme,
which binds to the T7P, repressing its activity (Studier, 1991). Finally, there is the
E. coli RNA polymerase (RNAP), which binds its promoter region to transcribe
multiple genes including the T7P, T7 lysozyme, the lac gene and the lac operon
genes.
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The lac operon is a series of genes that are required to transport and metabolise
lactose. The lac operon under the control of the lac operator, a RNAP promoter and
a catabolite activator protein (CAP) site (Studier, 1991; Fox and Blommel, 2009).
There are three genes in the lac operon; lacZ encodes β-galactosidase, the enzyme
that metabolises lactose; lacY encodes lactose permease, the membrane protein
that imports lactose; and lacA encodes galactosidase acetyltransferase, which is
proposed to reduce the toxicity of remaining metabolites (Studier, 2005; Marbach
and Bettenbrock, 2012). The lac operon is only expressed in presence of lactose (or
presence of an inducer such as isopropyl β-D-1-thiogalactopyranoside (IPTG)) and
an absolute absence of glucose.
In the presence of glucose, expression of the lac operon genes and target protein
is repressed. The lac repressor is bound at the lac operator sites, preventing RNA
polymerase binding to its promoter and transcription of the lac operon genes (from
the RNAP promoter), of T7P (from the lacUV5 promoter) and of the target protein
(from the T7P promoter) (Dubendorf and Studier, 1991). Basal expression of T7P
is also repressed by T7 lysozyme (Dubendorf and Studier, 1991). Furthermore,
the presence of glucose means there is no signal to up-regulate cyclic adenosine
monophosphate (cAMP) (Kimata et al., 1997). This is important because cAMP
assists the catabolite activator protein (CAP) binding at the CAP site, which is
located upstream of the RNA polymerase promoter of the lac operon genes (Griffiths
et al., 2000). Binding of cAMP/CAP at the CAP site assists RNA polymerase
binding to its promoter, meaning without cAMP, neither CAP not RNAP can bind
to their respective sequences (Griffiths et al., 2000). Finally, the uptake of lactose
by lactose permease is prevented by glucose through catabolite repression (Studier,
2005).
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Figure 3.1: Repression of Recombinant Protein Expression.
Schematic representation of the process by which expression is repressed in bacteria that
have a source of glucose and an absence of lactose. The expression of T7 lysozyme and
the lacI repressor is constitutive. T7 lysozyme binds to the T7 RNA polymerase (T7P) to
prevent it from binding its promoter. The lacI repressor is able to bind at the lac operator,
preventing RNA polymerase and T7P transcription of the lac operon genes and the target
protein. The presence of glucose means there is no need for the up-regulation of cAMP,
which therefore does not assist CAP binding the CAP site and helping the polymerase
bind the promoter site of the lac operon. This figure was created using BioRender.
When the glucose source is depleted, there is a metabolic switch to initiate lactose
uptake and metabolism, which generates allolactose as a by-product. Allolactose, or
lactose analogue IPTG, bind to the lac repressor and alter its structure, preventing
it binding to the lac operator and the lacUV5 promoter sequences (Daber et al.,
2007). This induces expression of the lac operon genes and the T7P (Studier, 2005).
Expression of the T7P, and the absence of the lac repressor at the lac operator site,
permits expression of the target protein (Studier, 2005). Furthermore, the depletion
of glucose signals to the cell to up-regulate cAMP, which binds to CAP (Griffiths
et al., 2000). CAP-cAMP can then bind to the CAP-site, which promotes RNA
polymerase binding at the promoter site and enables transcription of the lac operon
genes (Griffiths et al., 2000).
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Figure 3.2: Induction of Recombinant Protein Expression by IPTG or Lactose.
Schematic representation of the metabolic switch and induction of expression in bacteria
when lactose is present or isopropyl β-D-1-thiogalactopyranoside (IPTG) is added. The
depletion of glucose up-regulates cAMP, which binds to CAP and assists it binding to the
CAP site. The presence of CAP at the CAP site permits binding of the RNA polymerase
at the lac operon promoter site. The presence of IPTG and allolactose (generated as
a byproduct of lactose) prevents lacI repressor from binding the lac operon sequences,
permitting the RNA polymerase transcribing the genes expressing the lac operon genes
and the target protein. This enable a positive feedback loop to further increase expression.
This figure was created using BioRender.
Occasionally, the sudden and abundant expression of the recombinant protein
overwhelms the E. coli translational machinery, leading to the formation of
incorrectly folded insoluble aggregates called inclusion bodies (Burgess, 2009). One
way to combat insolubility is fusing the SUMO tag to the recombinant protein
because SUMO can exert a chaperoning effect by acting as a nucleation site for
the correct folding of recombinant protein (Costa et al., 2014; Marblestone et al.,
2006; Malakhov et al., 2004; Gaberc-Porekar and Menart, 2001). Solubility can also
be improved by reducing expression of the target protein to relieve the stress on
the translational machinery, reducing incorrect folding and subsequent aggregation
(Burgess, 2009; Kaur et al., 2018). One such technique to improve target protein
solubility is to induce recombinant protein expression using autoinduction, which
gradually expresses the protein as opposed to IPTG-induction, and therefore there
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is less stress on the bacterial translational machinery. Another technique is to use
Lemo-21(DE3) cells, which are an E. coli strain that have been stably transformed
with a plasmid that expresses T7 lysozyme under control of the rhaBAD promoter,
allowing tunable T7 lysozyme expression using L-rhamnose (Wagner et al., 2008;
Schlegel et al., 2012). Expression of the target protein is induced using IPTG but
the expression of T7 lysozyme can be increased by increasing the concentration of
L-rhamnose. T7 lysozyme reduces the expression of the T7P, which reduces target
protein expression and can improve target protein solubility (Studier, 1991; Wagner
et al., 2008).
3.1.3 Introduction to Chromatographic Methods of the
Purification of Recombinant Proteins
Introduction to Protein Purification
The aim of the protein purification process is to remove unwanted material,
concentrate the protein and transfer the protein to a stable environment, such as an
appropriate buffer. Chromatographic techniques are one of the most effective and
widely used protein purification methods. These techniques involve the retention of
molecules from their solvent (mobile phase) after their physical interaction with a
specific material (stationary phase). The most common experimental configuration
consists of a stationary phase packed into a column through which a mobile phase,
containing the target protein, is pumped. The degree of interaction between the
target protein (and other proteins in the mobile phase) and the stationary phase
determines how fast they are carried by the mobile phase. Different properties
of the target protein, such as size, charge, isoelectric point, hydrophobicity and
bio-molecular interactions, influence its interaction with the stationary phase, which
is exploited to purify it from the contaminating proteins. There are several types of
chromatography, which have different compositions, matrices and exploit different
properties of the protein. Often, multiple chromatographic techniques will be used
in combination, with metal affinity-based methods followed by either ion-exchange
or size-exclusion techniques, as was applied in this chapter.
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Immobilised Metal-Affinity Chromatography
Protein purification through affinity-based chromatography involves the reversible
interaction between the target protein and a ligand that is attached to a matrix,
followed by elution of the target protein from the matrix, without affecting any
of the protein’s properties. The interaction can be mediated through electrostatic
interactions, hydrophobic interactions, van der Waals forces or hydrogen bonding.
Immobilised metal-affinity chromatography (IMAC) is one of the most commonly
used chromatographic techniques for recombinant protein purification. IMAC
involves the addition of an affinity tag to the target protein, which interacts with
a metal ion ligand immobilised on the matrix (Bornhorst and Falke, 2000). In
most cases, an affinity tag comprising a minimum of six histidine residues (6xHis)
is added to the recombinant protein. The 6xHis tag interacts strongly with the
transition metal ions (most commonly Ni2+ but also Co2+, Cu2+ or Zn2+) that are
immobilised on a matrix (composed of nitrilotriacetic acid (NTA) for Ni2+ ions),
which is attached to the sepharose support resin (Gaberc-Porekar and Menart, 2001).
Histidine residues interact with the metal ions through their imidazole side chain,
which contains nitrogen atoms that are free to interact with the two unoccupied
co-ordination sites on the ions (Bornhorst and Falke, 2000). The number of histidine
residues present in the tag produces a stronger interaction of the target protein
than contaminating proteins, which either do not interact or the interaction can
be disrupted using a weak imidazole-containing buffer. The interactions between
the 6xHis tag of the recombinant protein and the metal ions can then be disrupted
through the addition of a buffer with a higher imidazole concentration, which can
out-compete to interact with the two unoccupied co-ordination sites on the ions
(Bornhorst and Falke, 2000; Gaberc-Porekar and Menart, 2001). This results in the
elution of the target protein.
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Figure 3.3: Chemical Composition of Ni2+-NTA Chromatography.
(A) Schematic representation of the Ni2+ ions, which are attached to the sepharose resin
through nitriloacetic acid. Two free coordination sites from the Ni2+ ions can be seen
and interact with the nitrogen from the side-chain of the poly-histidine tag on the target
protein. (B) Chemical structures of histidine and imidazole. The similarities between
imidazole and the histidine side-chain allow imidazole to compete with the target protein
for binding to Ni2+-NTA. Adapted from (Bornhorst and Falke, 2000)
Ion-Exchange Chromatography
Ion-exchange chromatography (IEC) exploits ionic interactions to separate proteins
based on their net surface charge. The basis of separation occurs through
competition of differently charged proteins for interaction with the oppositely
charged ion-exchange matrix. Proteins are ampholytes, which means they have
a complex mixture of positively-charged residues (such as histidine, lysine and
arginine) and negatively-charged residues (such as glutamate and aspartate)
(Hedhammar et al., 2006). The sum of the ionisable amino acid residues gives
the overall charge of the protein, but this is also subject to the buffer pH of the
protein (Hedhammar et al., 2006). The isoelectric point (pI) of a protein is the
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pH at which the protein has no net overall charge (Dunn and Pennington, 2003).
Altering the buffer pH to a pH below the pI of the target protein creates a net
positive charge, allowing interaction with a negatively-charged cationic exchange
chromatographic matrix (Hedhammar et al., 2006). Altering the buffer pH to a pH
above the pI of the target protein creates a net negative charge, allowing interaction
with a positively-charged anionic exchange chromatographic matrix (Costa et al.,
2014; Hedhammar et al., 2006). In order to achieve strong interaction between the
target protein and the oppositely-charged matrix, ion-exchange chromatography
is typically performed in buffers at least one pH unit above or below the target
protein’s pI. The target protein is separated from proteins with the same charge as
the matrix, or with a neutral charge, because those proteins pass straight through
the column whereas the target protein interacts with the matrix (Hedhammar et al.,
2006). The affinity of this interaction is then reduced either by altering the pH
or the ionic strength of the buffer. Altering the pH can lead to precipitation of
the target protein on the column, due to a decrease of solubility at pH closer to
the pI (Hedhammar et al., 2006). Therefore, increasing the ionic strength of the
buffer, through increasing the concentration of a non-buffering salt (i.e., NaCl)
is a more commonly used strategy. The ions compete with the bound proteins
for binding to the charged resin, and weaker interactions are disrupted at lower
NaCl concentrations and stronger interactions are disrupted at higher concentrations
(Costa et al., 2014; Regnier, 1982; Hedhammar et al., 2006).
IEC offers the advantage of performing chromatography under mild conditions,
therefore not disrupting the native conformation of the target protein. IEC is also
easy to perform and control, and the resins can be reused many times. However,
IEC does not offer the selectivity that other chromatographic methods can offer
(Hedhammar et al., 2006).
Size-Exclusion Chromatography
Another protein purification method is size-exclusion chromatography (SEC), which
is a technique that separates molecules based on the molecular size and shape
after their interaction with a porous matrix. Materials used for the matrices
include natural polymers (i.e., agarose or dextran) and synthetic polymers (i.e.,
polyacrylamide). These are inherently porous, but they can also be cross-linked,
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which can result in different pore sizes (Hedhammar et al., 2006). Molecules that
are bigger than the pores will not be able to enter and therefore pass straight through
the matrix, being the first to be eluted. Molecules that are smaller than the pores can
enter and are therefore retained for a longer period than larger molecules. Molecules
that are smaller than the smallest engineered pore are retained the longest and
this provides the basis by which the molecules are separated by size (Barth et al.,
1994; Hedhammar et al., 2006). Molecular shape also has an effect on whether
the molecules are excluded from the pores, whereby globular molecules, such as
proteins, access the pores more easily than linear molecules, such as nucleic acids or
polysaccharides, which occupy a larger hydrodynamic volume (Hedhammar et al.,
2006).
For the SEC experiments in this chapter, Superdex was used, which is composed
of dextran covalently bonded to highly cross-linked agarose. As an indication of
protein presence, elution from the column is monitored through the measurement
of absorbance at 280 nm with an ultraviolet (UV) light. This result is then mapped
onto a chromatogram, whereby the absorbance at 280 nm (protein concentration)
is plotted against elution volume (mL).
In addition to separation of proteins by size, SEC can also be used to determine
protein characteristics, such as oligomeric state or interactions with other molecules.
SEC can also be used for buffer exchange where proteins of interest are separated
from the buffer components e.g., salts.
3.1.4 Chapter Aims
The aims of this chapter were to express recombinant LCMV NP with a
6xHis-SUMO affinity tag from a bacterial expression system and to then purify
LCMV NP using a variety of chromatographic techniques. Purified LCMV NP was
then to be used as the priming antigen to generate polyclonal antibodies. The LCMV
NP antisera would permit analysis of LCMV infection through western blotting
analysis and immunofluorescence analysis. Furthermore, the LCMV NP antisera
would allow the development of a focus forming assay to assist the determination of
LCMV stock titres.
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3.2 Results
3.2.1 Construction of the pET-28a(+)-His-SUMO-LCMV
NP Vector
The native LCMV NP sequence (accession number: P09992) was successfully
isolated from a synthetic mammalian expression vector (pMK-RQ) using PCR,
which also permitted introduction of BamHI and XhoI restriction sites. The
PCR fragment and pET28a(+)-His-SUMO expression vector were digested with
BamHI and XhoI and ligated together to form the pET28a(+)-His-SUMO-LCMV
NP construct (figure 3.4A). This enabled the expression of LCMV NP, in frame with
the 6xHis-SUMO tag at the N-terminus of the NP, as shown in (figure 3.4B). The
amino acid sequence of 6xHis-SUMO-LCMV NP was predicted to have a molecular
weight of ~75.3 kDa and a theoretical pI of 8.04, using the ExPASy ProtParam
tool (Gasteiger et al., 2005). These parameters were also calculated for the LCMV
NP amino acid sequence (without the 6xHis-SUMO tag); the molecular weight was
~62.2 kDa and the theoretical pI was 8.80.
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Figure 3.4: Vector Map of pET-28a(+)-His-SUMO-LCMV NP.
Schematic representation of the LCMV NP open reading frame in the
pET28a(+)-His-SUMO expression vector (A), which produces LCMV NP fused to
the 6xHis-SUMO tag (B). The 6xHis-SUMO tag is removed at the site indicated by
the arrow, after cleavage using Ubiquitin-like-specific protease-1 (ULP1). The molecular
weights of 6xHis-SUMO-LCMV NP and untagged LCMV NP have been shown and
were predicted using the ExPASy ProtParam tool. The plasmid map was created using
SnapGene software.
3.2.2 Optimisation of Recombinant LCMV NP Expression
Expression Trials Using IPTG-Induction
Expression of pET28a(+)-His-SUMO-LCMV NP was trialled in a range of
BL21(DE3) E. coli strains; Gold, Star, Rosetta, Rosetta 2 and CodonPlus.
These bacterial strains all carry the T7 RNA polymerase (T7RP) gene to allow
T7RP-directed expression of recombinant proteins. Furthermore, these strains
are deficient in the Lon protease (naturally deficient) and the OmpT protease
(engineered to be deficient), which reduces degradation of the recombinant protein.
The Gold and CodonPlus strains do not express endonuclease A, limiting plasmid
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DNA degradation. The Star strain also has a mutation in the RNaseE gene, which
limits mRNA degradation. Finally, the Rosetta, Rosetta 2 and CodonPlus strains
are also engineered to express tRNA genes for codons that are rarely used in E.
coli, which assists expression of eukaryotic recombinant proteins. The CodonPlus
strain is engineered to express five additional tRNA genes, which supply codons
for arginine, isoleucine, leucine and proline. The Rosetta and Rosetta 2 strains
are engineered to express six and seven, respectively, additional tRNA genes, which
supply codons for arginine, isoleucine, leucine, proline and glycine.
Initially, pET28a(+)-His-SUMO-LCMV NP was transformed into the Gold, Star,
Rosetta, Rosetta 2 and CodonPlus E. coli strains. Expression of the tagged protein
was induced using 100 µM IPTG, and the cells were incubated at 37 ℃ for 24
hours, after which the cells were harvested. The cells were lysed (whole cell lysate)
and then separated into soluble and insoluble fractions. The whole cell lysates,
soluble and insoluble fractions were examined using SDS-PAGE analysis, followed
by Coomassie staining, in order to determine which strain yielded the highest
expression of soluble protein (figure 3.5). The CodonPlus strain appeared to result
in strongest expression, having the most abundant band of the correct predicted
molecular weight. However, the majority of the protein was in the insoluble fraction.
Figure 3.5: Initial Expression Trials of 6xHis-SUMO-LCMV NP by IPTG
Induction.
SDS-PAGE analysis, followed by Coomassie staining, of the initial expression trials of
6xHis-SUMO-LCMV NP (predicted molecular weight: ~75 kDa) in a variety of BL21(DE3)
E. coli strains; Gold, Star, Rosetta, Rosetta 2 and CodonPlus. Expression was induced
using 100 µM IPTG and the cultures were incubated at 18 ℃ for 24 hours before harvest.
The cultures were pelleted and resuspended in lysis buffer after which the lysates were
subjected to three freeze-thaw rounds. Soluble and insoluble fractions were collected by
centrifugation. The band thought to be 6xHis-SUMO-LCMV NP has been indicated by
an arrowhead.
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In an attempt to improve solubility of the recombinant protein, expression by
another E. coli strain was trialled. Lemo-21(DE3) cells have been proposed
to improve solubility of the target protein by reducing its expression through
increasing concentration of L-rhamnose. This allows more time for the correct
folding of the target protein, preventing its accumulation within inclusion bodies.
After Lemo-21(DE3) cells were transformed with pET28a(+)-His-SUMO-LCMV
NP, cultures were induced using 100 µM IPTG and increasing concentrations of
L-rhamnose were added. The cells were then incubated (at 37 ℃ for 24 hours) at
which point the cells were harvested, lysed and the soluble and insoluble fractions
were collected. SDS-PAGE examination, followed by Coomassie staining, of the
insoluble fractions revealed that increasing the concentration of L-rhamnose reduced
the expression of 6xHis-SUMO-LCMV NP, as expected. This was shown by a
reduction of the band size between 0 µM and 100 µM L-rhamnose, followed by the
disappearance of the band in higher L-rhamnose concentrations. The solubility of
6xHis-SUMO-LCMV NP was not improved because there were still no appropriately
sized bands in the soluble fractions (figure 3.6).
Figure 3.6: Expression of 6xHis-SUMO-LCMV NP in Lemo-21(DE3) E. coli.
SDS-PAGE analysis, followed by Coomassie staining, of the expression of
6xHis-SUMO-LCMV NP (predicted molecular weight: ~75 kDa) in the Lemo-21(DE3) E.
coli strain. Expression was induced using 100 µM IPTG but it is limited in the presence
of increasing concentrations (ranging between 0 µM and 2000 µM) of L-rhamnose, in an
attempt to reduce insolubility. Samples of Lemo-21 cells which had not been induced
with IPTG (uninduced) were also examined. The total cell lysate of the induced cells
were examined (induced) in addition to the soluble and insoluble fractions.
Autoinduction was then attempted as an alternative to IPTG-induction. This
approach was proposed to result in a more gradual induction of expression, which
can improve protein solubility. Therefore, pET28a(+)-His-SUMO-LCMV NP was
transformed into the CodonPlus strain and a starter culture was then used to
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inoculate autoinduction media (a mixture of glucose, lactose and glycerol), which
was incubated at either 37 ℃ or 18 ℃ (figure 3.7) for a total of 54 hours. Samples
were collected at 0, 3, 5, 8, 24, 32 and 54 hours post inoculation of the autoinduction
media. The samples were lysed and the soluble and insoluble fractions were analysed
by SDS-PAGE analysis, followed by Coomassie staining. This revealed that whilst
a large proportion of the expressed 6xHis-SUMO-LCMV NP remained insoluble,
an intensely stained band representing 6xHis-SUMO-LCMV NP was evident in the
soluble fraction. Expression of soluble 6xHis-SUMO-LCMV NP was thus achieved
using an autoinduction protocol, with harvesting at 54 h after incubation at 18 ℃
(figure 3.7: red box).
Figure 3.7: Expression of 6xHis-SUMO-LCMV NP by Autoinduction.
SDS-PAGE analysis, followed by Coomassie staining, of the expression of
6xHis-SUMO-LCMV NP (predicted molecular weight: ~75 kDa) in the CodonPlus
strain of E. coli. Cultures were used to inoculate autoinduction media, which was
incubated at either 37 ℃ or 18 ℃ for 54 hours (h), with samples collected at 0 h, 3
h, 5 h, 8 h, 24 h, 32 h and 54 h. Soluble and insoluble fractions were examined to
determine whether the solubility of 6xHis-SUMO-LCMV NP had been improved. A band
corresponding to the molecular weight of 6xHis-SUMO-LCMV NP in the soluble fraction
has been indicated using a red box.
3.2.3 Purification of Recombinant LCMV NP
Purification by Immobilised Metal-Affinity Chromatography
Following its expression, initial purification of soluble 6xHis-SUMO-LCMV NP
was attempted using immobilised metal-affinity chromatography (IMAC). However,
there was too little of the resulting purified 6xHis-SUMO-LCMV NP for any
downstream applications (data not shown). Therefore, in an attempt to increase the
abundance of purified 6xHis-SUMO-LCMV NP, batch purification trials with the E.
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coli strains Gold, Star, Rosetta, Rosetta 2 and CodonPlus were attempted. Initially,
all the strains were transformed with pET28a(+)-His-SUMO-LCMV NP and starter
cultures were used to inoculate autoinduction media, which was incubated at
18 ℃ for 54 hours. The soluble fractions were collected from each culture and
passed over Ni2+ resin. The resin was subsequently washed with increasing
concentrations of imidazole, before the target protein was eluted at 300 mM
imidazole (figure 3.8). Again, there was little resulting purified 6xHis-SUMO-LCMV
NP. However, this suggested that the Rosetta strain was expressing the most soluble
6xHis-SUMO-LCMV NP and therefore this was chosen for large-scale purification.
It also became evident, through SDS-PAGE analysis and Coomassie staining of the
purification steps of 6xHis-SUMO-LCMV NP, that there appeared to be two major
purification products of approximately 80 kDa (thought to be 6xHis-SUMO-LCMV
NP) and 58 kDa. These bands could not be separated by IEC or SEC (data
not shown). Mass spectrometry analysis (data not shown) revealed that both
bands had sequences that corresponded to LCMV NP and the 6xHis-SUMO tag,
suggesting that the 6xHis-SUMO-LCMV NP was potentially being degraded. This
degradation was later successfully abrogated by adding serine protease inhibitor,
phenylmethylsulfonyl fluoride (PMSF).
Figure 3.8: Initial Purification Trials of 6xHis-SUMO-LCMV NP
SDS-PAGE analysis, followed by Coomassie staining, of batch immobilised metal-affinity
chromatography (IMAC) purification of 6xHis-SUMO-LCMV NP (predicted molecular
weight: ~75 kDa), which was expressed by autoinduction in a variety of BL21(DE3) E. coli
strains; Gold, Star, Rosetta, Rosetta 2 and CodonPlus. Soluble fractions were collected
and passed over Ni2+ resin, which was washed with solutions containing increasing
concentrations of imidazole. 6xHis-SUMO-LCMV NP was eluted at 300 mM imidazole.
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Further Purification by Size-Exclusion Chromatography
The large-scale IMAC purification of 6xHis-SUMO-LCMV NP was performed and
sufficient amounts of 6xHis-SUMO-LCMV NP were eluted, using 500 mM imidazole,
from the IMAC column. The elutions collected were then examined by SDS-PAGE
analysis (figure 3.9A). To further purify from contaminants, SEC was performed.
The elution was passed over SuperdexTM 200 column and the absorbance at 280 nm
was measured to determine which fractions contained protein after elution from the
SuperdexTM matrix (figure 3.9B). These fractions were then analysed by SDS-PAGE
and Coomassie staining (figure 3.9C), which revealed that there was there was still
contamination of the target protein, despite removal of some lower molecular weight
contaminants. This suggested that 6xHis-SUMO-LCMV NP was either strongly
interacting with a bacterial protein, or it was being degraded. Due to the presence
of contaminants in the 6xHis-SUMO-LCMV NP sample after SEC, other purification
methods were investigated.
Figure 3.9: Purification of 6xHis-SUMO-LCMV NP by Size-Exclusion
Chromatography
6xHis-SUMO-LCMV NP (predicted molecular weight: ~75 kDa) expression was induced
by autoinduction in the Rosetta strain of E. coli. 6xHis-SUMO-LCMV NP was collected
in a series of fractions, after it was eluted from Ni2+ resin using 500 mM imidazole (A).
The elution was then resolved through size-exclusion chromatography. 3 mL fractions were
collected and analysed by absorbance readings at 280 nm (B) and SDS-PAGE analysis,
followed by Coomassie staining (C).
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Further Purification by Immobilised Metal-Affinity Chromatography
It was then thought the purity of the 6xHis-SUMO-LCMV NP eluted from the first
IMAC purification step could be improved by removing the 6xHis-SUMO tag and
performing a second round of IMAC purification. Simultaneously, the 6xHis-SUMO
tag was removed by ULP1 cleavage and dialysis was performed to reduce the
imidazole concentration. This resulted in a mixed population of the 6xHis-SUMO
tag, ULP1, uncleaved 6xHis-SUMO-LCMV NP and the desired untagged LCMV NP,
which was collected in the flowthrough from the second IMAC purification (figure
3.10A).
Further Purification by Ion-Exchange Chromatography
In order to further purify and concentrate LCMV NP, the flowthrough collected
from the second IMAC purification was then subjected to IEC. Fractions at each
salt concentration were collected and analysed by SDS-PAGE (figure 3.10B). The
fractions containing the highest concentrations of LCMV NP were pooled and then
concentrated to 1 mg/mL using a centrifugal concentrator with a 10 kDa molecular
weight cut off. Following densitometry calculated using ImageJ software, the purity
was estimated to be approximately >85 %. On this basis, the purified LCMV NP
was judged to be suitable to be used as the priming antigen for antibody production.
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Figure 3.10: Purification of 6xHis-SUMO-LCMV NP
6xHis-SUMO-LCMV NP (predicted molecular weight: ~75 kDa) was passed over Ni2+
resin, attaching by its 6xHis-SUMO tag. Contaminating proteins were washed from
the resin using increasing concentrations of imidazole and 6xHis-SUMO-LCMV NP was
eluted using 500 mM imidazole. The washes and elution were collected to be examined
by SDS-PAGE analysis, followed by Coomassie staining (A). The 6xHis-SUMO tag was
then cleaved from 6xHis-SUMO-LCMV NP, the imidazole concentration was reduced by
dialysis and LCMV NP (predicted molecular weight: ~62 kDa) was reapplied to Ni2+
resin, in order to further purify LCMV NP. LCMV NP was collected in the flowthrough
and the contaminating proteins collected in subsequent imidazole washes, all of which
were examined by SDS-PAGE analysis and Coomassie staining. The flowthrough from
the second Ni2+ column was then further purified through ion-exchange chromatography
and LCMV NP was eluted between 285 mM NaCl and 665 mM NaCl. Each fraction to
examine by SDS-PAGE analysis and Coomassie staining (B).
3.2.4 Generation of LCMV NP Antisera
Immunisation of a sheep using 0.9 mg purified LCMV NP was performed by
Antibody Applications Limited. Serum was collected pre-inoculation (day 0), post-1
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inoculation (collected on day 21), post-2 inoculations (collected on 49) and post-3
inoculations (collected on day 77). The final harvest, collected on day 77 after the
third inoculation, was used in the following western blotting and immunofluorescence
assays.
Enzyme-linked immunosorbent assays (ELISA) performed by Antibody Applications
Limited (data not shown) showed that the LCMV NP antisera was reactive to
the LCMV NP antigen. However, it was necessary to determine the ability of the
antisera to detect LCMV NP in complex cellular protein mixtures.
3.2.5 Validation of LCMV NP Antisera
Western Blotting Analysis
Initially, western blotting analysis was performed on ten-fold dilutions of the LCMV
NP antigen sample using the antisera at dilutions between 1:1000 to 1:5000. This
revealed that the LCMV NP antisera, at 1:5000, was capable of detecting 4.67 ng
of LCMV NP from the original purified sample on a western blot (figure 3.11A).
The LCMV NP antisera also reacted with several other bands at different molecular
weights, which could have resulted from LCMV NP degradation.
Western blotting analysis was then performed on lysates harvested from BHK-21 and
SHSY5Y cells, which had been infected with LCMV, at an MOI of 0.1, and incubated
at 37 ℃ for 48 hours (figure 3.11B). Western blot analysis was also performed on
lysates from vero and A549 cells, which had been infected with PICV, at an MOI of 1,
and incubated at 37 ℃ for 24 hours (figure 3.11(C)). These western blots were stained
with the LCMVNP antisera at a 1:1000 dilution and the GAPDH antibody (1:10000)
as a loading control. A band was clearly visible in LCMV- and PICV-infected cell
lysates, which was not present in mock-infected cell lysates, strongly suggesting the
band corresponds to the NP. The cross-reactivity between the LCMV NP antisera
and the PICV NP band also suggests that the LCMV NP antisera could be broadly
reactive with NPs from viruses from across the Mammarenavirus genus.
It was also investigated whether the LCMV NP antisera would be cross-reactive
to distantly related bunyavirus Hazara virus (HAZV). Western blot analysis was
performed on lysates from SW13 and BSR-T7 cells, which had been infected with
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HAZV, at an MOI of 0.1, and incubated at 37 ℃ for 48 hours. The western blot
was probed with LCMV NP antisera (1:1000) and GAPDH antibody (1:10000) as
a loading control (figure 3.11(D; α-LCMV NP)). There were no appropriately sized
bands that could correspond to the HAZV NP when probed with the LCMV NP
antisera, so the same western blot was then probed with HAZV NP antisera to
confirm there was a successful HAZV infection (figure 3.11(D; α-HAZV NP)). There
was a strong band corresponding to the HAZV NP after probing with the HAZV
NP antisera, which suggests the LCMV NP antisera was not cross-reactive with
HAZV. This was expected due to HAZV being classified within the Nairoviridae
family and possessing an NP that shows little similarity in terms of primary amino
acid sequence.
Figure 3.11: Validation of LCMV NP Antisera by Western Blotting
Western blotting analysis revealed that LCMV NP antisera (1:5000) was able to detect
4.67 nanograms of LCMV NP (A) from a purified sample. The antisera (1:1000) was
also reactive with LCMV NP from LCMV-infected (B) BHK-21 and SHSY5Y cell lysates
and with PICV NP from PICV-infected (C) vero and A549 cell lysates. The LCMV
NP antisera (1:1000) was not cross-reactive with the distantly related HAZV NP from
HAZV-infected SW13 and BSR-T7 cell lysates (D; α-LCMV NP) but the same samples
showed successful HAZV infection after probing with HAZV NP antisera (1:3000) (D;
α-HAZV NP). The position of relevant size marker bands have been indicated and the
un-cropped western blots of B, C and D have been shown in chapter 7, in figures 7.1, 7.2
and 7.3 respectively.
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Immunofluorescence Analysis
In addition to western blot analysis, the LCMV NP antisera was used to detect
the subcellular localisation of the LCMV NP by immunofluorescence (IF) analysis.
BHK-21 and SHSY5Y cells, which had been infected with LCMV at an MOI of 0.1
and incubated for 24 hours at 37 ℃, were fixed, permeabilised, stained with the
LCMV NP antisera (1:500 dilution) and then stained with an anti-sheep secondary
antibody conjugated to an Alexa-fluor 594 nm fluorophore, followed by mounting
using ProLong Gold Anti-fade Mountant containing DAPI. IF analysis was also used
to determine the distribution of the PICV NP in vero and A549 cells, which had
been infected with PICV at an MOI of 0.1 and incubated for 24 hours at 37 ℃
and then stained in the same manner as above. IF analysis with the LCMV NP
antisera was also performed on mock-infected BHK-21 and A549 cells, to determine
whether there was any cross-reactivity with cellular proteins. The IF analysis
revealed a cytoplasmic distribution of the LCMV NP in both infected BHK-21 and
SHSY5Y cells, and it appeared that the staining was either throughout the entire
cytoplasm, or present in distinct puncta of varying sizes, ranging from approximately
0.1 µm to 2.5 µm, some of which appeared to have a perinuclear localisation (figure
3.12). Several cells also showed both diffuse cytoplasmic distribution and perinuclear
puncta distribution of the LCMV NP, suggesting different localisation of the LCMV
NP throughout the viral lifecycle. The IF analysis also revealed a cytoplasmic
distribution of the PICV NP in infected A549 and vero cells, but as opposed to
LCMV, the PICV NP distribution showed primarily the formation of discrete puncta
of varying sizes, ranging from approximately 0.2 µm to 4.5 µm (figure 3.12). At the
24 hour timepoint, it appeared there was little diffuse cytoplasmic distribution of the
PICV NP in either A549 or vero cells, although there were many puncta were present
throughout the cytoplasm, with some puncta having a perinuclear localisation. The
mock-infected cells that were stained with LCMV NP antisera and analysed by IF
showed no evidence of cross-reactivity between the antisera and the cellular proteins
from either BHK-21 or A549 cells (figure 3.12).
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Figure 3.12: Validation of LCMV NP Antisera by Immunofluorescence
Immunofluorescence analysis confirmed that LCMV NP antisera (1:500) was able to detect
LCMV NP in infected BHK-21 and SHSY5Y cells and not in mock-infected BHK-21 cells
(top panels). The LCMV NP antisera (1:500) was also cross-reactive with PICV NP in
infected A549 and vero cells and not in mock-infected A549 cells (bottom panels).
3.2.6 Development of the LCMV Focus Forming Assay
The LCMV NP antisera was also used to develop an assay to determine the titre of
LCMV stocks. Previously, crystal violet staining had been performed on BHK-21
cells which had been infected with serially diluted LCMV (figure 3.13A). However,
due to a lack of cytopathic effect (CPE) on these cells, no discernible plaques were
evident, making LCMV stock titration problematical. One option that has proven
successful for other similarly non-cytolytic viruses is the use of focus forming assays,
in which viral antigens produced during infection of cells are detected and stained,
thus revealing infected cell foci. Here, BHK-21 cells were infected with serially
diluted LCMV, overlaid with methylcellulose, a semi-solid medium, and incubated
for three days at 37 ℃. The BHK-21 cells were then fixed, permeabilised, blocked
and stained with the LCMV NP antisera (diluted 1:1000). At this point, two
types of focus forming assay were developed, one which used a colorimetric method
(horseradish peroxidase [HRP]) to visualise foci and one which used fluorescence
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(EVOS). After LCMV NP antibody staining, the HRP focus forming assay was
washed with PBS and then stained with a HRP-conjugated anti-sheep secondary
antibody (1:500). Then, 4-chloro-1-naphthol (4C1N) was added to the cells, which is
converted into a purple precipitate in presence of HRP. This results in the formation
of purple foci that are visible by eye (figure 3.13B). Alternatively, for the EVOS
focus forming assay, the LCMV NP antibody staining was followed with staining
with an Alexa-fluor 594 nm fluorophore-conjugated anti-sheep secondary antibody
(1:1000). The entire well was then imaged at 4X magnification using the EVOS FL
2 automated microscope (figure 3.13(C)). In both types of focus forming assay, the
LCMV NP antisera was reactive with the infected cells and showed foci of infection,
with each arisen from a single infected cell, which can therefore provide a titre in
focus forming units (ffu). BHK-21 cells were also mock-infected in all these assays
(figure 3.13; Mock), incubated and stained in the same manner as the infected.
There were no discernible foci in the mock-infected BHK-21 cells, confirming the
foci had arisen from LCMV-infected cells. For titre determination in the future
chapters, the EVOS focus forming assay was used, due to the ease of visualising the
foci.
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Figure 3.13: Development of Focus Forming Assay to Determine LCMV Titre
The LCMV NP antisera was used to develop a focus forming assay in order to be able
to determine the titre of LCMV stocks. Previously crystal violet staining techniques
of LCMV-infected BHK-21 plaque assays were unsuccessful (A). BHK-21 cells were
infected with serial dilutions of LCMV and stained with LCMV NP antisera (1:1000).
Some LCMV-infected BHK-21 plaque assays were stained with anti-sheep secondary
antibodies, which were conjugated to horseradish-peroxidase (1:500), and then stained
with 4-chloro-1-naphthol to visualise a colour change at the infected foci (B). The
other LCMV-infected BHK-21 plaque assays were then stained with anti-sheep secondary
antibodies, which were conjugated to 594 nm fluorophores (1:1000), and fluorescent foci
were imaged on the EVOS FL 2 automated microscope (C). Magnified images from the
10-3 and 10-4 dilutions have been shown in (D). All images in (B), (C) and (D) had their
brightness and contrast adjusted using the same values, in ImageJ and PowerPoint.
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3.3 Chapter Summary and Discussion
This chapter describes the generation of LCMV NP antisera, which was successfully
used to analyse the subcellular distribution of LCMV NP during infection using
immunofluorescence and to identify infected cells as a means of determining the
titre of LCMV stocks. Here, the expression and the purification of the recombinant
LCMV NP from E. coli was optimised to produce sufficient recombinant LCMV NP
as an antigen for the generation of a polyclonal antibody. The antibody was reactive
with the LCMV NP from infected BHK-21 and SHSY5Y cells and did not react with
the unpurified lysates from mock-infected cells. The LCMV NP antisera was also
cross-reactive with PICV, a mammarenavirus classified within the New World clade
of the Mammarenavirus genus, but it was not cross-reactive with viruses in the
Nairoviridae family.
Immunofluorescence experiments performed in this chapter utilising the LCMV
NP antibody successfully identified a cytoplasmic localisation of the LCMV NP
in BHK-21 and SHSY5Y cell lines and of the PICV NP in A549 and Vero cell
lines. These experiments showed both a diffuse cytoplasmic distribution and
puncta-formation of the NP during the LCMV infection cycle, but it appeared
the NP predominantly adopted a puncta formation in PICV infected cells. This
was in accordance with previous research that found a cytoplasmic distribution and
puncta formation in LCMV NP-transfected and LCMV-infected cells and were able
to attribute the puncta formation to a single phosphorylated residue (T206) (Baird
et al., 2013; Knopp et al., 2015). The research here shows that the PICV NP
also appears to form puncta in infected cells, suggesting that this is a feature also
attributed to New World clade A arenavirus members. PICV NP also shares the
T206 residue identified in LCMV NP as the phosphorylated residue responsible for
puncta formation, which could suggest the same method of puncta regulation.
The LCMV NP antibody generated here could also be used to develop inexpensive
and robust diagnostic tools, such as colorimetric immunoassays (including
enzyme-linked immunosorbent assays and lateral flow assays). This could
allow easy and rapid identification of LCMV-infected individuals, which may
help prevent morbidity associated with organ transplantation-transmitted LCMV
infections. The reactivity with PICV also suggests a cross-reactivity with multiple
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mammarenaviruses and such a diagnostic tool could be extrapolated to easily
identify and diagnose cases of Lassa fever and New World haemorrhagic fevers,
permitting earlier therapeutic intervention and improving disease outcome. The
simplicity of these assays and the requirement of basic equipment would also permit
their use in lower economy countries.
Further work could involve improving the yield of soluble recombinant LCMV NP.
The yield of LCMV NP could be improved by expression from a different vector, such
as the pET46-ek/LIC vector or the pMAL-c2X-derived pLou3 vector, both of which
were successfully used to express full-length LASV NP in a bacterial expression
system and resulted in a high yield, which was suitable for crystallisation (Hastie
et al., 2011a; Qi et al., 2010). The LCMV NP yield could also be improved by
incorporating a bacterial signal peptide to translocate the protein to the periplasm
of E. coli for expression. The oxidising environment of the periplasm would
allow disulphide bond formation, which could provide a more native conformation,
improving solubility (Malik, 2016). In the trials attempted in this chapter, the
recombinant LCMV NP appeared to have the highest yield of soluble protein in the
Rosetta and CodonPlus strains, both of which have been supplied with rare codons
(Kaur et al., 2018). This suggests the need for either codon-optimisation of the
LCMV NP sequence or its expression in another system. Full-length LASV NP was
also successfully expressed using a baculovirus/insect expression system, suggesting
insect expression or eukaryotic expression systems would produce a higher yield of
soluble LCMV NP (Brunotte et al., 2011b). Alternatively, expression of individual
N-terminal and C-terminal domains may be more successful, as shown previously
(Hastie et al., 2011a,b; Zhang et al., 2013; Jiang et al., 2013; West et al., 2014;
Yekwa et al., 2017).
Increasing the yield of soluble recombinant LCMV NP significantly could allow the
determination of its full-length structure, either through x-ray crystallography or
electron microscopy techniques. This project demonstrated that bacterial expression
of LCMV NP resulted in low yield of full-length soluble LCMV NP, either due to
degradation or loss through insolubility. With the availability of the full-length
LASV NP structure and the C-terminal domain of LCMV NP, an alternative method
to predict the structure of the full-length LCMV NP could be to employ the use
of artificial intelligence software, such as AlphaFold or RosettaFold. Understanding
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the structure of the NP is important to determine the interactions between NP and
RNA and the mechanisms behind NP multimerisation for RNP formation, both of
which can be targeted for disruption in the development of antivirals.
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Chapter 4
Development of a Reverse
Genetics System to Recover
Infectious LCMV
4.1 Chapter Introduction
Reverse genetics systems allow the manipulation of viral genomes and the subsequent
investigation into the effects particular mutations have on the viral lifecycle. The
transfection of plasmids, which express the viral vRNA or cRNA and support
proteins, into cells allows the establishment of a viral replication-transcription cycle
and the formation of infectious virus particles. Introduction of mutations into the
viral genome and proteins permits further understanding of the virus lethality,
pathogenesis and identification of individual residues that can be responsible for
viral protein cellular localisation or protein-protein interactions.
This chapter describes the creation of a reverse genetics system designed to generate
recombinant infectious lymphocytic choriomeningitis virus (rLCMV) entirely from
complementary DNA (cDNA) sources within mammalian cells. This system was
constructed in order to provide a platform for the generation of genetically-altered
LCMV variants, as well as providing a source of infectious wild type (WT) LCMV
with a consistent genotype that exhibited stable growth properties and high viral
titres.
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4.1.1 Introduction to Forward and Reverse Genetics
Forward and reverse genetics are terms used to describe the workflow of genetic
analysis that aim to link genotype with phenotype, thus assigning functions to
genetic elements. Forward genetics described experiments in which an initially
observed phenotype is assigned to a subsequently identified genetic lesion. On
the contrary, reverse genetics describes an experimental workflow in which genetic
elements are first altered, after which an associated phenotype, and thus gene
function, is described. In the context of viruses, a reverse genetics system is one
that allows site directed manipulation of any part of the viral genome that can
subsequently be used to assign gene function. Some such systems allow the recovery
of autonomously replicating viruses that are indistinguishable from natural isolates,
whereas other systems generate truncated viral genomes known as "replicons" or
"mini-genomes", which require the co-expression of viral proteins to support gene
expression activities, and these "support" proteins are most often expressed from
transfected plasmids. Such mini-genome systems carry a major drawback in that
they do not represent authentic self-replicating entities, but they do offer an
important advantage in that they can often allow the study of mutations that would
be lethal in the context of infectious virus.
Virus reverse genetics provides the opportunity to study cis-acting sequences
involved in the control and regulation of gene expression, such as promoters,
secondary structure elements, transcription start and stop sites, and genome
packaging signals. Reverse genetics also allows interrogation of roles of trans-acting
factors such as entire proteins, their motifs, and single amino acid residues. The
introduction of specific mutations into the viral genome, via reverse genetics,
provides tools to help understand host-virus interactions and mechanisms of
viral virulence. Determining the genetic regulation over viral virulence also
assists with the development of safer attenuated recombinant arenavirus vaccines
(Martínez-Sobrido and de la Torre, 2016).
The use of reverse genetics systems also permits the manipulation of viral genomes
for studies not directly associated with gene function. A common example of this is
the generation of genetically altered viruses in which fluorescent proteins or epitope
tags have been fused to viral proteins, which, for example, can facilitate the analysis
128
CHAPTER 4. THE LCMV REVERSE GENETICS SYSTEM
of viral replication kinetics, identify subcellular localisation of viral proteins or assist
purification of viral complexes from cells.
4.1.2 Development of Viral Reverse Genetics Systems
The first virus to be rescued entirely from transfected DNA sequences was in 1976
and involved the rescue of infectious recombinant SV40 that contained phage λ
sequences (Goff and Berg, 1976). Then, the first RNA virus to be rescued from
transfected DNA sequences, in 1978, was bacteriophage Qβ (Taniguchi et al., 1978),
followed shortly in 1981 by the rescue of poliovirus from transfected cells (Racaniello
and Baltimore, 1981). The positive-sense RNA genomes of bacteriophage Qβ and
poliovirus are also in the messenger RNA sense, so their transcription from DNA
plasmids results in the presence of the correct sense genome that can express the
viral proteins and establish an infection. The development of reverse genetics
systems for negative sense RNA viruses proved more difficult because negative-sense
RNA genomes are not expressed in the messenger RNA sense, meaning viral
proteins will not be transcribed and translated to kick-start infection (Pekosz et al.,
1999). Furthermore, negative-sense vRNAs and the positive-sense cRNAs both
require encapsidation for recognition by the negative-sense viral polymerase and
subsequent replication and transcription (Pekosz et al., 1999). Therefore, in order
to generate infectious negative-sense RNA viruses, trans-complementation of all viral
proteins involved in viral transcription and replication is required, often by supplying
corresponding support plasmids (Pekosz et al., 1999).
In 1989, a "mini-genome" reverse genetics system was developed for influenza
A virus, a segmented negative-sense RNA virus, but it required infection with
"helper" influenza virus (Luytjes et al., 1989). Subsequently, in 1994, rabies
virus, a non-segmented negative-sense RNA virus, was successfully rescued from
transfected cDNAs, without the need of infection with "helper" virus (Schnell
et al., 1994). Following this, several other reverse genetics systems were developed
for non-segmented negative-sense RNA viruses including vesicular stomatitis virus
(VSV) (Whelan et al., 1995; Lawson et al., 1995), measles virus (Radecke et al.,
1995), Sendai virus (Garcin et al., 1995) and respiratory syncytial virus (Collins
et al., 1995). Then, in 1996, a reverse genetics system was developed to rescue
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Bunyamwera virus (BUNV), a segmented negative-sense RNA virus, which did
not require infection with "helper" virus (Bridgen and Elliott, 1996). This was
achieved through the transfection of cells with plasmids expressing the full-length
cDNA copy of each of the three BUNV genomic segments, which were flanked with
a bacteriophage T7 promoter and the hepatitis delta virus ribozyme sequence.
This enabled the expression of cRNA segments, which were transcription- and
replication-competent and could therefore establish an infection. This system has
since been applied to many other viruses, permitting in-depth analysis of how the
viral genomic elements are responsible for virulence and pathogenesis.
4.1.3 Arenavirus Mini-Genome Systems
The first mini-genome systems for the arenaviruses were developed in the early
2000s, for LCMV (Lee et al., 2000), TCRV (López et al., 2001) and LASV (Hass
et al., 2004), followed shortly by mini-genome systems for JUNV (Albariño et al.,
2009) and PICV (Lan et al., 2009). The process involves the transfection of the
necessary viral proteins and a short model genome, which expresses a reporter
gene such as chloramphenicol acetyltransferase (CAT). This therefore allows the
study of the transcription and replication stages of the viral lifecycle, but not
the study of entry, packaging or budding because the structural proteins that
are required for formation of infectious particles and subsequent entry (i.e., GPC
and ZP) have been replaced with the reporter gene. Mini-genome systems have
been instrumental for determining the multiple roles of the viral proteins and
the genomic regulatory elements. Their use has led to the recognition that the
LP oligomerises, which is necessary for its replicative and transcriptive activities
(Sánchez and de la Torre, 2005; Brunotte et al., 2011b). Furthermore, it was
through using mini-genome systems that endonuclease activity of the LP was
found to be necessary for viral transcription (Morin et al., 2010). Mini-genome
systems were also used for understanding the minimum residues in the 3’ and 5’
UTRs required to act as the LCMV LP promoter and the importance of these
residues in the formation of the genomic panhandle (Perez and de la Torre, 2003a).
Additionally, mutations introduced using mini-genome systems identified the IGR
as a transcription termination signal (Pinschewer et al., 2005).
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4.1.4 Arenavirus Reverse Genetics Systems for Recovery
of Infectious Virus
The first reverse genetics system for the recovery of infectious arenaviruses
was designed to rescue pseudotyped LCMV, which expressed VSV glycoproteins
(rLCMV/VSVG) (Pinschewer et al., 2003). Here, the LCMV GPC ORF was
replaced with the VSV G in the cDNA copy of the S segment (Pinschewer et al.,
2003). This was then transfected into cells, which were subsequently infected
with WT LCMV. Following this, a selective pressure was applied by passaging the
viruses through SKI-I/S1P-deficient cells and therefore selecting for rLCMV/VSVG
(Pinschewer et al., 2003). Whilst this method successfully generated infectious
recombinant LCMV, the genome of which could be mutated and analysed, it
was laborious and time-consuming. In 2006, this problem was solved through
the simultaneous development of two reverse genetics systems designed to rescue
infectious LCMV (Sánchez and de la Torre, 2006; Flatz et al., 2006). Another
reverse genetics system, designed to rescue docile and aggressive strains of LCMV,
was then developed in 2008 (Chen et al., 2008). It was quickly followed by reverse
genetics systems for PICV (Lan et al., 2009), JUNV (Albariño et al., 2009; Emonet
et al., 2011), LASV (Albarino et al., 2011), LUJV (Bergeron et al., 2012) and MACV
(Patterson et al., 2014). Recently, a reverse genetics system has been designed to
rescue TCRV (Ye et al., 2020).
Reverse genetics systems involve the transfection of plasmids expressing the positive
sense copy of the vRNA (cRNA) and the minimal trans-acting viral factors, which,
in the case of arenaviruses, is NP and L. This results in the synthesis of recombinant
infectious viruses. For PICV and JUNV, the cRNA segments are sufficient to
generate recombinant viruses, suggesting the cRNA may be able to function as
mRNA (Lan et al., 2009; Albariño et al., 2009). The development of reverse
genetics systems for the arenaviruses has allowed further study of LASV entry, the
cellular S1P/SKI-1 processing sites of the arenavirus GPC and the role of the NP
in subversion of the IFN-I induction pathway (Rojek et al., 2008b; Albariño et al.,
2009; Martínez-Sobrido et al., 2009). Furthermore, reverse genetics has allowed
identification of viral genetic determinants of virulence, by creating avirulent and
virulent forms of PICV (Lan et al., 2009; Liang et al., 2009) and docile and aggressive
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forms of LCMV (Chen et al., 2008). Finally, arenaviruses expressing reporter genes
have also been created, simplifying the screening platform for identifying necessary
host genes or successful antivirals (Emonet et al., 2009; Ngo et al., 2015; Caì et al.,
2018). Initially, in order to include a reporter gene in recombinant infectious viruses,
the reverse genetics system was used designed to rescue trisegmented arenaviruses
(Emonet et al., 2009). Here, the NP and GPC ORFs were physically separated
onto two S segments, offering a selective pressure on the virus to retain both S
segments, and providing two possible sites for the reporter gene (Emonet et al.,
2009). Subsequently, reverse genetics systems have been developed where the
reporter gene is upstream of the NP gene, but separated by a self-cleaving peptide
(Ngo et al., 2015; Caì et al., 2018).
4.1.5 Introduction to T7P-driven Reverse Genetics
Systems
In 2006, when the LCMV reverse genetics systems were developed simultaneously,
one system employed a T7P-driven expression (Sánchez and de la Torre, 2006) while
the other system utilised RNA polymerase I/II-driven expression (pol-I/II) (Flatz
et al., 2006). Both systems were successful and were found to have similar efficiencies
(Sánchez and de la Torre, 2006). T7P-driven reverse genetic systems have since been
developed for many other mammarenaviruses, including LASV (Cai et al., 2020),
PICV (Lan et al., 2009), TCRV (Casabona et al., 2009; López et al., 2001), LUJV
(Bergeron et al., 2012) and JUNV (Albariño et al., 2009). The T7P-driven system
was chosen for experiments performed in this chapter because the expression of the
pol I/II system in the nucleus raises the potential risk of splicing of the primary viral
RNA transcripts, which would severely limit the rescue of infectious virus (Flatz
et al., 2006). Moreover, the T7P-driven system can be functional in multiple cell
lines because the cells can be stably transfected with a plasmid expressing the T7P
whereas pol I/II-driven systems are reliant on the plasmids containing the promoter
sequence that corresponds to the species-specific polymerase and therefore can only
be performed in cell lines of that species (Flatz et al., 2006). Performing the reverse
genetics system in different cell lines can be useful when introducing mutations would
make the virus sensitive to host cell factors that are present in the current cell line;
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the system can therefore be transferred to a cell line deficient in these factors. Here,
we use the BSR-T7 cell line, which has been stably transformed with a plasmid
expressing T7P. BSR-T7 cells are derived from BHK-21 cells and both are deficient
in retinoic acid-inducible gene I (RIG-I) (Habjan et al., 2008). The initial T7P
transcript of the cRNA is not capped with M7G, exposing the 5’ triphosphate group
and strongly activating the RIG-I-mediated type I IFN response (Hornung et al.,
2006; Kim et al., 2004; Pichlmair et al., 2006; Plumet et al., 2007). This response is
circumvented by using the RIG-I-deficient BSR-T7 cell line (Habjan et al., 2008).
4.1.6 Chapter Aims
In this chapter, the aim was to design a reverse genetics system that generated
recombinant infectious LCMV from cDNA. Following this, subsequent aims were
to optimise this system in order to generate a high titre of recombinant LCMV.
Previous studies discovered that our current WT LCMV stock had issues with
repeated stock passaging and limiting titres, therefore generation of the recombinant
LCMV from this system provided a way to circumvent these issues. Another aim of
this chapter was to utilise the reverse genetics system to produce genetically-altered
LCMV variants that expressed fluorescent (eGFP) or purification (6xHis) tags, in
order to permit the development of anti-arenaviral-drug screening platforms and the
purification of RNPs from virally-infected cells.
4.2 Results
4.2.1 Design of the Reverse Genetics Plasmids
Based on studies by (Sánchez and de la Torre, 2006) and (Flatz et al., 2006), a reverse
genetics system designed to rescue recombinant wildtype LCMV (rLCMV-WT) was
developed. Plasmids pUC57-S and pUC57-L were designed to express the cRNA
species of the S and L segments of the clone 13 strain of LCMV, respectively
(GenBank accession numbers: S; DQ361065.2 and L; DQ361066.1). In pUC57-S and
pUC57-L, the S and L segments were flanked at their 5’ ends by a T7RP promoter
sequence (T7P) and at their 3’ ends with the hepatitis delta virus ribozyme (HDV
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Rz) and T7RP terminator sequences (T7T) (figure 4.1).
Typically, the T7P sequence end in three terminal G residues, which improves T7RP
activity for increased synthesis of primary RNA transcripts. The T7P sequences in
pUC57-S and pUC57-L lack two of the three G residues because the addition of
two non-viral G residues to the 5’ end of the cRNA reduces its recognition by the
viral LP (Perez and de la Torre, 2003a). Perez and de la Torre (2003) showed that
whilst a T7P containing a single terminal G residue did reduce the levels of T7RP
transcripts, it improved the subsequent amplification by the LCMV LP (Perez and
de la Torre, 2003a). The single terminal G residue improves amplification by the
LCMV LP because it acts as the non-templated G residue characteristically found
at the 5’ end of arenavirus cRNAs (Garcin and Kolakofsky, 1990, 1992).
The T7RP has low termination efficiency at the T7T sequence and can result in
runoff transcription (Mairhofer et al., 2015; Pattnaik et al., 1992). This can result in
the appearance of additional sequences on the 3’ end of the primary transcript, which
can negatively affect the formation of authentic arenavirus ends and the structure
of the panhandle. In order to promote the formation of authentic arenavirus ends,
a self-cleaving ribozyme, such as the HDV Rz, is added (Pattnaik et al., 1992). The
HDV Rz (complementary sense) was incorporated downstream of the 3’ UTR but
upstream of the T7T in both pUC57-S and pUC57-L. The HDV Rz is not influenced
by upstream sequences, except for the residue that is immediately 5’ adjacent to the
cleavage site, where C is the preferential residue and G is the least preferential
residue (Perrotta and Been, 1991; Perez and de la Torre, 2003a). The arenavirus
genome terminates with an essential G residue, which cannot be mutated because it
results in a complete lack of RNA synthesis (Perez and de la Torre, 2003a). However,
the presence of this G residue next to the cleavage site resulted in less than 1 % of
MG transcripts being cleaved (Perez and de la Torre, 2003a). In order to promote
ribozyme autolytic activity without affecting RNA synthesis, an additional C residue
was introduced between the 3’ end of the segment and the 5’ start of the ribozyme,
enabling site-specific cleavage and improving the processivity of the ribozyme (Ke
et al., 2004; Perez and de la Torre, 2003a; Sánchez and de la Torre, 2006). This
allowed a high rate of RNA synthesis with correctly formed arenavirus ends.
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We also constructed support plasmids to provide an initial source of LCMV NP and
LP. cDNAs representing these ORFs were successfully isolated from pUC57-S and
pUC57-L, using specific primers designed to amplify the NP and LP ORFs without
the segment-specific untranslated regions. The primers also introduced flanking
complementary restriction sites, NheI and XhoI, which were used to ligate the NP
and LP ORFs into the pUC57 vector, forming constructs pUC57-NP and pUC57-LP
(figure 4.2).
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4.2.2 Generation of Recombinant Wildtype LCMV
To generate recombinant wildtype LCMV (rLCMV-WT), pUC57-S, pUC57-L,
pUC57-NP and pUC57-LP (figures 4.1 and 4.2) were transfected into BSR-T7
cells, in addition to a T7RP-expressing plasmid (pUC57-T7), following the process
depicted in figure 4.3. pUC57-T7 was added to ensure uniform expression of the
T7RP in the BSR-T7 cells. Mock and control transfections in which either no
plasmids were provided (mock) or the plasmids pUC57-L and pUC57-LP were
omitted (-L) and for which rescue of rLCMV was not possible were performed
alongside.
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In order to monitor the success of the rescue procedure, lysates from transfected
BSR-T7 cells were harvested at every 24 hours up until 144 hours post transfection
(hpt) and were analysed by western blot analysis using LCMV NP antisera (figure
4.4A). Expression of LCMV NP served as a marker for virus amplification and thus
successful virus rescue. A band representing LCMV NP was first visible in the 48
hpt lysate. The LCMV NP band became increasingly more intense in the lysates
of the later (72-144 hpt). The most intense NP signal was detected in the 144
hpt harvested sample. There were no appropriately sized bands corresponding to
LCMV NP in the mock lysates, confirming that the band was not the result of
cross-reactivity with a host cellular protein. This western blot analysis suggests
that transfection of the reverse genetics plasmids results in LCMV NP expression,
but the subsequent increase indicates that infectious rLCMV virus was rescued and
was amplified within the BSR-T7 cell culture.
To confirm successful rescue of infectious rLCMV-WT, an additional experiment was
performed, in which supernatants from BSR-T7 cells (transfected with the reverse
genetics plasmids) were collected in triplicate. Supernatant samples were collected
every 24 hours up until 144 hpt. The viral titre of the harvested supernatants was
then determined by focus forming assay and the average titre was plotted onto a
graph (figure 4.4B). This revealed that the first detectable titre was in the 48 hpt
supernatant, coinciding with the LCMV NP band first being visible in the 48 hpt
cell lysate. The titres then steadily increase until the 144 hpt timepoint, which
contained the highest viral titre, with an average of 8.2x106 ffu/mL.
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Figure 4.4: Generation of Recombinant LCMV from Transfection
BSR-T7 cells were transfected with pUC57-L, pUC57-LP, pUC57-NP, pUC57-T7 and
pUC57-S. The cells were incubated for 144 hours with cell lysates and supernatant being
collected every 24 hours. The lysates were subject to western blot analysis, which was
stained for LCMV NP and GAPDH as a control (A). The supernatants were serially
diluted and used to infect BHK-21 cells, before staining for LCMV NP and determining
the titre by focus forming assay (B). The position of relevant size marker bands have been
indicated and the un-cropped western blot has been shown in chapter 7, in figure 7.4A.
4.2.3 Amplification of Recombinant Wildtype LCMV
In order to amplify the rescued rLCMV-WT, supernatant was collected from the
initially transfected BSR-T7 cells and was used to infect BHK-21 cells. Supernatants
from four initial rescue transfections were harvested at 120 hpt, pooled and used to
infect BHK-21 cells after which cell lysates were collected every 24 hours until 96 hpi.
Western blot analysis using LCMV NP antisera showed the LCMV NP band was
visible in all the timepoints examined and was not present in the mock cell lysate
(figure 4.5A). The most abundant LCMV NP band was in the lysate harvested at 96
hpi. Furthermore, the corresponding supernatants were also collected every 24 hours
up until 96 hpi. Here, the highest viral titre, which was determined by the focus
forming assay performed in triplicate, was seen at 48 hpi and was approximately
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3x106 ffu/mL (figure 4.5B). The subsequent timepoints (72 and 96 hpi) showed
a slight decrease in rLCMV-WT titre, whereas the NP band in the western blot
analysis actually slightly increases in size between 72 and 96 hpi.
Figure 4.5: Generation of Infectious Recombinant LCMV
The timepoint which produced the highest titre from transfected cells in figure 4.4 was
used to infect BHK-21 cells, after which the supernatant and cell lysates were collected
every 24 hours for 96 hours. The lysates were subject to western blot analysis and were
stained for LCMV NP and GAPDH as a control (A). The supernatants were serially
diluted and used to infect BHK-21 cells, before staining the cells for LCMV NP and using
a focus forming assay to determine the titre (B). The position of relevant size marker
bands have been indicated and the un-cropped western blot has been shown in chapter 7,
in figure 7.4B.
Upon comparison of the harvested lysates and supernatants from the transfected
BSR-T7 cells (figure 4.4) and the infected BHK-21 cells (figure 4.5), it appeared
that the NP band was larger in the infected BHK-21 cells, suggesting a greater
number of viruses was generated by infection of BHK-21 cells. However, the viral
titre was lower than the highest seen following transfection. Reasons for this are
unknown, but one possibility was an accumulation of defective interfering particles
as early as the first passage of virus.
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4.2.4 Validation of the Rescue System
In order to confirm the reverse genetics system was the source of LCMV-WT,
rather than a non-recombinant contaminant, site-directed mutagenesis was used to
introduce a silent, non-coding T1292 to C1292 change, which incorporated a XhoI
restriction site within pUC57-S, creating plasmid pUC57-S-XhoI (figure 4.6A). This
nucleotide change was chosen so as not to disturb any existing or potential RNA
regulatory signals (UTRs or IGR) or the NP amino acid sequence (figure 4.6B),
with the resulting XhoI site in pUC57-S allowing easy confirmation of successful
mutagenesis.
Additionally, in order to further prove that the LCMV NP band in the western
blot analysis of infected BHK-21 cell lysates had resulted from rLCMV-WT created
from transfection of the reverse genetics plasmids, control transfections were also
performed alongside, with either no plasmids (mock) or pUC57-S, pUC57-NP and
pUC57-T7 only (WT (-L)). The lack of LP (pUC57-L and pUC57-LP) present in the
cells would mean that the cRNA cannot be replicated and the virus lifecycle cannot
be established. Cell lysates were collected from transfected BSR-T7 cells at 120 hpt
and the supernatant was used to infect BHK-21 cells, which were incubated for 96
hours before the cell lysate was collected. The LCMV NP band was present, albeit
at lower levels, in the transfected BSR-T7 cells at 120 hpt, resulting from transient
plasmid-driven NP expression, and the band was not present in the mock-transfected
cells (figure 4.6C). The LCMV NP band appeared stronger in the BSR-T7 cells
that had been transfected with all the reverse genetics plasmids (WT), suggesting
that there was additional NP expression resulting from rLCMV-WT-specific gene
expression. A band corresponding to the LCMV NP was not seen in the cell lysate
of the BHK-21 cells infected with the "mock" or the "WT (-L)" supernatant, but
was present in the lysates of BHK-21 cells infected with "WT" supernatant. This
suggests the NP band in the infected cells arises from rLCMV-WT that has been
generated from the "WT" transfection (figure 4.6C).
BSR-T7 cells were also transfected with pUC57-L, pUC57-NP, pUC57-LP,
pUC57-T7P and pUC57-S-XhoI, which replaced pUC57-S. At 120 hpt, the BSR-T7
cell lysates were collected and the supernatant was used to infect fresh BHK-21
cells. At 96 hpi, the BHK-21 cell lysates were also collected. The cell lysates were
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examined by SDS-PAGE and western blotting analysis, and staining with LCMV
NP antisera showed that there was a similarly sized LCMV NP band, suggesting
there was little detriment to rLCMV-XhoI infectivity and replication (figure 4.6C).
Figure 4.6: Validation of the Generation of Recombinant LCMV expressing a
Silent Mutation
A silent mutation was introduced to show that the recombinant virus derived from the
transfected plasmids. T1929 (red) was mutated to C (red) introducing a XhoI restriction
site (underlined) without affecting the amino acid sequence (A). Primers were designed
to bind 510 bp upstream (C1421) from the mutation and 305 bp downstream (C2235) of
the mutation (B). BSR-T7 cells were transfected with pUC57-L, pUC57-LP, pUC57-NP,
pUC57-T7 and either pUC57-S (WT) or pUC57-S-XhoI (XhoI). The cells were incubated
for 120 hours and then the supernatant was used to infect fresh BHK-21 cells. The lysate
was collected from both the transfected cells and the infected cells at 120 hours and 96
hours respectively and was examined by western blot analysis, staining with anti-LCMV
NP and anti-GAPDH as a control (C). The position of relevant size marker bands have
been indicated and the un-cropped western blot has been shown in chapter 7, in figure
7.5. The supernatant from the infected BHK-21 cells was used to infect fresh BHK-21
cells and at 96 hpi, the supernatant was collected and RNA was extracted. The RNA
extracted from the virus was reverse transcribed into complementary DNA and digested
with XhoI before agarose gel electrophoresis analysis (D). A control experiment was set
up which did not have the reverse transcription step, demonstrating the bands had not
come from any contaminating DNA plasmids carried over from the transfected cells. The
XhoI restriction site is not present in the rLCMV-WT harvested RNA but is present in
the rLCMV-XhoI harvested RNA, which results in the ~800 bp band being cleaved into
~500 bp and ~300 bp bands.
Furthermore, the supernatants from the infected BHK-21 cells were collected and
used to infect a second set of BHK-21 cells to remove the possibility of supernatant
contamination with the original plasmid from the transfection. At 96 hpi, the
supernatant was collected for extraction of the viral RNA, which was used to
generate cDNA using reverse transcriptase. This cDNA was then used as template
for PCR amplification of an 800 base pair (bp) fragment using S segment-specific
primers, which included the introduced XhoI restriction site (as depicted in figure
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4.6B). The RT-PCR amplified cDNA fragments from both the rLCMV-WT and
rLCMV-XhoI infections were then digested with restriction enzyme XhoI and
analysed by agarose gel electrophoresis. This revealed a strong band of the correct
size (~800 bp) in the rLCMV-WT infection and two bands (~500 bp and ~300 bp) in
the rLCMV-XhoI infection (figure 4.6D). This confirms that the virus infecting the
BHK-21 cells has been generated from the plasmids transfected into the BSR-T7
cells. Alongside these experiments, a control experiment (no-RT) was also performed
to ensure the source of the cDNA used in the PCR amplification and digestion had
arisen from the viral RNA. Here, the RNA extracted from the supernatant was
not treated with reverse transcriptase. Following PCR, no cDNA amplification was
detected in the no-RT control (figure 4.6D), confirming the source of the amplified
cDNA was from viral RNA, and not contaminating plasmid carried over from
previous transfections. Mock-transfected/infected samples were also included to
show there was no contamination of the media (figure 4.6D).
4.2.5 Design of an LCMV Reverse Genetics System
Expressing eGFP
Reverse genetics systems allow the modification of viral genomes to express
fluorescent reporter proteins, such as enhanced green fluorescent protein (eGFP).
This provides useful viral tools for investigating the LCMV lifecycle, replication
kinetics and for screening anti-viral candidates. Here, we used the rLCMV reverse
genetics system to rescue an rLCMV variant (rLCMV-eGFP) in which eGFP ORF
was incorporated into the S segment, and expressed as a separate and non-fused
protein. The eGFP ORF was introduced into the LCMV S segment, upstream of the
LCMV NP ORF, generating the plasmid pUC57-S-eGFP (figure 4.7A). The eGFP
and LCMV NP ORFs were separated by the porcine teschovirus 1 2A self-cleaving
peptide linker sequence (P2A), which induces ribosome skipping on the S segment
mRNA, forming two independent mRNAs (figure 4.7B) (Donnelly et al., 2001;
Funston et al., 2008; Kim et al., 2011). Incorporating the eGFP sequence into
the S segment ensures its retention through passaging and separating the two ORFs
with the P2A sequence prevents the alteration of NP function by fusion of eGFP to
its N-terminal domain.
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Figure 4.7: Vector Map of pUC57-S-eGFP
Schematic representation of the LCMV S Segment expressing eGFP in the pUC57 vector
(A). The open reading frames have also been depicted separately to show the direction of
translation (B). The enhanced green fluorescent protein open reading frame (eGFP; green)
was put downstream of the T7RP promoter (T7P; white) and the S segment untranslated
region (pink diagonal). The eGFP ORF was in frame with the nucleocapsid protein ORF
(NP; light blue) but was separated by the porcine teschovirus 1 2A self-cleaving peptide
sequence (P2A; pink). The vector map was created using SnapGene software.
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CHAPTER 4. THE LCMV REVERSE GENETICS SYSTEM
4.2.6 Generation of Recombinant LCMV Expressing eGFP
The protocol for the rescue of recombinant LCMV expressing eGFP (rLCMV-eGFP)
was the same as for rLCMV-WT (figure 4.8), except pUC57-S was replaced
with pUC57-S-eGFP (figure 4.7A). The ability of the resulting rescued virus to
express eGFP allowed easy monitoring of transfection and infection success by
visualising eGFP expression as a representative of LCMV gene expression. BSR-T7
cells were either mock-transfected (mock), transfected with pUC57-NP, pUC57-T7
and pUC57-S-eGFP only (eGFP (-L)) or transfected with pUC57-L, pUC57-LP,
pUC57-NP, pUC57-T7 and pUC57-S-eGFP (eGFP). Every 24 hpt, supernatant
samples (in triplicate) were collected from the transfected BSR-T7 cells. These
samples were titred using the focus forming assay and the average titres were plotted
on a graph (figure 4.9A). Similarly to the results obtained with rLCMV-WT, the first
detectable titre of rLCMV-eGFP was in the 48 hpt supernatant. The rLCMV-eGFP
titres steadily increase until 120 hpt, which contained the highest viral titre, with
an average of 2.2x105 ffu/mL. At 120 hpt, the BSR-T7 cells were also imaged using
the EVOS FL 2 microscope (figure 4.9 (C)) and the lysates were subsequently
collected for SDS-PAGE and western blot analysis (figure 4.9B). The transfected
BSR-T7 cells were imaged using phase-contrast to show that the cells were equally
confluent. The transfected BSR-T7 cells were also imaged using green fluorescence,
which revealed that there was no fluorescence in the "mock"-transfected cells, but
there was fluorescence in the "eGFP (-L)" and "eGFP"-transfected cells, although
there were more fluorescent cells in the "eGFP"-transfected cells, suggesting that the
additional fluorescence was the result of rLCMV-eGFP replication and infection.
This was corroborated by the western blot analysis, where the bands, corresponding
to the LCMV NP and eGFP, were smaller in the "eGFP (-L)" lysate than the "eGFP"
lysate. "WT (-L)" and "WT" lysates, where the transfection was performed the same
but with pUC57-S instead of pUC57-S-eGFP, were also included to show that the
eGFP band was only present in the transfections performed with pUC57-S-eGFP.
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Figure 4.9: Generation of Recombinant LCMV expressing eGFP from
Transfection
BSR-T7 cells were either mock-transfected, transfected with pUC57-NP, pUC57-T7
and pUC57-S-eGFP only (eGFP(-L)) or transfected with the pUC57-L, pUC57-LP,
pUC57-NP, pUC57-T7 and pUC57-S-eGFP (eGFP). Control transfections were also
performed substituting pUC57-S-eGFP for wildtype pUC57-S (WT(-L) and WT). The
cells were incubated for a total of 120 hours and supernatant was collected every 24
hours and stored at -80 ℃. The titres of the supernatants collected every 24 hours were
determined through the focus forming assay, which was performed in triplicate (A).
Lysates were also collected at this 120 hpt for SDS-PAGE and western blot analysis,
whereby the western blots were stained with antibodies against LCMV NP (α-LCMV
NP) or GFP (α-GFP) and loading controls GAPDH (α-GAPDH) or actin (α-actin) (B).
The position of relevant size marker bands have been indicated and the un-cropped western
blots have been shown in chapter 7, in figure 7.6. At 120 hours post transfection (hpt),
phase-contrast and green fluorescent images of the mock, eGFP (-L) and eGFP-transfected
BSR-T7 cells were also collected on the EVOS FL 2 automated microscope (C).
4.2.7 Amplification of Recombinant LCMV Expressing
eGFP
Following the "mock", "eGFP (-L)" and "eGFP" transfections, the BSR-T7 cells
were incubated for 120 hpt before the supernatant was harvested and used to infect
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BHK-21 cells. Every 24 hours until 96 hpi, supernatant samples (in triplicate)
were collected from the infected BHK-21 cells. These samples were titred using the
focus forming assay and the average titres were plotted on a graph (figure 4.10A).
Comparably to the results obtained with rLCMV-WT, the highest viral titre was
seen at 48 hpi (approximately 6x105 ffu/mL) and subsequently there was a decrease
in rLCMV-eGFP titre. At 96 hpi, the BHK-21 cells were also imaged using the
EVOS FL 2 microscope (figure 4.10 (C)) and the lysates were subsequently collected
for SDS-PAGE and western blot analysis (figure 4.10B). The infected BHK-21 cells
were imaged using phase-contrast to show that the cells were equally confluent. The
infected BHK-21 cells were also imaged using green fluorescence, which revealed that
there was no fluorescence in the "mock"-infected cells or the "eGFP (-L)"-infected
cells, but there was fluorescence in the "eGFP"-infected cells, suggesting that the
fluorescence at this point was only the result of rLCMV-eGFP infection. This was
supported by the western blot analysis, where the bands, corresponding to the
LCMV NP and eGFP, were only present in the "eGFP" lysate. "WT (-L)" and
"WT"-infected lysates were also included to show that the eGFP band was only
present in the infections performed with rLCMV-eGFP.
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Figure 4.10: Generation of Infectious Recombinant LCMV expressing eGFP
The supernatants from the BSR-T7 cells that were transfected in figure 4.9 (including
mock, WT(-L), WT, eGFP(-L) and eGFP) were harvested and used to infect BHK-21 cells.
The BHK-21 cells were incubated for a total of 96 hours and supernatant was collected
every 24 hours and stored at -80 ℃. At 96 hours post infection (hpi), phase-contrast
and green fluorescent images of the cells were collected on the EVOS FL 2 automated
microscope (A). Lysates were also collected at this timepoint for SDS-PAGE and western
blot analysis, whereby the western blots were stained with antibodies against LCMV NP
(α-LCMV NP) or GFP (α-GFP) and loading controls GAPDH (α-GAPDH) or actin
(α-actin) (B). The position of relevant size marker bands have been indicated and the
un-cropped western blots have been shown in chapter 7, in figure 7.6. The titres of the
supernatants collected every 24 hours were determined through the focus forming assay,
which was performed in triplicate (C).
4.2.8 Determining the Influence of eGFP Expression on
rLCMV Growth
The data collected for the titres at 24 hour timepoints following transfection and
subsequent infection for both rLCMV-WT and rLCMV-eGFP rescues were then
compared to determine whether the growth efficiency was affected by inclusion of
the eGFP ORF (figure 4.11A and B). The first detectable titres of rLCMV-WT
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and rLCMV-eGFP, at 48 hpt, were very similar, suggesting that the corresponding
transfections were equally effective. The titres of the supernatants collected at the
later timepoints post transfection, where the titre increases are most likely due to
subsequent infection of the BSR-T7 cells, was where the titres of rLCMV-WT and
rLCMV-eGFP become discrepant, with a 1-log reduction in rLCMV-eGFP titre
(figure 4.11A).
After infection of BHK-21 cells with the 120 hpt supernatant from the transfected
BSR-T7 cells, the rLCMV-WT and rLCMV-eGFP supernatants were harvested
and titred every 24 hpi (figure 4.11B). Interestingly the 24 hpi timepoint was the
only timepoint where the titre of rLCMV-eGFP was higher than rLCMV-WT,
by approximately 1-log-fold. The following timepoints all show that the titre of
rLCMV-eGFP has returned to being 1-log-fold lower than the rLCMV-WT titre.
The titre of rLCMV-eGFP at 24 hpi could be higher than that of rLCMV-WT
because the titre of rLCMV-eGFP at 120 hpt was lower than rLCMV-WT, meaning
fewer viruses were used for the subsequent infection, which could potentially reduce
the effect of homologous interference. Homologous interference is the mechanism
by which viruses, including arenaviruses, restrict their own growth through the
production of defective interfering viruses (DIs) (Ziegler and Botten, 2020). DIs
are thought to be generated through viral polymerase-directed mutation or deletion
of the viral genome; these viruses then co-infect cells alongside competent virus
and out-compete the competent virus for access to the viral replication machinery
(Ziegler and Botten, 2020). Homologous interference is thought to be beneficial for
the establishment of persistent infections in the host, but can limit growth in vitro,
which means that infection at lower MOIs produces higher titres of competent virus
because the effect of homologous interference is reduced (Ziegler and Botten, 2020).
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Figure 4.11: Comparison of Recombinant Wildtype LCMV and Recombinant
LCMV expressing eGFP BSR-T7 cells were transfected with pUC57-L, pUC57-LP,
pUC57-NP, pUC57-T7 and pUC57-S-eGFP. The cells were incubated for a total of 120
hours and supernatant was collected every 24 hours and stored at -80 ℃. The titres of the
supernatants collected every 24 hours were determined through the focus forming assay,
which was performed in triplicate (A). The supernatants from the transfected BSR-T7
cells were harvested and used to infect BHK-21 cells. The BHK-21 cells were incubated
for a total of 96 hours and supernatant was collected every 24 hours and stored at -80 ℃.
The titres of the supernatants collected every 24 hours were determined through the focus
forming assay, which was performed in triplicate (B). BHK-21 cells were mock-infected or
infected with rLCMV-eGFP at an MOI of 0.01 and incubated for 24 hours. The BHK-21
cells were fixed, permeabilised and stained with LCMV NP antibodies (subsequently
stained with 594 nm flurophore-conjugated secondary antibody; red), GFP antibodies
(subsequently stained with 488 nm flurophore-conjugated secondary antibody; green) and
DAPI (blue) (C).
4.2.9 Determining the Influence of eGFP Expression on
LCMV NP Localisation
In order to confirm that the presence of eGFP did not affect the cellular localisation
of NP, and to ensure that the eGFP ORF was retained by the rLCMV-eGFP
viruses, BHK-21 cells were mock-infected or infected with rLCMV-eGFP at an
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MOI of 0.01. At 24 hpi, the BHK-21 cells were fixed, permeablised and stained
with LCMV NP antibodies, which were stained with 594 nm flurophore-conjugated
secondary antibody (red), and GFP antibodies, which were stained with 488 nm
flurophore-conjugated secondary antibody (green). The cells were then imaged using
confocal microscopy (figure 4.11C). This revealed that the cellular distribution of
LCMV NP was not altered when compared to the previous immunofluorescence
analysis (figure 3.12C), and the perinuclear puncta were still present. The eGFP
distribution was throughout the cytoplasm and was not associated with the LCMV
NP-puncta, which was concurrent with the eGFP being expressed as an individual
ORF. There was no fluorescence corresponding to the LCMV NP or eGFP in the
mock-infected cells, confirming there was no cross-reactivity with the antibodies and
a host cellular protein.
4.2.10 Development of rLCMV Expressing the 6xHis Tag
For further development of the LCMV reverse genetics system, we attempted to
rescue LCMV containing a 6xHis affinity tag at the C-terminus of the NP to allow
for concentration and purification of whole RNPs from virus. Previous studies have
shown that a HA tag can be introduced at the C-terminus of the NP, without
affecting its functions within a mini-genome system (Martínez-Sobrido et al., 2007).
Another study has shown that a Strep-tag can successfully be introduced to the
N-terminus of the LCMV NP in a reverse genetics system (Iwasaki et al., 2018). It
therefore appears that tags can be introduced to either termini of the LCMV NP
without disrupting its activities within the lifecycle.
We mutated the pUC57-S-eGFP plasmid to encode a 6xHis tag at the C
terminus of the NP, just prior to the stop codon (pUC57-S-eGFP-6xHis) (figure
4.12A). Transfection was carried out as before, where pUC57-S was replaced with
pUC57-S-eGFP-6xHis. After 120 hours, the supernatant was then collected and used
to infect BHK-21 cells, whilst the lysate was collected for western blot analysis.
After 96 hours, the BHK-21 cell lysates were collected and the supernatant was
used to infect fresh BHK-21 cells again and incubated for a further 96 hours, at
which point the BHK-21 cell lysates were once again collected and the supernatant
was harvested and stored at -80 ℃. The cell lysates from transfected BSR-T7 cells
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and subsequently infected BHK-21 cells were examined by western blot analysis,
after staining with antibodies raised against the LCMV NP (α-LCMV NP) or
6xHis (α-6xHis) (figure 4.12B). Mock-transfected and mock-infected BSR-T7 and
BHK-21 cell lysates were included to ensure the bands were not the result of
cross-reactivity with a host protein. Loading controls were also included by staining
with either GAPDH (α-GAPDH) or actin (α-actin). LCMV NP was not present in
the mock-transfected or mock-infected lysates but was present in the transfected and
rLCMV-6xHis-infected lysates. The same lysates also demonstrated that a similarly
sized band was reactive with the α-6xHis antibody in the same lysates as the LCMV
NP band, strongly suggesting that the NP was successfully tagged with the 6xHis
tag. To our knowledge, this is the first report of the generation of infectious rLCMV
expressing a C-terminally 6xHis-tagged NP.
Figure 4.12: Generation of Recombinant LCMV expressing a 6xHis tag on
the C-terminus of the Nucleocapsid Protein A 6xHis tag was introduced into the
C terminus of the nucleocapsid protein (NP) within the S segment to generate plasmid
pUC57-S-eGFP-6xHis, the open reading frames of which have been shown schematically in
(A). BSR-T7 cells were either mock-transfected or transfected with pUC57-L, pUC57-LP,
pUC57-NP, pUC57-T7 and pUC57-S-6xHis (6xHis). The cells were incubated for a total
of 120 hours (120 hpt), at which point the BSR-T7 cell lysates were collected for western
blot analysis and the supernatant was used to infect BHK-21 cells, which were incubated
for 96 hours (96 hpi). The supernatant from the BHK-21 cells was then used to infect
fresh BHK-21 cells, which were incubated for another 96 hours, as a second passage of
the virus (P.2). Lysates were collected at 96 hours post infection from the first infection
(96 hpi) and the second passage (P.2). All lysates were then examined by SDS-PAGE
and western blot analysis, whereby the western blots were stained with antibodies against
LCMV NP (α-LCMV NP) or 6xHis (α-6xHis) and loading controls GAPDH (α-GAPDH)
or actin (α-actin) (B). The position of relevant size marker bands have been indicated and
the un-cropped western blots have been shown in chapter 7, in figure 7.7.
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4.2.11 Comparison of Recombinant Wildtype LCMV and
Recombinant LCMV Expressing Genetic Tags
The development of this reverse genetics system provided a source of infectious
recombinant LCMV with a consistent genotype that exhibited stable growth
properties and high viral titres. It was previously discovered that our current WT
LCMV stock had issues with repeated stock passaging, reduced titres and difficulty
with titration (prior to the development of the focus-forming assay). The lack of a
stable, titred stock of infectious WT LCMV meant that we were unable to compare
growth properties and protein expression of recombinant LCMV with WT LCMV,
as a control.
In order to determine whether the insertion of eGFP or C-terminal NP 6xHis tag into
the S segment had any detrimental effects on the viral lifecycle, a direct comparison
was made between the replication efficiencies of rLCMV-WT, rLCMV-eGFP and
rLCMV-6xHis. This was distinct from section 4.2.8 because the experiments here
were carried out at a defined MOI, whereas the experiments performed in section
4.2.8 used the supernatant harvested from cells at 120 hpt, without titration. The
difference in titre at 120 hpt between rLCMV-WT and rLCMV-eGFP in figure
4.11A suggest the subsequent infection was performed at different MOIs. Therefore,
BHK-21 cells were infected in triplicate with either rLCMV-WT, rLCMV-eGFP or
rLCMV-6xHis at an MOI of 0.1. Supernatant was harvested at every 24 hours and
the titre was determined by focus forming assay. This revealed that introducing
the eGFP tag reduced the titre of rLCMV-eGFP by approximately one-log at every
collected timepoint, when compared to rLCMV-WT (figure 4.13). Introducing the
6xHis tag resulted in a greater reduction of the titre of rLCMV-6xHis, whereby
the highest titre measured was 3.8x104, which was approximately 3 logs lower than
rLCMV-WT. Despite the reduction in titre of the tagged LCMV variants, the growth
pattern was similar between WT and the variants, whereby the titre was lowest at 24
hours and rapidly increases to its highest titre at 48 hours. The titres then plateau
between 48 hours and 72 hours before experiencing a decrease at 96 hours.
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Figure 4.13: Comparison of Replication Efficiency between rLCMV WT and
rLCMV Tagged Variants To determine whether incorporation of the eGFP ORF or
the C-terminal NP His tag affected the growth efficiency of rLCMV, BHK-21 cells were
infected in triplicate with either rLCMV-WT rLCMV-eGFP or rLCMV-6xHis at a MOI
of 0.001 (both virus passage 2). Supernatant was collected from the cells every 24 hours
and was stored at -80 ℃. The supernatants were then titred by focus forming assay and
compared.
4.2.12 Purification of rLCMV-6xHis Ribonucleoprotein
Complexes
The 6xHis tag was introduced to the C-terminus of the LCMV NP in order to permit
purification of LCMV RNPs using immobilised metal-affinity chromatography. By
exploiting interactions between nickel ions on the chromatographic resin and the
histidine residues in the 6xHis tag, which would be present in multiple copies of NP
throughout the RNP, purification of the RNPs for further structural investigation
was attempted. In order to do this, BHK-21 cells were infected with rLCMV-6xHis
at an MOI of 0.001 and incubated for approximately 67 hours. After incubation, the
infected BHK-21 cells were lysed and the lysate was centrifuged. The supernatant
was collected and the pellet was resuspended in an equal volume of buffer. Samples
of the supernatant (soluble fraction) and the resuspended pellet (insoluble fraction)
were collected. The supernatant was then diluted 1:5 with 20 mM imidazole
binding buffer and passed over nickel resin. The flowthrough was collected and
the resin was then washed with the 20 mM imidazole binding buffer and a 40
mM imidazole wash buffer. The sample was eluted with 300 mM imidazole elution
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buffer and the elutions were collected in 1 mL fractions. Samples of all the washes,
elution fractions and the resin were collected for SDS-PAGE analysis, followed
by Coomassie staining (figure 4.14A) or western blot analysis and staining with
LCMV NP antibodies (figure 4.14B). Both of these showed the presence of a band,
corresponding to LCMV NP, in the soluble fraction, which was subsequently eluted
in elution fractions 3-6. This shows that the LCMV NP was successfully expressed
with the C-terminal 6xHis tag. The 6xHis tag was also sufficiently exposed to allow
interaction with the nickel resin and purification of the LCMV NP from infected
cell lysates. However, the concentration was too low to determine the presence of
RNA using spectrophotometry. To determine whether LCMV RNP complexes had
been successfully purified from infected cell lysates, the eluted samples (3-6) were
individually examined using negative-stain electron microscopy. No RNP complexes
could be identified (data not shown). Whether this was due to the low concentration
of the RNP complexes, degradation or aggregation remains to be determined.
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Figure 4.14: Purification of rLCMV-6xHis Ribonucleoprotein Complexes By
Immobilised Metal Affinity Chromatography BHK-21 cells were infected with
rLCMV-6xHis at an MOI of 0.001 and incubated for approximately 67 hours at which
point the cell lysate was harvested and centrifuged. The pellet was resuspended in buffer
and a sample was taken (insoluble). A sample of the supernatant was also taken (soluble)
before the supernatant was diluted with 20 mM imidazole binding buffer and passed over
nickel resin. The flowthrough was collected and the resin was then washed with the 20 mM
imidazole binding buffer and a 40 mM imidazole wash buffer. The sample was then eluted
with 300 mM imidazole elution buffer and the elutions were collected in 1 mL fractions.
Samples of all the washes, elution fractions and the resin were collected for SDS-PAGE
analysis, followed by Coomassie staining (A) or western blot analysis and staining with
LCMV NP antibodies (B).
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4.3 Chapter Summary and Discussion
This chapter describes the successful creation of a reverse genetics system, designed
to recover recombinant LCMV (rLCMV). Supernatant and cellular lysates were
collected at 24 hour intervals, post transfection and post infection, in order to
determine the optimal harvest time. This system enabled the generation of
rLCMV-WT, reaching titres of 107 ffu/mL. It was confirmed that the source of
rLCMV derived from the reverse genetic system plasmids, using mutational analysis
and RT-PCR. The reverse genetics system was modified to incorporate an eGFP
ORF into the S segment, which permitted the live-cell monitoring of successful
rLCMV-eGFP infection. The development of the rLCMV-eGFP reverse genetics
system also provided a system that could be exploited as a quick and simple
screening platform for the evaluation of anti-arenaviral drugs. The reverse genetics
system was also modified to introduce a C-terminal NP 6xHis tag. rLCMV-6xHis
was successfully rescued but the titre was significantly reduced compared to
rLCMV-WT. The differences in titres between the recovered recombinant viruses
suggest the introduced tags may be interfering with the functions of the NP. To
investigate this, monitoring of the other viral proteins, including the GPC, ZP
and the LP, could confirm that expression of these proteins is not reduced or their
subcellular localisation is not altered through the addition of the tag, which would
subsequently affect titre. This could be investigated through purchase or generation
of antibodies against each of the arenaviral proteins.
Stocks of rLCMV-6xHis were successfully generated that were used to infect BHK-21
cells and purification of RNP complexes was attempted. Whilst the purification of
the RNP complexes using IMAC was somewhat successful, further optimisation
is required in order to concentrate the RNP complexes without aggregation and
enable structural examination by electron microscopy. Steps to improve the
concentration of RNP complexes could firstly involve the optimisation of the growth
of rLCMV-6xHis to increase the titre; this would increase the number of infected cells
or the number of virions from which to purify the RNPs. Alternatively, trials could
be performed to determine whether changing the location of the 6xHis tag from the
C-terminus to the N-terminus of the NP may be less disruptive to the NP’s functions,
permitting higher titres and potentially allowing better exposure of the 6xHis tag.
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Figure 4.14 suggests that approximately half of the RNPs (as indicated by the NP
band) are collected in the flowthrough and 20 mM imidazole wash and therefore are
lost before purification. This indicates the 6xHis tag is inadequately exposed or the
sample is becoming insoluble. Attempting different purification buffers to improve
stability of the sample could be trialled, such as including glycerol or charged amino
acids L-Arg and L-Glu (Golovanov et al., 2004), or resins charged with alternative
ions, such as cobalt, which offers stronger interactions between the resin and 6xHis
tag.
We had also designed the rLCMV reverse genetics system to rescue other tagged
variants of rLCMV, including the addition of a split GFP tag onto the C-terminus
of the NP (rLCMV-GFP11) and the addition of a FLAG tag onto the C-terminus
of the GPC (rLCMV-FLAG). We successfully introduced the split GFP tag into the
C terminus of the NP (pUC57-S-GFP11) and a FLAG tag into the C terminus of
the GPC (pUC57-S-FLAG) but the rescues of rLCMV-GFP11 and rLCMV-FLAG
were unsuccessful.
First developed by Cabantous et al., the split GFP tag comprises the eleventh
strand of the GFP beta barrel and is only 16-amino acids long (Cabantous et al.,
2005). Its smaller size allows its incorporation into proteins with a reduced
disruption of the structure and function (Kamiyama et al., 2016). Cells can
then be transfected with a plasmid expressing GFP strands 1-10. Both GFP11
and GFP1-10 are independently non-fluorescent but together can self-associate to
generate fully-functional, fluorescent GFP. This provides a manner of tagging the NP
with GFP without introducing the entire GFP polypeptide sequence and disrupting
expression, folding, structure or function. Further optimisation is required in order
to rescue rLCMV-GFP11, which would then permit live cell fluorescent tracking of
the NP within the cell, and potential further exploration of any viral structures,
such as the LCMV NP puncta, within the cell by correlative light and electron
microscopy (CLEM).
It has previously been shown that a FLAG tag (and GGGS linker) can be added at
the C terminus of the GPC of both LCMV and LASV without affecting processing,
trafficking, function or infectivity of a pseudotype retrovirus (Capul et al., 2007).
However, its functionality in the reverse genetics system has not been tested. We
were unable to rescue rLCMV-FLAG at all, therefore further optimisation of the
161
CHAPTER 4. THE LCMV REVERSE GENETICS SYSTEM
system is needed. Introducing the FLAG tag into the GPC would permit further
mutational study into motifs required for interactions with cellular host trafficking
proteins that were suggested by an siRNA screen, performed as part of a Master’s
project. This could be further investigated for the mutational analysis of motifs in




Structural Determination of the
Arenavirus Glycoprotein Complex
5.1 Chapter Introduction
Electron microscopy (EM) has been vital in the research of many viruses, including
arenaviruses. For example, this technique was originally used to characterise
arenavirus isolates and led to the proposal of arenavirus incorporation of ribosomes
into virions (Murphy et al., 1970; Rowe et al., 1970b; Dalton et al., 1968; Wood
et al., 1970). Over recent years, there have been many advances in EM to improve
the way we can visualise viruses and increase the resolution of viral macromolecular
complexes. This has recently allowed the characterisation of the structure of the
LASV GPC, using cryo-electron tomography and sub-tomogram averaging (Li et al.,
2016). This gave insight into the ultra-structural organisation of the GPC and the
underlying ZP matrix layer, as well as the entry process of LASV.
This chapter describes the cryo-electron tomography and sub-tomogram averaging
of the glycoprotein complexes of PICV, a New World mammarenavirus, and LCMV,
an Old World mammarenavirus. Initially, the growth and purification of both
PICV and LCMV was optimised in order to generate highly concentrated and
highly pure virion preparations. These samples were analysed by negative-stain EM,
cryo-electron microscopy and cryo-electron tomography. Sub-tomogram averaging
of the viral spikes was performed in order to improve the resolution, in an attempt
to determine high-resolution structures of the PICV and LCMV GPC spikes. These
structures were then compared to the published LASV GPC structure to highlight
potential differences that can be seen between the Old World and New World
arenaviruses.
163
CHAPTER 5. STRUCTURE OF THE ARENAVIRUS GPC
5.1.1 Introduction to Electron Microscopy
EM offers a significant improvement in resolution compared to light microscopy
because the sample is imaged using an electron beam rather than visible light.
A beam of electrons possesses a much shorter wavelength than that of photons,
meaning the resolution is no longer limited at the wavelength of visible light.
However, EM does pose some challenges, particularly when imaging biological
samples. 1) The electrons are focused into a beam using a series of electromagnetic
lenses and the sample has to be imaged under vacuum conditions in order to prevent
gas molecules interacting with the electron beam. However, biological samples
are aqueous and therefore cannot withstand the vacuum conditions required (Ohi
et al., 2004). 2) There is a very small limit on the amount of the sample that
can be used to prepare EM grids, which means that the sample has to be highly
concentrated for examination. 3) Many atoms found in biological samples, such
as carbon and hydrogen, have a limited capacity for electron scattering, which
results in low contrast and reduces the ability to resolve finer detail (Ohi et al.,
2004). 4) Biological samples are also very susceptible to radiation damage from
the electron beam, limiting the electron dose that can be used for imaging (Ohi
et al., 2004; Cheng, 2015). However, there are techniques to counteract these
problems that biological samples pose. One such technique is negative-stain EM,
which coats the biological sample with a heavy metal (typically a uranyl-based salt).
Negative-staining quickly dehydrates the biological sample to allow imaging under
the vacuum conditions, and the heavy metal atoms interact with the electron beam
to significantly increase the signal-to-noise ratio (SNR) and thus the contrast of the
image (Thompson et al., 2016). However, the resulting dehydration in negative-stain
EM can cause deformation of the biological sample.
Cryo-electron microscopy (cryo-EM) provides the opportunity to image biological
samples in their native aqueous environment, whilst still protecting the sample
from the vacuum conditions of the microscope and radiation damage (Orlova and
Saibil, 2011). Here, the samples are frozen in a vitreous state, whereby the water
surrounding the sample is rapidly frozen, preventing the rearrangement of the water
molecules into an ice crystal formation that would damage the sample and reduce
image quality due to the ability of ice crystals to diffract electrons (Thompson
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et al., 2016). This method of preparation prevents dehydration and potential
deformation of the sample, that would typically occur with other methods including
negative-stain EM.
Whilst vitreous ice does offer some protection against radiation damage of the
biological sample, there is still quite a low limit of the electron dose before the sample
is damaged. Furthermore, the electron scattering by the biological atoms, rather
than the heavy metal atoms, is significantly reduced, lowering the SNR. Therefore,
in order to improve the SNR, several techniques can be combined with cryo-EM (or
negative-stain EM) to improve the resolution to such that it rivals other techniques
such as X-ray crystallography. Such techniques include single-particle analysis and
tomography.
Single-particle analysis (SPA) improves resolution of the structures within cryo-EM
images by aligning and averaging together multiple particles throughout the
2-dimensional (2D) plane (Cheng, 2015). A requirement of SPA is that the sample
needs to be homogeneous. If a sample is homogeneous then it can be assumed
all the particles of interest are the same, but in a different position or orientation.
Computationally altering these positions and orientations allows the particles to be
aligned and then averaged, improving the resolution. The presence of the particles in
different orientations also allows computational 3-dimensional (3D) reconstruction
of the particle (Cheng, 2015).
Cryo-electron tomography (cryo-ET) allows the generation of 3-dimensional (3D)
information through collecting a series of images of the sample at different angles,
which are then computationally combined to form a 3D volume called a tomogram
(Cope et al., 2011) (figure 5.1). Cryo-ET is particularly useful for the 3D
reconstruction of samples that do not contain regularly arranged particles that
could be reconstructed through SPA (Cope et al., 2011). The resolution of
irregularly arranged macromolecular complexes in reconstructed tomograms can
then be improved using a technique known as sub-tomogram averaging (STA), where
multiple individual particles are averaged in order to improve the resolution of the
feature of interest (Cope et al., 2011).
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Figure 5.1: Schematic Work Flow for Cryo-Electron Tomography The grid onto
which the sample (containing virus) is loaded onto an electron microscope. The stage
is then tilted from -60° to +60°, with images acquired every 2° increments. The images
acquired form a 2D tilt-series and can be computationally combined to reconstruct a 3D
tomogram, which can be used to generate a 3D model of the virus.
Furthermore, there has been significant improvement in the data collected from
cryo-EM, due to recent advances in cryo-EM technology. Such advances include
the development of direct-electron detectors (DEDs) as opposed to charged coupled
device cameras (CCDs) for the detection of the electrons which have passed through,
or been scattered by, the sample being imaged. CCDs use scintillators, which, when
an electron strikes it, induces photon emission that is transformed into electrical
signals. These electrical signals accumulate to build an electrical charge, which
is then amplified and an image is formed (Dillard et al., 2018; Thompson et al.,
2016). In contrast, DEDs use a very thin semi-conductor wafer that detects the
energy deposited by the electrons directly. Noise, created from the electrons being
back-scattered from the support matrix of the DED and hitting the semi-conductor
again, is reduced by making the support matrix of the DEDs as thin as possible
(Mitra, 2019; Thompson et al., 2016). DEDs also have a high frame rate, which
offers the benefit to detect the exposure as multiple frames, rather than a single
frame. These frames can then be aligned together to correct for any movement
that occurs during the exposure, which could be the result of specimen movement,
mechanical movement or beam-induced movement (Mitra, 2019; Thompson et al.,
2016).
In cryo-EM and cryo-ET, biological samples have to be imaged with a low electron
dose to prevent damage to the sample. In cryo-ET, the electron dose has to be even
lower because the same region of interest is imaged multiple times in the different
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projection angles. Imaging with a low electron dose poses a further challenge to
generate sufficient contrast in low contrast biological samples. Therefore, in order
to counteract the low electron dose and improve the SNR, several techniques can
be used. One conventional way is to apply defocus to the collection to increase the
contrast. Another way is to use a Volta phase plate. The phase plate allows imaging
to occur closer to focus and improves the SNR to introduce contrast to the specimen
by applying a phase shift to the scattered electrons (Danev and Baumeister, 2017;
Thompson et al., 2016).
5.1.2 Structural Understanding of the Arenavirus
Glycoproteins
In 1968, thin-section negative-stain EM was successfully used to observe the
morphology of LCMV (Dalton et al., 1968). This study, and subsequent research,
found that the viruses were spherical or pleomorphic, with diameters ranging
between 60 nm and 260 nm, and a well-defined membrane with surface projections.
The surface projections, which correspond to the arenavirus glycoprotein complexes,
were described as randomly distributed and approximately 5-10 nm long (Murphy
et al., 1970; Howard and Young, 1984; Murphy and Whitfield, 1975).
The subsequent advances in cryo-EM have allowed for further investigation into the
structure of the trimeric arenavirus glycoprotein complexes at higher resolutions.
In 2005, (Neuman et al., 2005) performed cryo-EM on PICV, TCRV and LCMV.
They confirmed the viruses were pleomorphic, enveloped and ranged in diameter
from 40 nm to 200 nm. They identified the spike projections as distinct stalk and
head domains and found them to be spaced approximately 10 nm apart and were
about 9 nm long (stalk; 3 nm and head; 6 nm).
Then, in 2013, the causative agent of Boid inclusion body disease (BIBD), a fatal
disease of snakes, was identified as a novel arenavirus; University of Helsinki virus
(UHV) (Hetzel et al., 2013). This study also performed cryo-ET on UHV and STA
on the UHV glycoproteins. They identified spikes, which were randomly distributed
across the entire virion surface, spaced 11-15 nm apart. The spikes had distinctive
stalk and head domains, which were approximately 10 nm long (stalk; 1 nm and
head; 9 nm), with the three head domains forming a cup-like structure (Hetzel
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et al., 2013). They also identified two groups of virus particles; virions (type 1),
which had surface projections, granular density and an additional secondary density
approximately 5 nm beneath the viral membrane and virus-like particles (type 2),
which were similarly sized and had granular density, but had reduced or no surface
projections and no secondary layer beneath the membrane (Neuman et al., 2005).
In 2016, the structure of the LASV GPC spike was solved through cryo-ET and STA
(Li et al., 2016) (figure 1.15A). The 3D tomographic reconstruction of fixed LASV
agreed with previous observations, whereby the virions were roughly spherical and
ranged in diameter from 110 nm to 150 nm (Li et al., 2016). These researchers
performed subtomogram averaging on the trimeric GPC spikes and they identified
the distinct head, stalk and tail domains (Li et al., 2016) (figure 1.15A). The
head/stalk was found to be 9 nm long and 10 nm wide and the three stalk domains,
which they assigned to the GP2 domain, were spaced 4 nm apart (Li et al., 2016).
They further identified densities attributed to the membrane bilayer, in addition
to two layers on the inner side of the membrane, one attributed to the GPC tails
and the other to the ZP matrix layer (Li et al., 2016) (figure 1.15A). Li et al. also
performed analysis on the structure of the LASV GPC in comparison to the structure
of the UHV GPC, which was actually found to have higher structural homology with
EBOV GPs than the LASV GPC (Li et al., 2016). Furthermore, the tomographic
structure of the LASV GPC was solved at pH 5 and in complex with its secondary
receptor, lysosomal-associated membrane protein 1 (LAMP1) (figure 1.15B). This
showed that the reduction in pH induced structural changes in the LASV GPC,
which allowed the GPC to interact with LAMP1 (Li et al., 2016).
The crystal structures of the prefusion GPCs of LCMV (Hastie et al., 2016a)
and LASV (Hastie et al., 2017) have been solved (figure 1.16), although the
transmembrane domain was omitted and mutations were introduced in order to
stabilise the proteins for x-ray crystallography. These structures added to the
numerous crystal structures available for independent GP1 and GP2 domains from a
range of arenaviruses (Bowden et al., 2009; Cohen-Dvashi et al., 2015, 2018; Israeli
et al., 2017; Shimon et al., 2017; Pryce et al., 2018; Hastie et al., 2017). High
structural homology is shared between the arenavirus GP1 domains and the crystal
structure of the LASV GPC aligned well with the tomographic reconstruction of the
LASV GPC (Li et al., 2016; Hastie et al., 2017; Hastie and Saphire, 2018) (figure
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1.15C). This provided information for the positioning of the histidine triad in the
crystallographic reconstruction of LASV GPC for its interaction with LAMP1 (figure
1.15D). The histidine triad is also conserved in the LCMV GPC, but LAMP1 has not
been shown to be required for LCMV infection (Jae et al., 2014). However, mutations
of the histidine triad residues are lethal, suggesting it performs a critical function,
perhaps for stability or for interaction with an additional, as of yet unidentified,
receptor for LCMV (Hastie et al., 2016a).
Old World mammarenaviruses such as LCMV and LASV require α-dystroglycan as
an entry receptor, and enter cells in a macropinocytosis-like manner (figure 1.20).
Alternatively, New World mammarenaviruses, classified within clade B, require
transferrin receptor 1 and enter cells through clathrin-mediated endocytosis (figure
1.20). PICV is a New World mammarenavirus classified within clade A, and the
cellular entry receptor and pathway have not yet been identified. The requirement
of a different entry receptor by PICV indicates that the GPC of the New World
clade A mammarenaviruses could be structurally different to the structures of the
GPC and GP1 from mammarenaviruses classified within the Old World group and
the New World group, clades B and D.
5.1.3 Chapter Aims
In this chapter, the first aim was to successfully optimise the propagation and
purification of two mammarenaviruses, PICV and LCMV, resulting in viral titres
reaching 107 plaque forming units per mL (pfu/mL) or ffu/mL. Once this was
achieved, the following aims were to investigate the ultra-structure of the viruses
using cryo-ET and to resolve the structure of the GPCs using STA. This would
allow for a structural comparison of the GPCs from Old World and New World
mammarenaviruses.
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5.2 Results
5.2.1 Optimisation of PICV Propagation
In order to generate a highly concentrated sample of PICV virions, it was first
necessary to determine the optimal protocol for the production of high titre stocks.
Initially, to determine the optimal initial MOI that resulted in the highest titre of
released virus, BHK-21 cells were infected with PICV at MOIs that ranged from 0.1
to 0.0001. Every 24 hours, until 72 hpi, a sample of the supernatant was collected.
The supernatants were then diluted ten-fold and used to infect vero cells, which
were overlaid with 1.6 % methylcellulose and incubated for six days, prior to crystal
violet staining to identify formation of plaques. This revealed that infection with
PICV at an MOI of 0.1 resulted in a higher titre (0.1; 4x105 pfu/mL) at 24 hours,
when compared to the titres after infection with PICV MOIs of 0.01, 0.001 or 0.0001
(respectively, 9x104 pfu/mL, 2x104 pfu/mL and 0.0001; 1x103 pfu/mL) (figure 5.2A).
However, the later timepoints after infection with PICV at MOIs of 0.1 or 0.01
showed little increase in the viral titre; in fact, there was a decrease at 72 hpi (0.1;
2x105 pfu/mL or 0.01; 3.5x105 pfu/mL) (figure 5.2A). This was in contrast to the
later timepoints after infection with PICV at an MOI of 0.001 or 0.0001, the titres
of which continued increasing and reached the highest titre at 72 hpi (0.001; 1.5x107
pfu/mL or 0.0001; 1.5x106 pfu/mL) (figure 5.2A). This showed that titres reaching
107 pfu/mL were achievable by infecting BHK-21 cells with PICV at an MOI of
0.001 and incubating for 72 hpi.
As the aim was to purify PICV for EM, it was reasoned that it would be beneficial
to remove any contaminants that could affect imaging prior to propagation, such
as foetal bovine serum (FBS). Therefore, BHK-21 cells were infected with PICV at
an MOI of 0.001 in either DMEM containing 2 % FBS (+FBS), DMEM containing
2 % FBS for the first 24 hours and then replaced with DMEM only (+FBS (24h))
or DMEM only (-FBS). The infected cells were incubated for a total of 96 hours,
with a sample of the supernatant harvested every 24 hours and titred by crystal
violet plaque assay as described above. This revealed that the presence of FBS was
required throughout the entire infection in order to reach a titre of 1.65x107 pfu/mL
(figure 5.2B; +FBS). When FBS was not present throughout the entire infection, the
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titre was consistently lower, resulting in a 2-log reduction in titre at 72 and 96 hpi
(figure 5.2B; -FBS). Including FBS for the first 24 hours of infection showed similar
titres to +FBS, at 24 and 48 hpi, as infections where FBS was present throughout
(figure 5.2B; +FBS(24h)), but the titres at 72 and 96 hpi showed approximately a
0.8-log reduction from those achieved by infections with FBS present throughout.
Additionally, this experiment showed that incubating the infection for 96 hours
instead of 72 hours offered no further increase in titre (figure 5.2B). Therefore, FBS
could not be removed from the infection media without significantly reducing the
titre of PICV.
Based on these results, propagation of PICV was subsequently performed by
infecting BHK-21 cells at an MOI of 0.001 in presence of FBS throughout, and
incubating for 72 hpi before the supernatant was harvested. Representative plaques
for the 10-4 and 10-5 dilutions, and the mock-infected control, have been shown in
figure 5.2C.
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Figure 5.2: Optimisation of PICV Propagation BHK-21 cells were infected with
PICV at multiplicity of infections (MOIs) ranging from 0.1 to 0.0001 and incubated at 37
℃ for a total of 72 hours. The supernatants were sampled every 24 hours and titred in
duplicate by crystal violet plaque assay. The titres were then plotted on a graph (A) to
determine the optimal MOI for infection. BHK-21 cells were then infected with PICV at
an MOI of 0.001 and incubated at 37 ℃ for 96 hours. Simultaneous infections were set
up whereby the infection was performed in either DMEM containing 2 % FBS (+FBS),
DMEM containing 2 % FBS for the first 24 hours and then replaced with DMEM only
(+FBS (24h)) or DMEM only (-FBS). Samples of the supernatant were collected every 24
hours and titred in duplicate by crystal violet plaque assay. The titres were then plotted
on a graph (B) to determine the optimal harvest time. BHK-21 cells were infected with
PICV at an MOI of 0.001 and incubated at 37 ℃ for 72 hours. The supernatants were
collected for further purification and a sample was serially diluted (10-fold) to determine
the titre by crystal violet plaque assay. Representative wells showing countable plaques
from the mock-infected control and the 10-4 and 10-5 dilutions have been shown (C).
5.2.2 Purification of PICV for Cryo-Electron Microscopy
For examination by EM, the virus sample must be highly concentrated and relatively
free of cellular contaminants. To achieve this, PICV was propagated as described in
section 5.2.1. The harvested supernatant was then clarified by centrifugation, before
being passed through a 0.45 µm filter and then a second round of centrifugation
(figure 5.3A). The clarified supernatant was then purified through a 30 % sucrose
cushion by ultracentrifugation at 150,000 x g in order to pellet PICV. The virus
pellet was then briefly dried and resuspended overnight at 4℃ in 0.1X PBS, which
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was supplemented with 0.1 mM CaCl2 and 0.1 mM MgCl2.
Samples were collected throughout the purification process to monitor concentration
and removal of contaminants (figure 5.3A). These samples were analysed by
SDS-PAGE through western blotting (using the LCMV NP antibody that was
previously shown to be cross-reactive with PICV NP; chapter 3, figure 3.11). The
western blot analysis revealed the NP band was only visible in the resuspended
pellet (purified PICV), showing successful concentration of PICV (figure 5.3B).
The samples were also examined using SDS-PAGE and silver staining to show
the total protein present in each sample. The silver stain showed a large band at
approximately 65 kDa that was present in the harvested supernatant and throughout
the purification. Due to the presence of FBS in the infection media, it was
thought that this band could represent bovine serum albumin (BSA), which is
the major constituent of FBS and is approximately 66.4 kDa. The majority of
the BSA was successfully removed by the sucrose cushion, because the band was
drastically smaller in the sucrose and purified PICV samples. The silver stain
revealed additional bands, which first become visible in the purified PICV sample,
that were a similar molecular weight to the predicted molecular weights of the other
structural viral proteins, including the LP (~252 kDa), the NP (~62 kDa), the
constituents of the GPC (GP1; ~44 kDa and GP2; ~35 kDa) and the ZP (~11 kDa)
(as indicated in figure 5.3C). Additional bands can also be seen, which may be the
result of cellular proteins that could be associated with the virus or contaminating
proteins that have not been successfully removed by the sucrose cushion.
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Figure 5.3: Purification of PICV (A) shows the process of PICV purification. BHK-21
cells were seeded one day before infection, to reach a confluency of 60-70 %. The BHK-21
cells were infected with PICV at an MOI of 0.001 and incubated at 37 ℃ for 72 hours. The
supernatant was harvested, centrifuged at 4000 x g for 30 minutes at 4 ℃, filtered through
a 0.45 µm filter and finally centrifuged again at 4000 x g for 30 minutes at 4 ℃. The
supernatant was underlayed with an 8 mL 30 % sucrose cushion, which was centrifuged
at 150,000 x g for 3 hours at 4 ℃. The PICV pellet was briefly air-dried and resuspended
overnight in 0.1 X PBS buffer supplemented with 0.1 mM CaCl2 and 0.1 mM MgCl2. The
resuspended pellet was then examined by negative-stain EM, cryo-EM and tomography.
Samples were taken throughout the process, as indicated, for western blotting analysis
with the LCMV NP antibody (B) and silver stain analysis (C). Potential bands in the
silver stain that could correspond to viral proteins have been indicated.
5.2.3 Examination of PICV using Negative-Stain Electron
Microscopy
In order to further assess the purity, concentration and morphology of purified PICV,
the sample was diluted 1:10 and loaded onto glow-discharged carbon-coated grids,
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where it was stained with 2 % heavy metal uranyl acetate solution and examined by
electron microscopy. Images were taken at 5000 x magnification, to gain an overview
of the amount of virus present (figure 5.4A). These images showed there was virus
present, which appeared to be undisrupted after the ultracentrifugation process.
There was some background that could have been the result of contaminating
proteins or erupted viruses, but overall it was easy to identify the virions of interest,
which had a predominantly spherical morphology. Images were also collected
at 30,000 x magnification to further investigate the size and morphology of the
individual virions, which have been indicated by white arrowheads (figure 5.4B). The
higher magnification showed a mixture of larger viruses (average diameter 104.6 nm
± 16.9 nm) and smaller viruses (average diameter 59.7 nm ± 8.2 nm). The viruses
did not appear to be perfectly spherical, with some viruses presenting as oval-shaped
or dented. The viruses showed a speckled appearance, attributed to the GPC spike
projections, which suggests that the purification of PICV was successful and the
sample could be taken forward to cryo-EM.
Figure 5.4: Examination of PICV by Negative-Stain Electron Microscopy
Purified PICV was diluted 1:10 and examined by negative-stain EM to assess sample
concentration and purity. The sample was stained with 2 % uranyl acetate and imaged
at 5000 x magnification (A) and 30,000 x magnification (B) at 120 kV on a JEOL 1400
transmission electron microscope. Scale bars represent 500 nm (A) and 100 nm (B).
Individual virions have been indicated with white arrowheads.
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5.2.4 Examination of PICV using Cryo-Electron
Microscopy
Cryo-EM was then performed to assess the suitability of the purified PICV sample
for cryo-ET and to confirm that the background contamination was sufficiently low.
The purified PICV sample was mixed 1:1 with Protein A conjugated with 10 nm
colloidal gold (Aurion), which would act as fiducial markers for subsequent tilt series
alignment. This was then immediately added to glow-discharged Quantifoil R 2/2
grids and incubated for 1 minute. The grid was then blotted to leave a very thin
film of liquid. The grid was subsequently vitrified by immediate submersion into
liquid ethane and transferred to liquid nitrogen for all further handling, storage and
imaging steps. This method results in virions suspended within the carbon holes in
a thin layer of vitreous ice.
QUANTIFOIL R 2/2 (2 µm holes spaced 2 µm apart) 400-mesh (number of squares
per inch) grids, which have regularly spaced, circular holes, were chosen for cryo-EM
and cryo-ET investigation. Images were taken at 9,000 x magnification, which
revealed a lack of ice crystal formation and the majority of viruses in the sample were
distributed evenly across the hole in the carbon, although there were some viruses
present on the carbon itself too (figure 5.5A). Images taken at higher magnifications
(29,000 x and 59,000 x) showed the presence of roughly spherical viruses, which had
dense interiors and a membrane bilayer. The viruses also possessed an irregular
spiky exterior, which was likely to be the result of projections from the membrane
that correspond to the GPC spikes (figure 5.5B, C and D). The cryo-EM images
also showed the presence of a low level of background contamination but this was
not significant enough to affect cryo-ET. The structure of the GPC could not be
resolved at this stage. Overall, cryo-EM confirmed that the sample of purified PICV
was suitable for cryo-ET.
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Figure 5.5: Examination of PICV by Cryo-Electron Microscopy The purified
PICV sample was mixed 1:1 with Protein A conjugated with 10 nm colloidal gold, added
to glow-discharged Quantifoil R 2/2 grids and vitrified. The grid was transferred to liquid
nitrogen and imaged using the Titan Krios 2 transmission electron microscope. Images
were taken at 9000 x magnification (A), 29,000 x magnification (B and C) 59,000 x
magnification (D). Scale bars represent 500 nm (A) and 200 nm (B, C and D). Individual
virions have been indicated with white arrowheads.
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5.2.5 Examination of PICV using Cryo-Electron
Tomography
To understand the structure of the native GPC spikes on the PICV surface, it
was necessary to create 3D reconstructions of the viruses, and then apply STA
to average the spikes. Arenaviruses are pleomorphic, enveloped viruses, as seen in
the negative-stain EM and cryo-EM examination (figures 5.4 and 5.5). Furthermore,
the arenavirus glycoprotein spikes were also not regularly arranged across the virion.
This meant that cryo-EM and single-particle analysis could not be used to generate
3D reconstructions of the pleomorphic arenaviruses or the irregularly arranged GPC
spikes (Cope et al., 2011).
Cryo-ET allows to generate the 3D reconstructions of pleomorphic, irregular
particles, through collecting multiple micrographs of the same feature of interest at
different projection angles, forming what is called a tilt-series. Typically in cryo-ET,
the holder is physically tilted from -60° to +60° and images are collected at every 1°
or 2° increments. For the cryo-ET of PICV, the mesh size of the chosen grid was too
small and the grid bars obstructed the electron beam at higher tilts. To account for
this, the PICV tilt series were acquired from -50° to +50° with 2° increments (figure
5.1). Due to 51 images being collected from the same region, a low electron dose
was used to limit radiation damage of the sample. In order to improve the SNR, a
Volta phase plate was used, which introduced contrast to the specimen by applying
phase shift to the scattered electrons (Danev and Baumeister, 2017; Thompson et al.,
2016). The 2D tilt-series are then computationally combined to form a 3D volume
(tomogram) (figure 5.1). STA can then be performed on repeated structures within
a tomogram; particles (such as the GPC spikes) are selected and aligned to one
another to generate an average, which improves the SNR and resolution.
A total of 24 single-axis tilt-series were collected on PICV, using a Titan Krios
transmission electron microscope and Tomography 4 software for an automated data
collection. Using the Etomo program from the IMOD package, 3D tomograms were
reconstructed from all the tilt-series collected (Kremer et al., 1996). The tilt-series
were initially aligned using the gold particles as fiducial markers, which acted as
constant reference points in all the images of the tilt-series. Two of the tilt-series
were unable to be reconstructed due to either poor contrast or a low number of gold
178
CHAPTER 5. STRUCTURE OF THE ARENAVIRUS GPC
particles present, affecting the alignment, resulting in 22 reconstructed tomograms.
These tomograms were binned by 2, to speed up image processing, giving a final
pixel size of 5.44 Å.
Figure 5.6: Examination of PICV by Cryo-Electron Tomography Cryo-ET was
performed following the process depicted in figure 5.1. A series of images were collected at
every 2° increment between -50° to +50°. This tilt-series was then used to reconstruct a 3D
tomogram (A). Virions displaying glycoprotein spikes can be clearly seen in (A). Enlarged
images of individual virions have been shown in (B), with white arrowheads indicating the
positions of the glycoprotein spikes. Scale bars have been included, representing 100 nm
(A) and 50 nm (B). All the images were filtered in ImageJ using Gaussian Blur 3D.
The 3D tomographic reconstruction of PICV allowed visualisation of the lipid bilayer
and the GPC spikes present on the virion surface, which have been indicated with
white arrowheads (figure 5.6B). The electron density within the virions was too
disordered to determine the structural organisation and packing of the viral genomic
RNPs (figure 5.6). It was also too disordered to determine whether ribosomes were
present in the virions, but there was no clear indication of their presence (figure
5.6).
Figure 5.7A shows multiple sections taken throughout the Z-plane of a PICV virion.
The top (1) and bottom (6) slices show the GPC spikes on the exterior of the virion
surface. This revealed that the GPC spikes appeared to be randomly distributed.
The slices 2, 3, 4 and 5 show the cross-section of the GPC spikes present with the
membrane bilayer (figure 5.7A). The GPC spikes were on average approximately 8.7
nm (±1.4 nm) long (measured from the membrane) and 6.6 nm (±0.9 nm) wide
(measured at from the top and bottom views). A triangle shape, indicating trimeric
organisation, was apparent, with a few GPC spikes in the top and bottom views,
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Figure 5.7: Visualisation of PICV in Slices Through the Virus Sections (1-6)
throughout the Z-plane of a single virus have been shown, which were taken approximately
every 30 slices working from the top of the virus (1) to the bottom of the virus (6) (A).
There is an additional layer that can be seen in image (4), which could potentially represent
the ZP matrix layer. The arrangement of these slices for the reconstruction of a 3D volume
is shown schematically in (B). Scale bars represent 50 nm. All the images were filtered in
ImageJ using Gaussian Blur 3D.
as indicated by red circles (figure 5.7A). Furthermore, slice 4 showed an additional
electron density that was running parallel to the membrane bilayer, which may
represent the ZP matrix layer, as can be seen in the zoomed-in image (figure 5.7C).
To further resolve the structure of the GPC spikes, STA was performed to generate
an average of the structure.
5.2.6 Sub-Tomogram Averaging of the PICV Glycoprotein
Complex
The STA of the PICV GPC spikes, which involves several iterations of alignment,
averaging and refinement, was performed using the PEET (Particle Estimation for
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Electron Tomography) software from the IMOD package (Nicastro, 2006; Heumann
et al., 2011; Li et al., 2016; Cope et al., 2011; Punch et al., 2018). Approximately
2,800 spikes were selected manually and an initial orientation perpendicular to the
viral membrane was provided. The spikes were then subject to alignment and
averaging, which involved iterative refinements whereby PEET searched for the
position (the position of the spike on the membrane) and orientation (the rotation
of the spike) of the particles in order to include them in the final average.
The spikes were initially averaged without any alignment to generate an initial
reference (figure 5.8A). The average generated from this first stage, had C120
symmetry applied (using the Bsoft programme; bsym) to remove any features that
the reference could have. This C120-symmetrised average was used as the initial
reference in the next stage of refinement.
The first stage of refinement (figure 5.8B) allowed for a wide search around the
particle position and orientation in order to allow the program to correct the
position of particles that were not properly centred during manual picking, and
the orientation of particles that was not correctly estimated (e.g. because they
were not perpendicular to the membrane). Spherical masking, which was centred
on the spike, was applied to focus the programme on aligning the electron densities
that correspond to the spike. The reference spike was allowed to improve with
the iterations to drive improvement of subsequent averages. PEET was also set to
remove particles that were identified as duplicates, which were any particles that
were within 5.44 nm of another particle.
In the second stage of refinement (figure 5.8C), there were several iterative steps
where the angular searches to improve the spike positioning were increasingly
restricted. The final average of this run was band pass filtered (to remove high
and/or low spatial frequencies) and used for the reference in the next stage.
In the third stage of refinement (figure 5.8D), the GPC spikes displayed C3
symmetry. The C3 symmetry was further confirmed by masking only glycoprotein
base, where C3 symmetry would be most evident, and searches were limited to the
twist orientation of the particles around the Y-axis. The averages from this run
confirmed C3 symmetry and therefore C3 symmetry was applied to the average to
form the reference for the next stage of refinement.
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In the final stage of refinement (figure 5.8E), the C3 symmetrised average from the
previous run was used as the reference and the mask, which was still centred on the
GPC spike, was increased to 20 pixels to focus on gaining high resolution information
from the spike only. The initial iterations only refined the angle around the Y-axis,
but the final iterations refined all the angles to very small searches.
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Figure 5.8: Stages of Sub-Tomogram Averaging of PICV GPC In each stage, the
following has been shown; the reference particle used as the template particle for that stage
(reference), the isosurface rendering of the average generated in that stage (model) and
sagittal and transverse sections of the average generated in that stage (sagittal section and
transverse section). The STA performed with the PICV GPC began with the averaging of
all the manually selected particles (A), followed by averaging using a C120 symmetrised
reference (B). The particles were then initially aligned (C), where C3 symmetry was
identified. C3 symmetrisation of the average provided the reference for the next stage of
refinement (D) before minute adjustments in the final stage of refinement (E).
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The final average shows the trimeric organisation of the PICV GPC spike (figure
5.9). Figure 5.9A shows the electron densities of the average derived from the
final round of refinement, whereby the black indicates the regions of high electron
density. Image 1 shows a sagittal sections of the GPC spike, image 2 shows another
sagittal section of the GPC spike (from the position indicated by "2" in image 1) and
image 3 shows a transverse section of the GPC spike (from the position indicated
by "3" in image 1). The membrane bilayer can be clearly defined and the GPC
spike on one side of the bilayer and the GPC cytoplasmic tails can also be seen
(figure 5.9A). The GPC spike measures approximately 9.6 nm across and 9 nm long
(from the membrane) whereas the GPC tail measures approximately 4 nm long
(figure 5.9A). Image 3 shows the trimeric organisation of the GPC spike, where
the three stalks of each monomer were clearly visible. The isosurface rendering of
the spike (figure 5.9B) shows the GPC head, stalk and tail from each monomer, in
addition to the membrane bilayer. The trimeric organisation was easily identified
throughout the model, but becomes more evident in the head region when the model
has been tilted 45° toward the viewer and then again when the transverse plane has
been shown at 90°, which was sectioned at the stalk region. The resolution of our
electron density was calculated by Fourier shell correlation (FSC), using a 0.5 cut-off
(black line), and was estimated to be ~22.7 Å (figure 5.9C). The other lines (blue,
orange, yellow, purple) were the FSC plots calculated for averages generated from
fewer sub-tomograms, which show that the resolution was not significantly improved
through addition of more particles, suggesting the resolution was not limited by the
number of particles. This may be due to an error during the data collection, where
only one frame for each angle projection was collected, in contrast to the usual four,
which are then averaged together. To improve the resolution therefore, this work
has been repeated and is ongoing.
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Figure 5.9: Sub-Tomogram Averaging of the PICV Glycoprotein Complex STA
on the reconstructed PICV tomograms was performed on 2,754 manually-picked PICV
GPC spikes, which were averaged and subject to refinement through several iterations
using the IMOD PEET software. The sagittal planes (1 and 2) and the transverse plane
(3) of the electron density averages of the GPC spikes have been shown (A). The crossed
lines on image 1 correspond to the sections used for images 2 and 3. Scale bars depict
10 nm. The isosurface rendered model of the GPC spike reveals three regions; head,
stalk and tail and a trimeric organisation (B). The GPC spike model has also been tilted
forward in the X-plane by 45° to show the top of the head domain (central panel). The
GPC spike model has been further tilted forward in the X-plane by a total of 90° to show
the transverse section of the GPC spike and the trimeric organisation (right panel). This
model was visualised using UCSF Chimera X. To determine the resolution, an FSC plot
was used and the resolution was found to be ~22.8 Å at the 0.5 cut-off (black line) (C). "n"
represents the number of particles included in the averaging and the green line represents
the maximum number of particles included (1,377).
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5.2.7 Optimisation of LCMV Propagation
At this point, it had been determined that a titre of 107 pfu/mL was achievable
for PICV after infection of BHK-21 cells with an MOI of 0.001 (figure 5.2). It
had also been determined that a titre of 107 ffu/mL was achievable for rLCMV after
infection of BHK-21 cells with an MOI of 0.001 (figure 4.13). To see whether the titre
could be increased further, and to limit the introduction of mutations into the viral
genome through repeated passaging, BHK-21 cells were infected, at an MOI of 0.001,
with rLCMV-WT harvested directly from the transfection of BSR-T7 cells with the
reverse genetics plasmids (at 120 hpt). The infected cells were incubated for a total
of 96 hours, with samples of the supernatant taken every 24 hours and titred by focus
forming assay. There was a steep 3-log-fold increase in titre between 24 (1.6x103
ffu/mL) and 48 hours (5x106 ffu/mL) (figure 5.10A). The titre then increased further
at 72 hours, reaching 1.6x107 ffu/mL, before decreasing again at 96 hours (6x106
ffu/mL; figure 5.10A). The titre harvested here was not significantly different to
the titre collected in figure 4.13. However, it was thought that viruses harvested
from an earlier passage would have fewer mutations and fewer defective interfering
particles. Therefore, in order to generate the stock of rLCMV-WT (hereby referred
to as LCMV) for further purification and cryo-ET, BHK-21 cells were infected with
LCMV (which had been generated from the transfected BSR-T7 cells) at an MOI of
0.001 and incubated for 72 hours. The supernatant was collected and a sample was
taken for the titre to be determined by focus forming assay (figure 5.11B; Harvest).
Unfortunately, on this occasion, the titre was one-log lower than was previously
achieved (1.5x106 ffu/mL), but purification was continued anyway.
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Figure 5.10: Optimisation of LCMV Propagation BHK-21 cells were infected with
LCMV at MOI of 0.001 and incubated at 37 ℃ for 96 hours. Samples of the supernatant
were collected every 24 hours and titred in triplicate by focus forming assay. The titres
were then plotted on a graph (A) to determine the optimal harvest time. BHK-21 cells
were then infected with LCMV at an MOI of 0.001 and incubated at 37 ℃ for 72 hours.
The supernatants were collected for further purification as detailed in figure 5.11. Samples
were collected throughout the purification process; the supernatant prior to purification
(harvest), the supernatant after centrifugation at 90,000 x g for 3 hours (90,000 x g), the
sucrose cushion used for purification (sucrose) and the resuspended LCMV pellet (purified
LCMV) (B). The titres of these samples were determined by focus forming assay and were
plotted on a graph (B). Representative wells of each of the purification samples showing
countable plaques have been shown, and the dilution specified in brackets (C).
5.2.8 Purification of LCMV for Cryo-Electron Microscopy
In order to purify LCMV for electron microscopy, a similar propagation and
purification protocol as was performed for PICV was carried out, although with a
reduced sucrose concentration (20 % instead of 30 %) and with ultracentrifugation
performed at 90,000 x g (instead of 150,000 x g) (figure 5.11A). Following
resuspension, the resuspended LCMV pellet was flash frozen in liquid nitrogen and
stored at -80 ℃.
Samples were collected throughout the purification process to monitor the titre
of infectious LCMV. The harvested supernatant (180 mL) had a titre of 1.5x106
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ffu/mL and the purified LCMV pellet was resuspended in 90 µL, suggesting a
2000-fold concentration of the harvested supernatant, which would result in a titre
of 3x109 ffu/mL. However, the titre of the purified LCMV pellet was calculated to
be 2.2x107 ffu/mL (figure 5.10B). The titre of the remaining supernatant after the
ultra-centrifuge spin (90,000 x g; 180 mL) was 5x103 ffu/mL whilst the titre of the
sucrose cushion (sucrose; 48 mL) was 1.7x105 ffu/mL (figure 5.10B). It was evident
that a proportion of infectious LCMV does not pellet through the supernatant and
the sucrose, suggesting that the samples may need to be centrifuged at a higher
speed or for longer. However, the loss of infectious virus in the supernatant and
sucrose does not account for the lack of appropriate increase in the titre of the
purified LCMV pellet. This may be due to inactivation of the virions occuring at any
number of stages, including the 90,000 x g centrifuge, the pellet drying out process,
the overnight resuspension, the liquid nitrogen flash freeze of the resuspended
pellet or the subsequent defrost. Further optimisation of the purification protocol
of LCMV may be required, in order to understand where this loss of infectious
LCMV happened and to recover the highest possible amount of infectious LCMV
for subsequent examination.
Samples were also collected throughout the purification process to monitor the
concentration of LCMV and the successful removal of contaminants. These samples
were analysed by western blotting (stained with the LCMV NP antibody), which
revealed the NP band was visible in the samples prior to ultracentrifugation, but
the band was more abundant in the purified LCMV sample, confirming LCMV
had been successfully concentrated (figure 5.11B). The samples were also examined
using SDS-PAGE and silver staining. The silver stain showed that the large band
at approximately 65 kDa, which was thought to represent BSA from the FBS in
the PICV purification, was similarly removed by the 20 % sucrose barrier as the
band was less abundant in the sucrose and purified LCMV samples. The silver
stain revealed additional bands in the purified LCMV sample that had comparable
molecular weights to those seen in the PICV purification (figure 5.3) and could
represent the other viral proteins (figure 5.11C). Additional bands could also be seen
but may have resulted from associated cellular proteins or contaminating proteins
that purified through the sucrose cushion.
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Figure 5.11: Purification of LCMV LCMV was purified following the process depicted
in (A). BHK-21 cells were seeded one day before infection, to reach a confluency of 60-70
%. The BHK-21 cells were then infected with LCMV at an MOI of 0.001 and incubated
at 37 ℃ for 72 hours, at which point the supernatant was harvested and centrifuged at
4000 x g for 30 minutes at 4 ℃. The supernatant was filtered through a 0.45 µm filter
before it was centrifuged again at 4000 x g for 30 minutes at 4 ℃. The supernatant was
then underlayed with an 8 mL 20 % sucrose cushion and centrifuged at 90,000 x g for 3
hours at 4 ℃. The supernatant and sucrose cushion were removed and the LCMV pellet
was briefly air-dried and resuspended overnight in 0.1 X PBS buffer supplemented with
0.1 mM CaCl2 and 0.1 mM MgCl2. The resuspended pellet was flash frozen in liquid
nitrogen and stored at -80 ℃. Purified LCMV was then defrosted once for examination by
negative-stain EM, cryo-EM and cryo-ET. Samples were taken throughout the process, as
indicated, for SDS-PAGE analysis through western blotting with the LCMV NP antibody
(B) and silver stain (C). Bands in the silver stain that could correspond to viral proteins
have been indicated.
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5.2.9 Examination of LCMV using Negative-Stain
Electron Microscopy
To characterise the purity, concentration and morphology of purified LCMV,
the sample was diluted 1:10, loaded onto glow-discharged carbon-coated grids,
and stained with 2 % uranyl acetate solution. Images were taken at 10,000 x
magnification (figure 5.12A) and 20,000 x magnification (figure 5.12B). Individual
virions have been indicated by white arrowheads. There was very little background
and the majority of the viruses appear whole (figure 5.12A). However, there were a
few virions which had stain present on the inside of the virion, suggesting a breach
of membrane integrity. Figure 5.12B revealed a mixture of larger viruses (average
diameter 110.6 nm ± 32.4 nm) and smaller viruses (average diameter 66.9 nm ± 10.9
nm). Similarly to PICV, the viruses had a predominantly spherical morphology and
showed the speckled appearance, consistent with the presence of the GPC spikes.
The negative-stain EM confirmed that the sample was suitably concentrated and
purified for cryo-EM. The purified LCMV sample (figure 5.12) appeared to have a
lower level of background contamination and an increased concentration of virions,
when compared to the purified PICV sample (figure 5.4).
Figure 5.12: Examination of LCMV by Negative-Stain Electron Microscopy
A sample of the resuspended LCMV pellet was examined by negative-stain EM to assess
sample concentration and purity. The sample was stained with 2 % uranyl acetate and
was imaged at 10,000 x magnification (A) and 20,000 x magnification (B) on a JEOL
1400 transmission electron microscope. Scale bars represent 500 nm (A) and 100 nm (B).
Individual virions have been indicated with white arrowheads.
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5.2.10 Examination of LCMV using Cryo-Electron
Microscopy
The purified LCMV sample was screened using cryo-EM, as described for PICV,
although the mesh size of the grids was increased (to 200-mesh) to minimise the
metallic mesh obstructing the electron beam. Furthermore, the purified LCMV
sample was mixed 1:1 with a different brand of colloidal gold labelled Protein A
(Boster Bio), which had to be centrifuged (16,000 x g, 30 minutes) and resuspended
in an equal volume of 0.1X PBS to remove the buffer components. The grid was
then screened, confirming a lack of ice crystal formation and the presence of viruses
spread evenly across the hole in the carbon (figure 5.13A). Images taken at higher
magnifications (53,000 x) showed spherical viruses with dense interiors, a membrane
layer and membrane projections (figure 5.13B, C and D). The cryo-EM images
showed a low level of background contamination, which would not affect cryo-ET.
This sample of purified LCMV was suitable for continuation to cryo-ET.
191
CHAPTER 5. STRUCTURE OF THE ARENAVIRUS GPC
Figure 5.13: Examination of LCMV by Cryo-Electron Microscopy The purified
LCMV sample was added to glow-discharged Quantifoil R 2/2 grids and incubated at room
temperature for 1 minute, before the sample was blotted and the grid was immediately
frozen by submersion into liquid ethane. The grid was transferred to liquid nitrogen and
imaged using the Titan Krios 2 transmission electron microscope. Images were taken at
9000 x magnification (A) and 53,000 x magnification (B, C and D). Scale bars represent
500 nm (A) and 100 nm (B, C and D) Individual virions have been indicated with white
arrowheads.
5.2.11 Examination of LCMV using Cryo-Electron
Tomography
Cryo-ET was performed on LCMV, as described for PICV, although images were
collected from -60° to +60°, every 2° increments. 3D tomograms were reconstructed
for all the tilt-series collected using batchtomo (Etomo; IMOD). The gold particles
were not well distributed across the image, potentially due to the centrifugation step
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and poor resuspension of the gold pellet, therefore any of the tilt-series that were
unable to be reconstructed using batchtomo were manually reconstructed. After
reconstruction, the tomograms were binned by 2, resulting in a final pixel size of
5.44 Å.
The 3D tomographic reconstruction of LCMV, allowed clear visualisation of the
GPC spikes present on the virion surface, which have been indicated with white
arrowheads (figure 5.14B). However, whilst the viral membrane was visible, the
membrane bilayer was not well resolved, suggesting some issues with the image
acquisition. Again, there was no clear electron density within the virions that would
reveal the structural organisation of the viral genomic RNPs or the inclusion of
ribosomes in the virions (figure 5.14B).
Figure 5.14: Examination of LCMV by Cryo-Electron Tomography Cryo-ET of
purified LCMV (A). Virions displaying glycoprotein spikes can be clearly seen in (A) and
larger images of two individual virions, in different Z-frames, have been shown in (B and
C), with white arrowheads indicating the positions of the glycoprotein spikes. Scale bars
represent 100 nm (A) and 50 nm (B and C). All the images were filtered in ImageJ using
Gaussian Blur 3D.
Figure 5.15A shows sagittal sections that were collected throughout the Z-plane of
the LCMV virion. Top (1) and bottom (6) slices revealed the GPC spikes on the
exterior of the virion surface. Similarly to PICV, the GPC spikes seemed to be
randomly distributed. The slices 2, 3, 4 and 5 showed the cross-section of the GPC
spikes present with the membrane bilayer (figure 5.15A). In particular, slice 4 showed
an additional electron density that was running parallel to the membrane bilayer,
which may represent the ZP matrix layer, as has been indicated in the zoomed-in
image (figure 5.15C).
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Figure 5.15: Visualisation of LCMV in Slices Through the Virus Sections (1-6)
throughout the Z-plane of a single virus have been shown, which were taken approximately
every 30 slices working from the top of the virus (1) to the bottom of the virus (6) (A).
There is an additional layer that can be seen in image (4), which could potentially represent
the ZP matrix layer. The arrangement of these slices for the reconstruction of a 3D volume
is shown schematically in (B). Scale bars represent 50 nm. All the images were filtered in
ImageJ using Gaussian Blur 3D.
The 3D tomographic reconstructions also revealed the presence of two distinct
variants of LCMV GPC; GPC spikes that closely resembled what had been
seen before with PICV and LASV (Li et al., 2016) (termed "compact") (figure
5.16B; "compact" GPC spikes indicated by white arrowheads), as described above.
However, there were GPC spikes that did not show the typical morphology as the
"compact" GPC spikes (termed "extended") (figure 5.16C; "extended" GPC spikes
indicated by black arrowheads). Occasionally, virions that had predominantly
"compact" GPC spikes also displayed a few "extended" spikes, as seen in figure
5.16B ("compact" GPC spikes indicated by white arrowheads and "extended" GPC
spikes indicated by black arrowheads). A rough estimation of the virions present was
performed and approximately 60 % of virions displayed "compact" GPC spikes, 30 %
of virions displayed "extended" GPC spikes and 10 % of virions displayed a mixture
of "compact" and "extended" spikes. These "extended" spikes were on average 13.16
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nm ± 3.0 nm long (as measured from the membrane), which was almost double the
length of the "compact" spikes (7.6 nm ± 1.0 nm). Some "extended" spikes appeared
to retain the globular head, of a similar size to the "compact" spikes, whilst other
"extended" spikes appeared to just have the stalk domain. Attempts were then made
to resolve the structure of the "compact" LCMV GPC spikes using STA.
Figure 5.16: Comparison of LCMV Virions Displaying "Compact" Versus
"Extended" GPC Spikes After tomogram reconstruction, virions displaying two distinct
types of GPC spikes ("compact" or "extended") were found. In this tomogram (A), two
virions displaying "compact" spikes can be seen (white box; 1 and 2) and two virions
showing "extended" spikes can also be seen (black box; 3 and 4). These images have
been enlarged in (B) and (C), where (B) represents the two virions displaying "compact"
GPC spikes, which have been indicated using white arrowheads, and (C) represents the
two virions displaying "extended" GPC spikes, which have been indicated using black
arrowheads. A few "extended" GPC spikes (indicated by black arrowheads) were seen on
the virions predominantly displaying "compact" GPC spikes in (B). Scale bars represent
50 nm. All the images were filtered in ImageJ using Gaussian Blur 3D.
5.2.12 Sub-Tomogram Averaging of the LCMV
Glycoprotein Complex
The STA of the LCMV GPC spikes was performed as for PICV. From 15 tomograms,
1,765 spikes were manually selected and an initial orientation perpendicular to the
viral membrane was provided. The spikes were then aligned and averaged, following
the iterations used in the initial averaging and the first refinement stage of the PICV
GPC (figure 5.8A-C). At this point, it was becoming evident that the averages were
not improving and the membrane bilayer was not being resolved (figure 5.17A).
Figure 5.17B shows the isosurface rendering of the spike average from figure 5.17A,
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which had C3 symmetry applied. The resolution was calculated to be 26.3 Å using
calcFSC (figure 5.17C).
Figure 5.17: Sub-Tomogram Averaging of the LCMV Glycoprotein Complex
STA of manually picked LCMV spikes. 1,765 sub-tomograms were averaged and subject
to refinement through several iterations using the IMOD PEET software. The sagittal
planes (1 and 2) and the transverse plane (3) of the electron density averages of the
GPC spikes have been shown (A). The crossed lines on image 1 represent the view of
image 1 represented in images 2 and 3. Scale bars have been included and depict 10
nm. The isosurface rendering of the GPC spike has also been shown before and after
C3-symmetrisation (B). This model was visualised using UCSF Chimera X. To determine
the resolution, an FSC plot was used and the resolution was found to be ~26.3 Å at the 0.5
cut-off (black line) (C). "n" represents the number of particles included in the averaging
and the green line represents the maximum number of particles included (730).
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5.2.13 CTF-Corrections of the LCMV Tomograms
In an attempt to improve the resolution, the individual projections were corrected
for the contrast transfer function (CTF) of the microscope, which is typically
calculated from the defocus across a 2D plane. However, CTF-corrections prove
more challenging for tilt-series samples because of the low SNR, resulting from the
low electron dose in each image and the tilting of the sample, which makes the
sample appear thicker. Furthermore, the defocus values within a given projection
vary, due to the fact the stage is tilted during acquisition (Turoňová et al., 2017). The
reduction in the signal and the changes in defocus makes applying CTF-corrections
less reliable. Therefore, we attempted to estimate the CTF in a two stage process:
we first calculated the defocus and phase shift per projection without limiting the
phase shift; and then we performed a second CTF estimation by using a phase shift
minimum of 65 and a phase shift maximum of 115, which were±25 around the initial
phase shift average, which was 90. Using this estimates for defocus and phase shift,
the projections were CTF-corrected, and new tomograms were then calculated.
It was also thought that excluding some of the extreme tilt angles may improve the
resolution of the final tomogram by removing some of the extra noise. However,
it also increases the effect of the missing wedge. To determine which angles to
include in the reconstruction of the final tomogram, two tomograms were recreated
with views from the extreme angles excluded from the reconstruction. The same
position was then compared between the non-CTF corrected tomogram, and the
CTF-corrected tomograms which had either; included all angles (CTF, -60° to +60°),
only included angles from -60° to 0° (CTF, -60° to 0°), only included angles from -30°
to +30° (CTF, -30° to +30°), or only included angles from -46° to +46° (CTF, -46°
to +46°). The most improvement in resolution appeared to be in the CTF-corrected
version, which had only included angles from -30° to +30°, as judged by the presence
of a better defined membrane (figure 5.18; CTF, -30° to +30°). Therefore, STA was
then performed with these tomograms.
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Figure 5.18: CTF Corrections of the LCMV Tomograms CTF-corrections were
estimated and applied to the tomograms. The tomograms were then reconstructed, with
a range of angles excluded from the tomograms in an attempt to improve resolution. The
same position was then compared between the non-CTF corrected tomogram (non-CTF,
-60° to +60°) and the CTF-corrected tomograms which had either; included all angles
(CTF, -60° to +60°), only included angles from -60° to 0° (CTF, -60° to 0°), only included
angles from -30° to +30° (CTF, -30° to +30°), or only included angles from -46° to +46°
(CTF, -46° to +46°). To avoid any image distortion due to filtering, these images were
not filtered using Gaussian Blur 3D.
5.2.14 Sub-Tomogram Averaging of the CTF-Corrected
LCMV Glycoprotein Complex
Once the new CTF-corrected tomograms (CTF, -30° to +30°) were reconstructed,
a new STA was calculated. Any manually picked spikes that were on the top or
bottom of the virus were excluded, because the omission of the angles increased the
missing wedge effect, distorting the information at those positions. Again, the spikes
were initially averaged without any angular searches, and C120 symmetry applied,
to be used as a reference for the next stage. In order to identify the membrane
bilayer and show that it could be resolved, only one iteration was performed, with
a wide search in the orientation of the spike (without searching for the rotation
along the Y-axis) and a large search distance (figure 5.19). Unfortunately, this did
not improve resolution of the membrane bilayer (35.7 Å; figure 5.19C) and it was
198
CHAPTER 5. STRUCTURE OF THE ARENAVIRUS GPC
assumed that the limit of this tomographic data collection had been reached.
Figure 5.19: Sub-Tomogram Averaging of the CTF-Corrected LCMV
Glycoprotein Complex STA of the CTF-corrected reconstructed LCMV tomograms
was performed on 865 LCMV GPC spikes, which were averaged and subject to refinement
through several iterations using the IMOD PEET software. The sagittal planes (1 and
2) and the transverse plane (3) of the electron density averages of the GPC spikes have
been shown (A). The crossed lines on image 1 represent the view of image 1 represented
in images 2 and 3. Scale bars represent 10 nm. The isosurface rendering of the GPC spike
has also been shown before and after C3-symmetrisation (B). This model was visualised
using UCSF Chimera X. To determine the resolution, an FSC plot was calculated and the
resolution was found to be ~35.7 Å at the 0.5 cut-off (black line) (C). "n" represents the
number of particles included in the averaging and the green line represents the maximum
number of particles included (378).
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In an attempt to understand why the tomograms were limited at such a low
resolution, we collected cryo-EM images of the purified LCMV grid at different
defocus levels. By imaging the sample at a range of defocus levels, we aimed to find
out the conditions to resolve the lipid bilayer. The same grid used for cryo-ET was
re-imaged using a Titan Krios transmission electron microscope. Several positions
were automatically selected and imaged at different defocus levels, ranging from -1.7
µm to -4.4 µm, without a phase plate. This was in comparison to the defocus used
in the tomographic acquisition, which ranged from -0.5 µm to -1 µm due to the
phase plate allowing imaging to take place closer to focus. These images revealed
that the membrane bilayer of the virions was distinguishable at all the defocus levels
(figure 5.20). This suggests that the tomographic acquisition perhaps should have
been performed at a higher defocus to introduce sufficient contrast or that the phase
plate during the tomographic acquisition did not function correctly.
Figure 5.20: Imaging LCMV at Different Defocus Heights Purified LCMV was
re-imaged using the Titan Krios transmission electron microscope. Several positions were
automatically selected and imaged at different defocus levels, ranging from -1.7 µm to -4.4
µm. The images shown here represent defocus values of -2 µm, -2.5 µm, -3.1 µm, -3.6 µm,
-3.9 µm and -4.3 µm. The membrane bilayer is clearly distinguishable at all these defocus
levels.
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5.2.15 Comparison of Arenavirus Glycoprotein Complexes
Despite not achieving the expected level of resolution, the final PICV and LCMV
virion surface models allowed a comparative analysis of the corresponding spikes
with previously published spike structures from LASV and UHV (Li et al., 2016;
Hetzel et al., 2013).
The isosurface rendered averages of the PICV (light blue) and LCMV GPC (purple)
spikes were compared with those of LASV (EMD-3290; dark blue; Li et al., 2016) and
University of Helsinki Virus (UHV; EMD-2424; teal; Hetzel et al., 2013). Similarities
in size and trimeric organisation were seen between PICV, LCMV and LASV, which
were significantly different to the cup-like structure exhibited by the UHV GPC
spike. The LCMV GPC spike, even at the low resolution of 26.3 Å, was very similar
to the LASV GPC spike in both size and shape, but the cryo-ET data will have to be
collected again in order to improve the resolution and have a thorough comparison
of the two structures.
Figure 5.21: Comparison of Arenavirus Glycoprotein Complex Models
Isosurface rendering averages of the GPC spikes from PICV (this study; light blue),
LCMV (this study; purple), Lassa virus (LASV; EMD-3290; dark blue; Li et al., 2016) and
University of Helsinki Virus (UHV; EMD-2424; teal; Hetzel et al., 2013). The averages
are at the same scale for comparison. These model were visualised using UCSF Chimera
X.
Next, it was attempted to fit the electron density of the PICV GPC spike (light blue)
into the electron density of the LASV GPC spike (figure 5.22A; EMD-3290; dark
blue). The LASV GPC spike, which was also the result of cryo-ET and STA, reached
a resolution of 14 Å (Li et al., 2016). The PICV and LASV GPC spikes aligned
quite well (correlation value: 0.9228; membrane was included in the correlation
score), in particular the stalk domains and the head domains. However, there were
some differences at the very top of the head domain, where the tips of each PICV
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GPC monomer have twisted slightly and do not align with the tips of each LASV
GPC monomer (figure 5.22A; second row). Furthermore, each of the GPC spike
cytoplasmic tails of PICV were present in the area surrounding the LASV GPC
spike cytoplasmic tail density (figure 5.22A; third row). Whilst this could be the
result of the lower resolution that the PICV spike reached, it could also be that the
New World (clade A) mammarenaviruses adopt a slightly different GPC structure.
It was then attempted to fit the electron density of the PICV GPC spike (light blue)
into the electron density of the University of Helsinki Virus (UHV) GPC spike (figure
5.22B; EMD-2424; teal). The UHV GPC spike, which was solved by cryo-ET and
STA to a resolution of 32 Å (Hetzel et al., 2013). The PICV and UHV GPC spikes
did not align as well as the PICV and LASV GPC spikes (correlation value: 0.7219;
membrane was included in the correlation score). However, the head domains of
the PICV GPC spike, whilst not as long as those of the UHV GPC spike, had the
same positioning of each of the monomers at the tip of the head domains (figure
5.22B; second row), unlike what was seen in the comparison of the PICV and LASV
GPC spikes (figure 5.22A; second row). The electron density of the GPC tails of
PICV and UHV, despite the low resolution, also appeared to be arranged similarly
(figure 5.22B; third row), more so than that of the LASV and PICV GPC tails
(figure 5.22A; third row). The resolution of the PICV GPC spike would need to be
improved further in order to investigate these structural differences, and therefore
the cryo-ET data will have to be collected again. However, the data collected here
does suggest that there were small structural differences between the PICV (New
World) and LASV (Old World) GPCs, and large structural differences between the
PICV and UHV GPCs.
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Figure 5.22: Overlay of PICV GPC with LASV GPC and UHV GPC The
electron density of the PICV GPC spike (this study; light blue) was fitted into electron
densities of the Lassa virus GPC spike (A; EMD-3290; dark blue; Li et al., 2016) and
University of Helsinki Virus (B; EMD-2424; teal; Hetzel et al., 2013), all of which were
derived from cryo-ET and STA. The models have been tilted forward in the X-plane by
90° to show the head domains of the GPC spikes. The models have then been flipped 180°
in the X-plane to show the tail domains the GPC spikes. These model were visualised
using UCSF Chimera X.
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5.3 Chapter Summary and Discussion
This chapter has described the successful purification of highly concentrated
preparations of PICV and LCMV for their subsequent examination using cryo-ET.
Furthermore, this chapter has used STA to determine the structure of the PICV
and LCMV GPC spikes. Initially, the growth of PICV and LCMV was optimised
in order to reach titres of 107 pfu/mL (for PICV) and 107 ffu/mL (for LCMV). The
virions were then successfully concentrated and purified using ultracentrifugation
and a sucrose cushion. Negative-stain EM was used to examine the purified virus
samples, which showed the virions were generally spherical, with some that were
pleomorphic, and had diameters that ranged from 50 nm to 140 nm for PICV and
from 40 nm to 130 nm for LCMV. The purified virus samples were shown to be
suitably concentrated and pure for vitrification and cryo-EM examination. Cryo-EM
confirmed that the viruses and the fiducial markers were suitably dispersed within
vitreous ice for continuation onto cryo-ET.
The cryo-ET performed on PICV was successful and 3D tomograms showed viruses
displaying a membrane bilayer and GPC spikes that were approximately 8.7 nm
long and 6.6 nm wide. STA was performed on the GPC spikes and the PICV GPC
spike structure was successfully solved to a resolution of 22.7 Å. The resolution was
limited due to only one frame (out of four used for standard tomographic collections
at Leeds) being collected for each tilt angle of the cryo-ET session. Despite the
low resolution, the PICV GPC model generated was compared to that of the LASV
GPC, showing slight differences in the orientation of the tops of the head domains
and the GPC tails. These differences in the PICV GPC appeared to match the
protomer arrangement seen in the UHV GPC, suggesting a different arenavirus
GPC structure, which shows similarities to both the Old World mammarenaviruses
and the reptarenaviruses. Further investigation into this is required, which would be
assisted through gaining a higher resolution structure of the PICV GPC. This could
be achieved by attempting CTF corrections on the PICV dataset collected here.
However, it would be more successful to repeat the cryo-ET collection on purified
PICV. This would involve repeating the growth and purification of PICV, in the
same manner as described in this chapter, but instead purifying through a 20 %
sucrose cushion at 90,000 x g in order to limit virion damage. Following this, prior
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to vitrification, PICV would be loaded onto 200-mesh grids instead of 400-mesh,
allowing collection of the full tilt range. Finally, collection of tomographic data on
vitrified virions should also ensure all four frames are collected to attain the best
resolution possible. To our knowledge, this is the first structure of the GPC from a
New World clade A mammarenavirus.
The cryo-ET performed on LCMV was somewhat successful because the 3D
tomograms showed viruses that had GPC spikes, but the membrane bilayer was
not resolved, which may be the result of phase plate misalignment or insufficient
charging, or the session needed to be performed at a different defocus level. Despite
STA being performed on the LCMV GPC spikes, the resolution was limited at 26.3
Å and the membrane bilayer could not be resolved. CTF-corrections were applied
to the tomograms, but these did not increase the resolution. In order to improve the
dataset collected on LCMV, the cryo-ET will have to be repeated. LCMV purified
in this chapter was flash-frozen in liquid nitrogen, which means there is no need to
repeat the growth and purification of LCMV. However, new vitrified grids will have
to be made using gold fiducial markers from another manufacturer (Aurion) in order
to ensure a better fiducial marker distribution, which would improve subsequent
alignments in the tomographic reconstruction. When cryo-ET on LCMV is repeated,
several tests will have to be performed to assess the functioning of the phase plate
and determine that it is charging and functioning properly. Alternatively results
may be improved by not using the phase plate and collecting the data at a specified
defocus.
One thing that did become apparent during the tomogram reconstruction of LCMV
was the presence of two types of GPC spikes; "compact" and "extended". "Compact"
GPC spikes were similar in size to PICV GPC spikes, approximately 7.6 nm in
length. "Extended" GPC spikes however were found to be on average 13.16 nm
long, which was almost double the length of the "compact" GPC spikes. This is of
particular interest because the "extended" GPC spikes could potentially represent
a post-fusion conformation or an intermediate conformation between pre- and
post-fusion. However, the "extended" GPC spikes seen here were not similar to
the LASV spikes at pH 5 (figure 1.15B) or pH 3 (Li et al., 2016), which mimicked
conditions experienced by the viral GPC during entry through the endocytic
pathway, where it mediates viral and host membrane fusion. Therefore, these
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"extended" GPC spikes could represent a fusion intermediate conformation that
has not been previously documented for the arenaviruses. Recently, cryo-EM was
used to determine the structure of the S glycoprotein trimers from SARS-CoV-2,
and they identified two distinct conformations of S trimers on the virion surface,
which represented the pre-fusion (majority) and post-fusion (minority) forms of S
(Ke et al., 2020). This may be similar to what we have seen with the LCMV GPC
spikes here. It is not known why "compact" and "extended" GPC spikes were not
seen in the purified PICV dataset; it could suggest that the two viruses have slightly
different fusion triggers, it could be related to the changes in sucrose concentration
and centrifugation speed that were performed with the LCMV purification or it
could be an effect of the improper functioning of the phase plate. The cryo-ET of
LCMV will have to be repeated in order to gain a higher resolution of the LCMV
GPC spike and to further investigate this. A higher resolution will allow for better
comparison between the LCMV GPC, the LCMV pre-fusion GPC crystal structure
and the LASV GPC spike and identification of any structural changes, which could
be attributed to differences in LAMP1 affinities. A repeat of cryo-ET will also
allow further investigation into the nature of these "extended" GPC spikes, to
determine whether they represent a fusion intermediate structure or the post-fusion
conformation. The availability of a post-fusion crystal structure of LCMV GP2
will help reveal whether these "extended" GPC spikes represent a post-fusion GPC
structure on the virion.
Interestingly, at no point throughout this chapter did any electron microscopic
investigation reveal the suggestion of ribosomes or granules present in the arenavirus
virions. Previously, electron microscopy studies suggested that arenavirus particles
contained electron-dense granules that were sensitive to ribonuclease and measured
20 to 30 nm in diameter (Dalton et al., 1968). Ribosomal RNA had also
been isolated from purified virus samples, leading to the suggestion that the
electron dense granules in arenavirus particles were ribosomes (Murphy et al., 1970;
Pedersen and Konigshofer, 1976). However, the granules were slightly bigger and
more electron-dense than cytoplasmic ribosomes, in addition to requiring a longer
incubation in ribonuclease for their disappearance (Dalton et al., 1968; Mannweiler
and Lehmann-Grube, 1973). Therefore, it could be that these granules represented
RNP complexes instead, although the variation in number of granules between
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virions added doubt to this theory (Dalton et al., 1968). Electron-dense granules
within virion particles were not seen during this project, although the sample
preparation differs from previous investigations. Firstly, the cryo-EM performed
here does not utilise heavy metal staining, reducing the electron density of the
sample. Secondly, the negative-stain EM performed here was on whole virions, as
opposed to thin sections. The cryo-ET performed here showed that the technique
was unable to offer insight into the internal organisation of the virions. Therefore,
whilst electron-dense granules were not able to be seen, it could be because the
techniques used did not permit resolution of the internal organisation. To further
reveal whether the electron-dense granules are present, and whether they represent
host-derived ribosomes or RNP complexes, negative-stain EM, cryo-EM and cryo-ET
could be performed on thin-sections of the virion sample instead, permitting





The main goal of this project was to investigate the structural architecture of the
arenavirus GPC spikes, but in order to achieve this, several molecular tools had to
be developed. Three main objectives, which were previously described in section 1.6,
were established for the completion of this goal. These objectives were successfully
fulfilled during this project, which has been briefly discussed below.
Generation of LCMV NP antisera for its use as an arenavirus detection tool
Arenavirus NPs are an integral and essential component in the arenavirus lifecycle;
it provides the structural backbone by which the genome is supported and protected,
it assists the LP in genome replication and it counteracts multiple host defences to
ensure successful viral infection. The NP is also the most abundant viral protein
synthesised during arenavirus infection. Preparations of concentrated and highly
pure NP can be used for structural determination, functional assays or it can be
used for the generation of specific antibodies.
Using a bacterial expression system and a combination of chromatographic
techniques, LCMV NP was successfully purified and concentrated to be used as the
priming agent for the generation of a polyclonal antibody. It was then demonstrated
that the antibody was specifically reactive with the LCMVNP from infected BHK-21
and SHSY5Y cells and did not react with unpurified mock-infected cell lysates. The
LCMV NP antisera was also cross-reactive with PICV, which is classified within the
New World group of the Mammarenavirus genus, but it was not cross-reactive with
HAZV, which is classified in the Nairoviridae family of the Bunyavirales order.
The confirmation of the LCMV NP antibody specificity permitted investigation
into the intracellular localisation of NP during LCMV infection, through
immunofluorescence analysis. This study showed that both the LCMV and PICV
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NPs had a cytoplasmic localisation, which presented either as a diffuse distribution
or a puncta formation, in agreement with previous research which attributed puncta
formation to a single phosphorylated residue (T206) (Baird et al., 2013; Knopp
et al., 2015). This residue is conserved in both LCMV and PICV NPs. This
could be further investigated, using the reverse genetics system developed here,
to determine whether this residue, and the ability to switch between diffused and
puncta formation, is essential for the successful viral infection.
Certain strains of LCMV establish persistent, non-cytolytic infections in cell culture
(Abdel-Hakeem, 2019). Previous studies were able to perform crystal violet-based
plaque assays, which rely on cytolysis, for the titration of LCMV-ARM strain
(Ziegler et al., 2016). However, the experiments performed here showed that
cytolysis did not occur with the LCMV-Cl13 derivative, suggesting interesting
differences in cytopathic effect between the LCMV-Cl13 derivative and the
LCMV-ARM parent strain. Nevertheless, this necessitated the development of a
titration method for LCMV-Cl13. Using the LCMV-NP antibody, a focus-forming
assay was successfully developed, using fluorescence microscopy to detect regions of
infected cells (foci) that had originated from a single infected cell. This method was
quicker and easier because the fluorescent foci were visible at an earlier timepoint
and were imaged at a higher magnification using the microscope, making the foci
more detectable. The major benefit of this focus-forming assay was that the titre of
LCMV-Cl13 could now be determined, allowing optimisation of the reverse genetics
system and investigation into the propagation of engineered LCMV strains.
The future directions of work performed in this chapter could either focus on further
optimisation of recombinant LCMV NP expression and purification or it could
focus on development of detection assays using the antibody that was generated
here. Further optimisation of recombinant LCMV NP expression would involve
attempting LCMV NP expression in an alternative expression system, one more
suited to expression of eukaryotic proteins, utilising a different solubility tag,
expressing the LCMV NP in the periplasm of bacteria to enable disulphide bond
formation or codon optimising the LCMV NP gene to be more suited for bacterial
expression. Further work on the development of detection assays which would
utilise the antibody would involve determining the cross-reactivity of the antibody
between other members of the Arenaviridae family, as well as its reactivity with
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other bunyaviruses. Understanding the cross-reactivity of this antibody with other
viruses would reveal whether it reacted against pathogenic arenaviruses, including
LASV, JUNV, SBAV, GTOV, CHAPV and MACV. If the antibody was reactive
against these viruses, diagnostic tools, such as ELISAs and lateral flow assays, could
be created to assist in early diagnosis and therapeutic intervention of these diseases.
Development of a reverse genetics system designed to recover infectious LCMV
Reverse genetics systems are extremely versatile tools, permitting further
investigation into the viral genome and proteins in the context of the viral lifecycle
to understand cellular interactions, cellular localisation, lethality and pathogenesis.
This investigation takes place through mutational analysis of the viral genome and
proteins or the introduction of specific epitope tags or fluorescent molecules.
The design of plasmids expressing the positive-sense copies of S and L segments,
in addition to NP and LP support plasmids, were transfected into BSR-T7 cells to
successfully recover infectious recombinant LCMV. Using the focus-forming assay
developed with the LCMV NP antibody, the optimal harvest times post-transfection
and post-infection were determined, permitting the generation of a high titre stock
of rLCMV. This was extremely important for subsequent structural examination of
LCMV by cryo-ET, as discussed shortly.
This LCMV reverse genetics system was engineered to incorporate the eGFP ORF
into the S segment, which generated infectious rLCMV stably expressing eGFP
(rLCMV-eGFP). This permitted the live-cell fluorescent monitoring of successful
rLCMV-eGFP infection, which could be used to better understand the replication
kinetics of rLCMV. rLCMV-eGFP was also used to further develop and optimise
the focus-forming assay, allowing live-cell monitoring of the foci development and
confirming the foci were not the result of cross-reactivity with host cell proteins.
Future work could employ rLCMV-eGFP in the development of a quick, easy
and high-throughput screening platform for the evaluation of anti-arenaviral drugs
and siRNA targets. Through measuring the fluorescent signal, large libraries of
anti-viral inhibitors, small-molecule compounds and siRNA targets can be screened
for anti-viral activity against the arenaviruses. Development of this assay will allow
easier identification of drugs and could potentially lead to the identification of
treatment for LCMV infections. Drugs identified using this assay may also have
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anti-viral activity against other pathogenic arenaviruses. Furthermore, the ability
that this reverse genetics system offers to introduce mutations into the viral proteins
could help identify the specific viral targets of the anti-viral drugs.
This reverse genetics system was also engineered to fuse a 6xHis tag onto the
C-terminus of the NP, successfully generating infectious rLCMV that stably
expressed 6xHis-tagged NP (rLCMV-6xHis). This permitted the chromatographic
purification of RNP complexes from BHK-21 cells infected with rLCMV-6xHis.
Further optimisation is still required to increase the concentration and to reduce
potential aggregation or degradation. However, the ability to extract and purify
RNP complexes from infected cells offers huge opportunity to further resolve the
RNP structure, using cryo-electron microscopy, and add to research of arenavirus
RNPs that was last performed in the 1980s (Young and Howard, 1983). The creation
of rLCMV-6xHis offers huge advantages to the arenavirus field, through permitting
structural analysis of RNP complexes that could further the understanding of the
interactions between the NP and the RNA genome and between NP monomers.
These interactions could then be exploited for the development of small molecule
inhibitors that would target and interrupt the interactions.
In this project, it was also attempted to recover other tagged variants of
LCMV, including LCMV expressing NP that was C-terminally tagged with GFP11
(rLCMV-GFP11) and LCMV expressing GPC that was C-terminally tagged with
a FLAG tag (rLCMV-FLAG). The plasmids were successfully sub-cloned but the
recoveries of infectious virus were unsuccessful. Recovery of rLCMV-GFP11 was
attempted because it would have permitted live cell fluorescent tracking of the NP
within the cell during viral infection. This could have provided further information
on the temporal dynamics of the RTCs and structural investigation into the RTCs,
using techniques such as correlative light and electron microscopy (CLEM). The
future directions for successful recovery of the rLCMV-GFP11 variant would involve
altering the position of the GFP11 tag within the NP, potentially at the N terminus.
This tag placement could reduce interference with the NP’s functions and allow
rescue of infectious rLCMV-GFP11. Recovery of rLCMV-FLAG was also attempted
to have a manner by which to detect the cellular localisation of the GPC, through
staining with FLAG antibodies. This would allow mutational analysis of motifs in
the GPC, in order to determine which are necessary for trafficking between the ER
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and the Golgi. Through co-staining host factors and the GPC, it could also allow the
identification of potential secondary entry receptors for LCMV, which could then
be structurally investigated using cryo-ET. The future directions for this would also
be to try a different position of the tag, potentially on the GPC SSP, or to produce
highly-specific LCMV GPC antibodies.
Structural examination of the PICV and LCMV GPCs by cryo-electron tomography
Recent technological advances in EM have significantly improved the resolution
at which macromolecular structures can be solved. This has allowed the
structural determination of native GPC spikes on the virion surface, which, for
the arenaviruses, has been performed on LASV and reptarenavirus UHV.
Here, high titre preparations of PICV (as a representative of the New
World mammarenaviruses) and LCMV (as a representative of the Old World
mammarenaviruses) were successfully concentrated and purified for examination
using cryo-ET. The high titres achieved for LCMV would not have been possible, if
not for the development of the molecular tools in the first two objectives. Following
the detection of the GPC spikes on the virion surface, STA was performed to align
the spike structures to one another, forming an average with an increased resolution.
The 3D tomograms of PICV virions showed GPC spikes that were approximately
8.7 nm long and 6.6 nm wide. Through STA, the PICV GPC spike structure
was successfully solved to a resolution of 22.7 Å, providing, to our knowledge, the
first structure of the GPC from a New World clade A mammarenavirus. Despite
the low resolution, comparison of the PICV GPC model with that of the LASV
GPC showed that the tops of the heads of individual protomers appeared to
adopt a slightly different position. Furthermore, examination of the PICV GPC
cytoplasmic tails presented at a 45° angle as opposed to those of LASV, which were
central to the GPC spike. These differences in the PICV GPC appeared to match
the protomer arrangement seen in the UHV GPC, suggesting an arenavirus GPC
structure that shows similarities to both the Old World mammarenaviruses and the
reptarenaviruses.
The 3D tomograms of LCMV virions also displayed GPC spikes, but the membrane
bilayer was not resolved. Despite this, STA was performed on the LCMV GPC
spikes from the original 3D tomograms and CTF-corrected 3D tomograms, in an
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attempt to improve the resolution. However, the resolution was limited at 26.3 Å.
Nevertheless, even at this resolution, it was clear that the LCMV GPC spike was
showing a similar structure and size to the LASV GPC. The resolution was not high
enough to resolve structural differences between the LCMV GPC, the PICV GPC
and the LASV GPC.
During the reconstruction of the LCMV 3D tomograms, two types of GPC spikes
were seen, termed "compact" and "extended". "Compact" GPC spikes were similar
in size to PICV GPC spikes, approximately 7.6 nm in length, whereas "extended"
GPC spikes were approximately 13.16 nm long. It was thought that the difference
in the appearance of the "extended" GPC spikes, i.e. the increase in length and
the occasional loss of the globular head domain, could represent the significant
structural change that the GPC undergoes in order to perform fusion of the viral
and host membranes. Therefore, the "extended" GPC spikes seen in this study
could be the first documentation of post-fusion arenavirus GPC spikes that are
present on the virion surface. The significant structural differences that the LCMV
GPC encounters through the fusion process have been shown by solving the crystal
structures of pre-fusion and post-fusion LCMV GP2, and the extension of the heptad
repeats in the alpha-helix bundle of GP2 could account for the increase in length
seen in the "extended" GPC spikes here (figure 1.17) (Hastie et al., 2016a). This was
not seen in the LASV GPC spikes, which were subjected to lowering pH to induce a
post-fusion form (Li et al., 2016). This could be due to different fusion requirements
between LCMV and LASV, or because the LASV GPC spikes were present on VLPs
rather than native virions. Similarly extended forms have also been seen in cryo-ET
of SARS-CoV-2 (Ke et al., 2020). It is interesting to note that "extended" GPC
spikes were not seen in the cryo-ET of PICV, which could be related to different
fusion triggers of each virus or differences in the protocols.
The repeat of the cryo-ET data collection for both PICV and LCMV is ongoing, in
an attempt to improve the resolution of the GPC spike. The work here determined
that the future repeats of electron microscopic investigation of LCMV and PICV
should purify the viruses through 20 % sucrose at 90,000 x g for 3 hours, after which
the sample can be flash frozen using liquid nitrogen. The virus samples should then
be mixed 1:1 with gold fiducial markers (Aurion) and loaded onto Quantifoil R2/2
grids with a 200-mesh. After plunge-freezing into liquid ethane, these grids can
213
CHAPTER 6. CONCLUDING REMARKS
then be examined by cryo-ET, collecting data every 2° increments from ± 60°. This
investigation will further knowledge on the structure of arenavirus glycoproteins and
differences in entry receptor requirement and entry pathways. Through working with
BSL-2 pathogens, the cryo-ET studies here could be performed on LCMV and PICV,
which had not been chemically fixed. This allowed the arenavirus GPC to adopt
multiple different intermediate conformations, further investigation of which could
offer information into the structural changes that the arenavirus GPC undergoes
in order to direct fusion of the host and viral membrane. Understanding these
entry requirements and the different structures allow these to be therapeutically
targeted to interrupt the entry process of pathogenic arenaviruses. Furthermore, it
offers understanding into which sites on the GPC are exposed for recognition by the
host antibodies, potentially allowing the development of vaccines to raise antibodies
against that susceptible site.
Improving the resolution of the GPC spikes will also allow further investigation
into the structural differences between PICV, LCMV, LASV and UHV, providing
information on the differences between New World mammarenavirus, Old World
mammarenaviruses and reptarenaviruses. The difference in entry receptor
requirement between PICV (unknown), LCMV (α-DG) and LASV (α-DG and
LAMP1) suggest that there could be structural differences in the GPC spike,
which can only be investigated with higher resolution structures. In particular,
the histidine triad has been identified for LASV GPC LAMP1 binding, and whilst
the mutation of these histidine residues is lethal for LCMV, LCMV infection does
not require LAMP1 (Cohen-Dvashi et al., 2015; Jae and Brummelkamp, 2015; Hastie
et al., 2016a). Therefore, perhaps the histidine residues adopt a different position,
which does not allow their interaction with LAMP1. This could be resolved by
docking the crystal structures of the LCMV and LASV GPCs into the tomographic
reconstructions of the GPC spikes on the virion surface. This analysis could also
support the identification of other residues in GP1 that are positioned for receptor
interaction and this could be investigated using the reverse genetics system described
here. The rLCMV-eGFP screening platform developed here could also be used to
identify potential secondary receptors for LCMV, using siRNA knock-down methods.
Cryo-ET could also be performed to identify the interactions mediated between the
LCMV GPC and α-DG, by solving the structure of the LCMV GPC in presence of
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α-DG.
In conclusion, the results presented here have led to the development of successful
molecular tools that allow monitoring and investigation of arenavirus infection. The
creation of rLCMV-eGFP can be exploited for the development of a high-throughput
screening platform, which could be used to discover novel anti-arenaviral compounds
or host cellular components that could be targeted in antiviral therapy. The
generation of rLCMV-6xHis allows successful purification of RNPs, which could be
investigated to provide a high-resolution structure of an arenavirus RNP complex.
Finally, the investigation into the structural organisation of the PICV and LCMV
GPC spikes here has indicated some significant structural differences between the
NewWorld and Old World GPCs, in addition to the potential presence of post-fusion
conformations of the GPC on the LCMV virion surface. Further structural
information on the PICV and LCMV GPCs could be exploited for the design of
small molecule inhibitors, which target the GPC structure. Any potential for the
development of anti-arenaviral compounds is important, in order to identify effective




The following chapter includes the un-cropped western blots from figures throughout
this thesis in order to depict the size marker (Ma) and reveal the cross-reactivity of
the LCMV antisera that was generated here.
216
CHAPTER 7. APPENDIX
Figure 7.1: Reactivity of LCMV NP Antisera with LCMV-Infected Cell
Lysates The un-cropped western blot from figure 3.11B has been shown. The LCMV NP
antisera (1:1000) generated in chapter 3 was reactive with LCMV NP from LCMV-infected
BHK-21 and SHSY5Y cell lysates. The sizes of relevant size marker bands has also been
included and the bands representing LCMV NP and loading control GAPDH have been
indicated.
Figure 7.2: Reactivity of LCMV NP Antisera with PICV-Infected Cell Lysates
The un-cropped western blot from figure 3.11C has been shown. The LCMV NP antisera
(1:1000) generated in chapter 3 was reactive with PICV NP from PICV-infected (either at
MOI 0.1 or 1) vero and A549 cell lysates. The sizes of relevant size marker bands has also




Figure 7.3: Reactivity of LCMV NP Antisera with HAZV-Infected Cell
Lysates
The un-cropped western blots from figure 3.11D have been shown. The LCMV NP antisera
(1:1000) generated in chapter 3 was not reactive with HAZV NP from HAZV-infected
SW13 and BSR-T7 cell lysates (A). The same lysates were also probed with HAZV NP
antisera to demonstrate successful HAZV infection (B). The sizes of relevant size marker
bands has also been included and the bands representing HAZV NP and loading control
GAPDH have been indicated.
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Figure 7.4: Generation of Recombinant LCMV from Transfection and
Subsequent Infection
The un-cropped western blots from figures 4.4A (A) and 4.5A (B) have been shown.
BSR-T7 cells were transfected with pUC57-L, pUC57-LP, pUC57-NP, pUC57-T7 and
pUC57-S and cell lysates were collected every 24 hours for 144 hours (A). Supernatant
was collected from the transfected cells at 120 hours post transfection (hpt) and was used
to infect BHK-21 cells, after which the cell lysates were collected every 24 hours for 96
hours post infection (hpt) (B). The size of relevant size marker bands have been depicted
and the bands representing LCMV NP and loading control GAPDH have been indicated.
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Figure 7.5: Generation of Recombinant LCMV expressing a Silent Mutation
The un-cropped western blot from figure 4.6C has been shown. BSR-T7 cells were
transfected with pUC57-L, pUC57-LP, pUC57-NP, pUC57-T7 and either pUC57-S (WT)
or pUC57-S-XhoI (XhoI). The cells were incubated for 120 hours and then the supernatant
was used to infect fresh BHK-21 cells. The lysate was collected from both the transfected
cells and the infected cells at 120 hours post transfection (hpt) and 96 hours post infection
(hpi) respectively and was examined by western blot analysis. The size of relevant size
marker bands have been depicted and the bands representing LCMV NP and loading
control GAPDH have been indicated.
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Figure 7.6: Generation of Recombinant LCMV expressing eGFP from
Transfection and Subsequent Infection
The un-cropped western blots from figures 4.9B and 4.10B have been shown. BSR-T7 cells
were either mock-transfected, transfected with pUC57-NP, pUC57-T7 and pUC57-S-eGFP
(eGFP(-L)) or transfected with the pUC57-L, pUC57-LP, pUC57-NP, pUC57-T7 and
pUC57-S-eGFP (eGFP). Control transfections were performed alongside substituting
pUC57-S-eGFP for pUC57-S (WT(-L) and WT). Lysates were collected at 120 hours
post transfection (hpt) (A). Supernatant collected from the transfected cells at 120 hpt
was used to infect BHK-21 cells, after which the lysates were collected at 96 hours post
infection (hpi) (B). Western blotting analysis was performed, using either LCMV NP
antisera (and loading control GAPDH) (A) or GFP antisera (and loading control actin)
(B). The size of relevant size marker bands have been depicted and the bands representing
LCMV NP, eGFP and loading controls GAPDH and actin have been indicated.
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Figure 7.7: Generation of Recombinant LCMV expressing a 6xHis tag on the
C-terminus of the Nucleocapsid Protein
The un-cropped western blots from figure 4.12B have been shown. BSR-T7 cells were either
mock-transfected or transfected with pUC57-L, pUC57-LP, pUC57-NP, pUC57-T7 and
pUC57-S-6xHis (6xHis). The cells were incubated for a total of 120 hours post transfection
(120hpt), at which point the BSR-T7 cell lysates were collected for western blot analysis
and the supernatant was used to infect BHK-21 cells, which were incubated for 96 hours
post infection (96 hpi). The supernatant from the BHK-21 cells was then used to infect
fresh BHK-21 cells, which were incubated for another 96 hours, as a second passage of
the virus (P.2). Lysates were collected at 96 hpi from the first infection (96 hpi) and
the second passage (P.2). Western blotting analysis was performed on these lysates, using
either LCMV NP antisera (with GAPDH as a loading control) (A) or 6xHis antisera (with
actin as a loading control) (B). The position of relevant size marker bands have been
indicated and the bands representing LCMV NP, 6xHis and loading controls GAPDH and
actin have been indicated.
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